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ABSTRACT OF THE DISSERTATION
The Mechanism of the Gastric Epithelial Stem Cell Response to Metaplastic Injury
by
Shradha Sachin Khurana
Doctor of Philosophy in Developmental, Regenerative and Stem Cell Biology
Washington University in St. Louis, 2013
Professor Jason C. Mills, Chair

Almost nothing is known about the identity of the epithelial stem cell of the gastric corpus, either
during normal turnover or in response to injury. Our lab has shown that injection of the selective
estrogen receptor modulator tamoxifen leads to near complete atrophy of parietal cells by 3 days
and induces expansion of an undifferentiated cell population within the normal stem cell niche in
the isthmus of the gastric unit. Here we show that CD44 labels the membranes of such
undifferentiated isthmal cells, both in the normal gastric epithelium and when those cells expand
fourfold upon injury with tamoxifen. Loss of CD44, either in knockout mice or by blocking its
interaction with its ligand, leads to reduced proliferation. We found CD44 regulates proliferation
by binding to active STAT3 and occupying the CyclinD1 promoter; accordingly, blocking
STAT3 activity completely abrogates atrophy induced proliferation. We screened for signaling
kinases potentially responsible for increased CD44 and/or proliferation and found only ERK
MAPK was activated during early stages following injury (as few as 6 hours following
tamoxifen injection). This burst of ERK activation is localized to non-differentiated cells of the

xv

isthmus, and blocking ERK activation with the inhibitor U0126 blocked the expansion of CD44positive cells.
To determine which cytokines induced ERK in progenitor cells, we assayed sera of mice treated
with tamoxifen for 6h. Compared to control injected mice, tamoxifen treated mice have a
significant increase in the STAT3-inducing cytokine IL-6 levels, correlating with increased
F4/80+ macrophages in the gastric mesenchyme. Isolated peritoneal macrophages treated ex vivo
with tamoxifen showed significantly increased IL-6 expression, and depletion of bone-marrow
derived macrophages in vivo blocks tamoxifen induced metaplasia and increased progenitor cell
proliferation. Depletion of macrophages also blocks activation of ERK and expression of the
stress signal, iNOS, in parietal cells. Inhibition of iNOS and scavenging of nitric oxide blocks
parietal cell atrophy and stem cell expansion. Taken together, our data suggest that CD44 marks
a population of undifferentiated epithelial cells within the stem-cell niche of the gastric unit,
which greatly expands on injury and is regulated by ERK-MAPK signaling. ERK, in turn, is
potentially regulated by cytokines like IL-6 secreted by peritoneal and resident macrophages.
Once induced, CD44 associates with pSTAT3 to increase Cyclin D1 expression and consequent
stem/progenitor cell proliferation. In conclusion, this thesis identifies a marker and pathway for
the presumptive stem cell of the gastric epithelium during response to atrophy and during normal
homeostasis.

xvi

CHAPTER 1: Introduction

1

I.

The Stomach
a. Development

The source of nutrients for an embryo is obviously different from that of a neonate. Until birth,
the developing embryo procures its nourishment from the placenta and from substances in the
swallowed amniotic fluid, which might also contain factors that aid in development. As the
newborn develops, maturation and gland formation in the gastrointestinal tract continue, with the
rate of growth peaking at around three weeks in rodents. The stomach grows at a more rapid rate
just after birth as compared to the rest of the body. At birth, gastric acid secretion capacity is
low, but it rapidly increases by about threefold during the first 3 days post-partum. The gastric
epithelium undergoes continuous renewal throughout the life of the animal.
b. Structure and organization
The mouse stomach is divided into four regions from the proximal to distal end: forestomach,
corpus, antrum, and pylorus. The forestomach is lined by squamous epithelium and is absent in
humans. Mature, differentiated cells that aid in digestion of food are situated in the glandular,
columnar epithelium of the corpus, which is found in all mammals. A schematic of the
architecture of a typical mammalian stomach is shown in Fig.1. The corpus epithelium is
comprised of gastric units which are tubular invaginations that extend into the lamina propria.
Each gastric unit can be divided into four different regions depending upon the cell types
occupying each region. The region closest to the gastric lumen is the pit where surface mucous
pit cells reside. The next is the isthmus where gastric stem/progenitor cells reside, followed by
the neck which is populated by mucous neck cells. The deepest region is the base which is
mainly occupied by zymogenic or chief cells. Parietal cells (acid-secreting) and endocrine cells
are dispersed in all four regions (Fig. 1). The antrum is the distal part of the stomach adjacent to
2

the duodenum and lacks parietal cells and differentiated zymogenic cells. Gastrin secreting Gcells are found in the antrum. Gastrin stimulates release of histamine and acid in the corpus. The
pylorus is the distal muscular sphincter that connects the antrum to the duodenum and regulates
flow of gastric chyme into the intestine.
In constantly renewing tissues such as the stomach and intestine, mechanisms must exist to
balance stem cell division and cell lineage allocation, so that the correct number of cells of each
lineage is constantly generated. This renewal occurs due to the proliferation and differentiation
of the multipotent stem cells that are present in the isthmus region of the adult gastric unit. The
stem cells give rise to precursors that move bi-directionally (toward the lumen and toward the
base) in the unit, giving rise to three main lineages with 11 cell types, that is:
1. Pit (also known as surface-associated/foveolar) cell lineage: Pre-pit cell precursors, pre-pit
cells, pit cells [marked by AAA lectin and TFF1]
2. Zymogenic Cell (ZC) lineage: Pre-neck cell precursors, pre-neck cells, neck cells [marked by
GSII lectin and TFF2], pre-ZCs, and ZCs [marked by intrinsic factor (GIF), pepsinogen (PGC),
Mist1]
3. Parietal Cell (PC) lineage: Pre-PC precursors, pre-PCs, and PCs [marked by H/K-ATPase and
VEGF-B]
Secretory granule-free pre-pit cells within the isthmus give rise to mucous secreting pit cells
when they enter the pit region by upward migration in the gastric unit. 87% of pit cells
differentiate from pre-pit cells, while the remaining 13% come from their own mitoses [1]. The
process of pit cell migration to the surface takes 3 days [1]. On the other hand, cells of the

3

zymogenic lineage migrate in the opposite direction from the isthmus, down towards the base of
the unit.
Members of the zymogenic lineage differentiate during a downward migration from the isthmus.
A granule-free pre-neck cell precursor produces pre-neck cells, which are transformed to neck
cells as they migrate from the isthmus to the neck. Neck cells complete their journey through the
neck region in 14 days [1]. Upon arrival at the upper portion of the base of gastric units, they
become pre-zymogenic cells. Terminal differentiation to zymogenic cells occurs during a
continued downward descent to the lower portion of the base of gastric units. Zymogenic cells
die by necrosis or apoptosis. The sequence is completed in 190 days [1]. Conversion of
undifferentiated granule-free cells to pre-parietal cells occurs in the isthmus and takes 1 day [1].
Differentiation of pre-parietal to parietal cells also takes place in the isthmus. Parietal cells
subsequently undergo a bipolar migration to both the pit and base. Death ensues and cells are
disposed of by extrusion or phagocytosis. The overall turnover time for parietal cells is 54 days
[1].
In addition to these lineages, endocrine cells are also scattered throughout the gastric unit. Even
though there is emerging literature on the mechanisms by which the different cell types are
formed, many gaps remain. For example, even though the location of the stem cell within the
isthmus region of the gastric corpus has been well established by ultrastructure and turnover
analysis, its molecular identity has not been well characterized [2].

4

Figure 1.1: Typical anatomy and histology of a mammalian stomach. There are a number of
variations in mammalian gastric anatomy. For example, mice have a forestomach with
keratinized squamous epithelium, whereas humans have a pronounced cardiac region with
simpler mucous glands that mark the transition region between the esophagus and corpus.
However, the most prominent regions in most mammals are a proximal corpus, encompassing
most of the stomach volume, and a distal antrum or pylorus. The corpus epithelium is organized
into repeating gastric units that are invaginations from the surface and contain multiple cell
lineages in 4 distinct zones. In the diagram, acid-secreting parietal cells are blue, digestive
enzyme secreting zymogenic (chief) cells are red, mucous neck cells are green, and the mucussecreting pit cells nearest the surface are purple. In the antrum, the gastric units are simpler,
with few parietal or zymogenic cells. Antral units contain 2 distinct types of mucous cells: those
lining the surface (purple) are similar to the surface cells of the corpus, and those nearer to the
base have properties intermediate between zymogenic cells and mucous neck cells of the corpus
(red-yellow). The interfaces between esophagus and corpus and between corpus and antrum are
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not abrupt but marked by transitional mucosae. Endocrine cells (not depicted) are also present
throughout the corpus and antrum epithelium. (Adapted from [3])
II.

The Gastric Epithelial Stem Cell

It is believed that all gastric mucosal cells originate from stem cells that reside in the isthmus
region of the gastric unit [4, [5], because 32P-radiolabeled cycling cells appeared in this region.
Studies by Leblond in the 1940s showed that one or a few cells in the isthmus constantly
regenerate cells that migrate bi-directionally, up to the mucosal surface and down to the gland
base, as they differentiate into mature cells of the gastric unit [6] (Fig. 1.2).

Figure 1.2: Origins of principal corpus epithelial lineages. The self-renewing stem cell gives
rise to each of the principal epithelial lineages of the corpus. There is ultrastructural evidence
for the transient intermediates for each lineage; however, available evidence indicates greater
complexity in the zymogenic lineage, which arises from a long-lived (≥1 week in mice)
intermediate, the mucous neck cell, with its own distinct ultrastructure and probable function.
(Adapted from [3]).
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In 1966, Robert Corpron identified small, undifferentiated cells, with high nucleus:cytoplasm
ratio, open chromatin and lack of granules in the isthmus of the gastric units of rats [7], which
repopulated the entire unit. Karam et al. were able to identify a similar subset of cells in the
isthmi of human gastric units [8]. In 2002, Bjerknes and Cheng demonstrated that the entire
gastric unit, corporal and antral, could arise from a single cell, i.e. the stem cell [5]. They utilized
lineage tracing to identify clones that had lost LacZ expression in the mutagenized ROSA26
reporter mouse. They found clones that spanned entire gastric units and ones that were long lived
(48 weeks), confirming that the mutagen hit the stem cell in these instances. Over time, many
putative stem cell markers have emerged, but none has satisfied the gold standard requirements
of tracing of all lineages and in vitro gland formation for the gastric corpus. The different
putative stem cell markers are listed below (adapted from [9]):
Table 1: Putative stem cell markers of the gastrointestinal tract

Lineage
tracing

Marker

Location

Villin
promoter

Mainly
antral; below
isthmus, but
mobile
in
gland base
after IFNγ

Give rise
to all cell
types

Lgr5

Mainly
antral; gland
base

Give rise
to all cell
types

Mature chief
cells
of
corpus gland

Give rise
to SPEM

Mist1

Life span

Response to pathogenic
stimuli

Ref.

>1 year

Increased
proliferation
and gland replacement
after IFNγ

[10]

>638 days

Can give rise to tumors
after conditional Apc
deletion

[11]

As chief
cells

Lost during metaplasia,
dysplasia, and carcinoma

[12,
[13]
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Location

Lineage
tracing

base

lineage

Tff2

Corpus,
isthmus zone
(mRNA)

Give rise
to mucous
neck cells,
chief
cells,
parietal
cells only

BMDSC

Do
not
normally
engraft in the
absence of
injury

Prominin
1
(CD133)

Base
gastric
glands

Dclk1
(DCAM
KL1)

Corpus, one
cell per gland
(at isthmus)

CD44

Corpus/antru
m;
gland
base

Marker

Life span

Response to pathogenic
stimuli

>200 days

Amplified by DMP-777

[14,
[15]

>52 week
s

Widespread in epithelial
engraftment
after
extensive chronic injury
and
Helicobacter
infection

[16]

N/D

Highly expressed
gastric carcinomas

[17,
[18,
[19]

N/D

Amplify in
environment

N/D

Increased in tumors.
Isolated cells give rise to
tumors in xenograft
model

of
N/D

N/D

N/D

Ref.

a

in

Kras

[20,
[21]

[22,
[23,
[24]

N/D not done, IFNγ interferon gamma, BMDSC bone marrow derived stem cells.

In spite of identifying the location of the gastric epithelial stem cell within the unit, little is
known about its niche or markers that label this population specifically.
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a. Salient features of the stem cell
The gastric stem cell is different when compared to stem cells of other regions of the digestive
tract. For one, the gastric stem cell is located much higher in the glandular unit than the intestinal
stem cell, which is located in the base of the crypt [3]. Due to its location, it is more likely to
come in contact with external stimuli and react to them. Second, its progeny undergo
bidirectional migration to fuel the turnover of cells in the gastric unit [3]. Third, life-spans of
different gastric epithelial lineages are very diverse, ranging from ~3 days for pit cells to several
months for ZCs, compared to 3-5 days for enterocytes or 2 weeks for paneth cells in the intestine
[3]. This forces the gastric stem cell to generate different numbers of precursors for each lineage
in each differentiation cycle. Fourth, the steady-state gastric corpus does not rely on Wnt
signaling for maintaining homeostasis, like the intestine [3]. However, the antrum or pylorus of
the stomach might be considered a hybrid between the gastric corpus and intestine, since antral
stem cells label with LGR5, the Wnt-responsive, intestinal stem cell marker, and depend on Wnt
signaling for homeostasis [3]. Moreover, ApcMin and Apc1322T mice, which develop intestinal
polyps due to inactivation of the Wnt-regulatory gene Apc, develop adenomas in the gastric
antrum but not in the corpus [3]. Loss of Apc in Lgr5+ cells rapidly results in formation of antral
but not corpus adenomas [3]. These observations indicate that the antrum has Wnt-responsive
stem cells that are distinct from those that mediate corpus mucosal self-renewal. Also, antral
stem cells rarely generate PCs or ZCs [3]. Gastric corpus stem cells do not stain with markers of
intestinal stem cells. While there has been significant advancement in identification of intestinal
stem cell markers by virtue of lineage tracing, the promoters have failed to trace any of the
gastric lineages. For example, Lgr5 [25], Bmi1 [26], Prom1/CD133 [27, [28], Sox9 [29] label
stem cells in the intestine but fail to do so in the gastric corpus. Lgr5 is expressed in antral stem
9

cells, but is conspicuous by its absence in the adult corpus [11]. Identification of a marker to
trace corpus stem cells will enable us to understand signaling pathways that maintain stem cell
homeostasis as well as those that respond to external stimuli and injuries.
b. Response of the gastric epithelial stem cell to injury:
Although gastric cancer is the second leading cause of cancer related deaths worldwide [30],
little is known about its cause, pathophysiology and treatment strategies. According to the gastric
carcinogenesis model proposed by Correa [31], cancer occurs by serial progression from
superficial gastritis, atrophic gastritis, intestinal metaplasia, finally culminating into gastric
cancer. Chronic infection of the stomach with the gram-negative bacterium Helicobacter pylori
is a major risk factor for developing gastric cancer. Infection with H. pylori causes inflammation
along with dramatic reorganization of the epithelium by directly or indirectly causing PC death,
dedifferentiation of ZCs and activation of stem cells. Whether PC death is the causative agent for
affecting the differentiation state of ZCs and stem cell proliferation remains to be determined.
Metaplasia is defined as a potentially reversible change from a fully differentiated cell type to
another. Human gastric metaplasias are of two main types: Intestinal Metaplasia (IM) and
Spasmolytic Polypeptide Expressing Metaplasia (SPEM). The presence of intestinal goblet cells
in the gastric epithelium is the hallmark of IM, since goblet cells are not normally present in the
stomach. Goblet cells in IM are positive for markers such as Muc2 and Trefoil Factor 3 (TFF3)
[32]. Evidence shows that IM in the stomach has a high risk of developing into cancer and is,
therefore, defined as a precancerous condition [33]. Epidemiological studies have linked H.
pylori infection with IM [34] and hence, H. pylori has been implicated as a major cause of IM. A
second, possibly preneoplastic metaplasia has been identified in the presence of parietal cell
atrophy, which is known as SPEM (Spasmolytic Polypeptide Expressing Metaplasia). SPEM is
10

characterized by glands that resemble antral glands rather than those of the corpus, and express
high amounts of Muc6 and TFF2 (Trefoil Factor 2 or Spasmolytic Polypeptide) [35]. SPEM is
associated with 90% of all resected gastric cancers [36, [37, [38]. Therefore, both, IM and SPEM
are precancerous gastric lesions and the signaling intermediates that cause the progression from
metaplasia to cancer remain to be elucidated.

Figure 1.3: Current model for the origin and progression of gastric metaplasias. Chief cell
transdifferentiation into SPEM is triggered by loss of parietal cells in the corpus mucosa. In the
presence of inflammation, such as during H. pylori infection, SPEM can expand into a
proliferative metaplasia. With continued chronic inflammation, intestinal metaplasia (IM)
evolves in the setting of pre-existing SPEM and can come to dominate the entirety of the glands.
(Adapted from [39])
1. Spasmolytic Polypeptide Expressing Metaplasia (SPEM):
While infection of human stomachs with H. pylori leads to the development of IM, those of mice
fail to develop IM when infected with the mouse adapted strain, H. felis. Chronic infection of
11

mice with H. plori or H. felis leads to loss of parietal cells and inflammation throughout the
mucosa [40, [41, [42]. Mice infected with H. felis develop SPEM after 6 months of infection
[43] which eventually progresses to dysplasia, without ever developing IM. Since inflammation
is a confounding factor in Helicobacter dependent development of SPEM, various other nonpathogenic models have been developed to assess the contribution of PC death alone in SPEM
development.
i.

Genetic ablation of PCs: In 1996, Li et. al [44] generated a transgenic mouse line
containing a fragment of the attenuated diphtheria toxin (DT-A tox176) driven off the
H+/K+-ATPase β-subunit promoter, which is specifically expressed in PCs.
Expression of tox176 led to ablation of PCs and development of metaplasia,
characterized by a 4-5 fold increase in proliferation extending into the base of the
gastric unit and dedifferentiated zymogenic cells in adult transgenic mice [44]. These
mice also showed a twofold increase in pit cell number and a modest increase in prepit cells [44]. These data confirm the point of view of PCs being the differentiation
signaling hub of the gastric unit.

ii.

DMP-777: In 2000, Goldenring et. al [45] identified that DMP-777, a cell-permeant
inhibitor of neutrophil elastase that caused specific PC death when rats were gavaged
with 200mg/kg /day of the drug for 3 months. PC atrophy was unaccompanied by
inflammation. Mice treated with DMP-777 developed SPEM 10-14 days after
administration, with PC atrophy around day 3, without developing dysplasia even a
year after administration [45, [46]. This suggests that inflammation might be a key
determinant of development of neoplasia.

iii.

Tamoxifen: In 2012, Huh et. al [47] identified a tamoxifen induced mechanism for
12

causing PC death and associated metaplasia. Tamoxifen is a selective estrogenreceptor modulator frequently used in humans for the treatment of breast cancer and
in mice for spatiotemporally deleting genes using the Cre-ERT/loxP system [47].
Mice treated with a single injection of 5mg/20g body weight of tamoxifen undergo
PC atrophy, expansion of proliferating progenitor cells and dedifferentiation of
zymogenic cells within 3 days of treatment [47]. This method of SPEM induction is
completely reversible within two weeks of tamoxifen administration [47]. The
mechanism by which tamoxifen induces PC atrophy is uncertain, although, the proton
pump inhibitor, omeprazole, partially rescues the effects of tamoxifen like DMP-777
[47]. Therefore, it is believed that the mode of action of tamoxifen is similar to DMP777 [47].
Figure 1.4 demonstrates the epithelial changes characteristic of SPEM caused by the
above mentioned methods.

Figure 1.4: Cellular mechanisms of SPEM. Chronic inflammation of the corpus in mammals
leads to characteristic changes in differentiation in the gastric unit. Parietal cells are lost
13

(atrophy), and the zymogenic chief cell lineage is reprogrammed so that genes that are normally
expressed only in mucous neck cells, such as spasmolytic polypeptide/TFF2 (shown in green),
are expressed at high levels in cells at the base. Zymogenic cell markers (such as pepsinogen
C; red) are co-expressed with neck cell markers. Proliferation is increased and occurs more
basally in the unit. The pattern of basal proliferation and coexpression of neck and zymogenic
cell genes is similar to the histologic pattern in the normal antrum and pylorus, which is why it is
called pseudopyloric metaplasia. The most common metaplasia-inducing inflammation is caused
by H pylori infection, although autoimmune gastritis (in which autoantibodies target parietal
cells) can cause the same metaplasia pattern.
2. Intestinal Metaplasia
Intestinal metaplasia (IM) is considered a preneoplastic lesion of the stomach in which the
normal gastric mucosa is replaced by mucosa which resembles the intestine. Morphologically,
IM can be identified by the presence of goblet cells, which are normally absent in the stomach.
Although IM is considered to be a risk factor for developing gastric cancer, it is unclear whether
IM causes gastric cancer or is a marker for increased cancer risk [48]. Since infection with H.
pylori is the greatest predisposing factor for developing gastric cancer, early investigations
studied the association of infection with presence of IM. However, it was found that IM occurred
at an equal frequency in patients with dysplasia and gastric cancer regardless of their H. pylori
status [48]. Also, eradication of H. pylori did not benefit patients whose mucosa had already
progressed to IM, suggesting that development of IM marks a point of no return in the
progression to cancer [49].
The genetic events in IM are not well understood. According to published data, some genetic
markers that change during progression to IM and cancer are listed below in Table 2.
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Table 2: Expression of genes during normal turnover, IM and gastric cancer (Adapted from
[48]).
Gene

Normal Mucosa

Intestinal Metaplasia Gastric Cancer

CDX1

-

↑↑↑↑

↑↑

CDX2

-

↑↑↑↑↑

↑

TFF1

↑↑↑↑↑

↑↑↑

ND

TFF2

-

↑↑

ND

TFF3

ND

↑↑↑↑↑

ND

Villin

-

↑↑↑

ND

Sox2

↑↑↑

↑↑

-

Pdx1

↑

↑↑

↑↑↑

OCT-1

↑

↑↑↑

↑↑↑

RUNX3

↑↑

↑

-

Shh

↑↑↑

-

ND

↑: relative degree of upregulation, ND: Not Defined, -: Absent
CDX, caudal type homeobox; OCT, octamer binding transcription factor; PDX, pancreatic and
duodenal homeobox; RUNX3, runt related transcription factor; shh, sonic hedgehog; TFF,
trefoil factor.
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Since IM is the conversion of normal gastric mucosa to a more intestinal type, it is expected to
find upregulation of intestinal genes during IM. Accordingly, the homoeobox developmental
genes, Cdx1 and Cdx2, which confer intestinal identity, are upregulated in IM. Interestingly, their
expression is decreased during the progression of IM to cancer [50]. Liu et. al. [50] suggest that a
sufficiently high expression of Cdx genes converts gastric epithelium to a terminally
differentiated intestinal epithelium. In order to further progress to gastric cancer, the level of Cdx
must be decreased to cause sufficient dedifferentiation and proliferation. Another homoeobox
gene, Sox2, is expressed in the gastric mucosa but is almost absent in the intestinal epithelium
during development. However, during IM development, Sox2 levels decrease while Cdx2 levels
increase. While ectopic expression of Cdx2 in gastric tissue leads to the appearance of goblet
cells [51], ectopic expression of Sox2 in prospective intestinal tissues leads to a more gastric
phenotype [52].
The function of the gastric stem cell during development of IM is unknown. Since Helicobacter
infected mice do not develop IM prior to dysplasia like humans do, they do not serve as ideal
model organisms for studying IM progression. Other models such as Cdx2 expressing transgenic
mice or Mongolian gerbils infected with Helicobacter have been used to determine the
mechanisms responsible for the conversion of the epithelium from gastric to intestinal [48] and
the response of the stem cell.

Conclusions
Most gastric injuries, such as SPEM, IM and cancer, depend on the response of the stem cell to
external stimuli. Therefore, it is imperative to understand mechanisms that lead to stem cell
16

homeostasis during normal turnover and those that lead to stem cell activation during injury. The
above mentioned models of metaplasia help in determining signaling pathways that regulate stem
cell proliferation. We have utilized a number of models of metaplasia to understand mechanisms
that lead to parietal cell atrophy, stem cell activation and entry of cells into the cell cycle. In
Chapter 2, we have described, in detail, the tamoxifen induced model of metaplasia and its
advantages over other chronic models of metaplasia. In Chapter 3, we utilize tamoxifen induced
atrophy in identifying CD44 as a marker of gastric epithelial stem cells, the role of CD44 in
expansion of stem cell proliferation during metaplasia and the signaling pathways that regulate
proliferation downstream of CD44. In Chapter 4, we explore the role of circulating factors and
cytokines that are upstream modulators of parietal cell atrophy, which transduces the first signal
to stem cells to start proliferating.
Therefore, in this thesis, we have:
i.

Established a new model for studying parietal cell atrophy and stem cell activation –
Tamoxifen treatment of mice;

ii.

Determined the signaling cascade by which stem cell proliferation is regulated during
normal turnover and tamoxifen induced atrophy;

iii.

Determined potential mechanisms by which parietal cells are damaged in different
models of SPEM:

iv.

Identified potential circulating factors secreted by the innate immune system in
regulating parietal cell atrophy and subsequent stem cell activation

17

References
1.

Karam, S.M. and C.P. Leblond, Dynamics of epithelial cells in the corpus of the mouse
stomach. II. Outward migration of pit cells. Anat Rec, 1993. 236(2): p. 280-96.

2.

Huh, W.J., et al., Location, allocation, relocation: isolating adult tissue stem cells in
three dimensions. Curr Opin Biotechnol, 2006. 17(5): p. 511-7.

3.

Mills, J.C. and R.A. Shivdasani, Gastric epithelial stem cells. Gastroenterology, 2011.
140(2): p. 412-24.

4.

Thompson, M., et al., Gastric endocrine cells share a clonal origin with other gut cell
lineages. Development, 1990. 110(2): p. 477-81.

5.

Bjerknes, M. and H. Cheng, Multipotential stem cells in adult mouse gastric epithelium.
Am J Physiol Gastrointest Liver Physiol, 2002. 283(3): p. G767-77.

6.

Leblond, C.P., C.E. Stevens, and R. Bogoroch, Histological Localization of Newlyformed Desoxyribonucleic Acid. Science, 1948. 108(2811): p. 531-3.

7.

Corpron, R.E., The ultrastructure of the gastric mucosa
hypophysectomized rats. Am J Anat, 1966. 118(1): p. 53-90.

8.

Karam, S.M., et al., Defining epithelial cell progenitors in the human oxyntic mucosa.
Stem Cells, 2003. 21(3): p. 322-36.

9.

Qiao, X.T. and D.L. Gumucio, Current molecular markers for gastric progenitor cells
and gastric cancer stem cells. J Gastroenterol, 2011. 46(7): p. 855-65.

10.

Qiao, X.T., et al., Prospective identification of a multilineage progenitor in murine
stomach epithelium. Gastroenterology, 2007. 133(6): p. 1989-98.

11.

Barker, N., et al., Lgr5(+ve) stem cells drive self-renewal in the stomach and build longlived gastric units in vitro. Cell Stem Cell, 2010. 6(1): p. 25-36.

12.

Nam, K.T., et al., Mature chief cells are cryptic progenitors for metaplasia in the
stomach. Gastroenterology, 2010. 139(6): p. 2028-2037 e9.

13.

Ramsey, V.G., et al., The maturation of mucus-secreting gastric epithelial progenitors
into digestive-enzyme secreting zymogenic cells requires Mist1. Development, 2007.
134(1): p. 211-22.

14.

Quante, M., et al., TFF2 mRNA transcript expression marks a gland progenitor cell of
the gastric oxyntic mucosa. Gastroenterology, 2010. 139(6): p. 2018-2027 e2.

18

in

normal

and

15.

Peterson, A.J., et al., Helicobacter pylori infection promotes methylation and silencing of
trefoil factor 2, leading to gastric tumor development in mice and humans.
Gastroenterology, 2010. 139(6): p. 2005-17.

16.

Houghton, J., et al., Gastric cancer originating from bone marrow-derived cells. Science,
2004. 306(5701): p. 1568-71.

17.

Zhao, P., Y. Li, and Y. Lu, Aberrant expression of CD133 protein correlates with Ki-67
expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer, 2010.
10: p. 218.

18.

Ishigami, S., et al., Prognostic impact of CD133 expression in gastric carcinoma.
Anticancer Res, 2010. 30(6): p. 2453-7.

19.

Futagami, S., et al., Celecoxib inhibits CD133-positive cell migration via reduction of
CCR2 in Helicobacter pylori-infected Mongolian gerbils. Digestion, 2010. 81(3): p. 193203.

20.

Okumura, T., et al., K-ras mutation targeted to gastric tissue progenitor cells results in
chronic inflammation, an altered microenvironment, and progression to intraepithelial
neoplasia. Cancer Res, 2010. 70(21): p. 8435-45.

21.

Giannakis, M., et al., Molecular properties of adult mouse gastric and intestinal
epithelial progenitors in their niches. J Biol Chem, 2006. 281(16): p. 11292-300.

22.

Takaishi, S., et al., Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells, 2009. 27(5): p. 1006-20.

23.

Ghaffarzadehgan, K., et al., Expression of cell adhesion molecule CD44 in gastric
adenocarcinoma and its prognostic importance. World J Gastroenterol, 2008. 14(41): p.
6376-81.

24.

da Cunha, C.B., et al., De novo expression of CD44 variants in sporadic and hereditary
gastric cancer. Lab Invest, 2010. 90(11): p. 1604-14.

25.

Barker, N., et al., Identification of stem cells in small intestine and colon by marker gene
Lgr5. Nature, 2007. 449(7165): p. 1003-7.

26.

Sangiorgi, E. and M.R. Capecchi, Bmi1 is expressed in vivo in intestinal stem cells. Nat
Genet, 2008. 40(7): p. 915-20.

27.

Zhu, L., et al., Prominin 1 marks intestinal stem cells that are susceptible to neoplastic
transformation. Nature, 2009. 457(7229): p. 603-7.

19

28.

Snippert, H.J., et al., Prominin-1/CD133 marks stem cells and early progenitors in mouse
small intestine. Gastroenterology, 2009. 136(7): p. 2187-2194 e1.

29.

Furuyama, K., et al., Continuous cell supply from a Sox9-expressing progenitor zone in
adult liver, exocrine pancreas and intestine. Nat Genet, 2011. 43(1): p. 34-41.

30.

Lozano, R., et al., Global and regional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
2010. Lancet, 2012. 380(9859): p. 2095-128.

31.

Correa, P., Human gastric carcinogenesis: a multistep and multifactorial process--First
American Cancer Society Award Lecture on Cancer Epidemiology and Prevention.
Cancer Res, 1992. 52(24): p. 6735-40.

32.

Ectors, N. and M.F. Dixon, The prognostic value of sulphomucin positive intestinal
metaplasia in the development of gastric cancer. Histopathology, 1986. 10(12): p. 12717.

33.

Walker, M.M., Is intestinal metaplasia of the stomach reversible? Gut, 2003. 52(1): p. 14.

34.

Sakaki, N., et al., Ten-year prospective follow-up study on the relationship between
Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed
by endoscopic findings. Aliment Pharmacol Ther, 2002. 16 Suppl 2: p. 198-203.

35.

Goldenring, J.R., et al., Spasmolytic polypeptide-expressing metaplasia and intestinal
metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.
Gastroenterology, 2010. 138(7): p. 2207-10, 2210 e1.

36.

Schmidt, P.H., et al., Identification of a metaplastic cell lineage associated with human
gastric adenocarcinoma. Lab Invest, 1999. 79(6): p. 639-46.

37.

Halldorsdottir, A.M., et al., Spasmolytic polypeptide-expressing metaplasia (SPEM)
associated with gastric cancer in Iceland. Dig Dis Sci, 2003. 48(3): p. 431-41.

38.

Yamaguchi, H., et al., Identification of spasmolytic polypeptide expressing metaplasia
(SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis
Sci, 2002. 47(3): p. 573-8.

39.

Goldenring, J.R., K.T. Nam, and J.C. Mills, The origin of pre-neoplastic metaplasia in
the stomach: chief cells emerge from the Mist. Exp Cell Res, 2011. 317(19): p. 2759-64.

40.

Wang, T.C., et al., Mice lacking secretory phospholipase A2 show altered apoptosis and
differentiation with Helicobacter felis infection. Gastroenterology, 1998. 114(4): p. 67589.
20

41.

Fox, J.G., et al., Hypertrophic gastropathy in Helicobacter felis-infected wild-type
C57BL/6 mice and p53 hemizygous transgenic mice. Gastroenterology, 1996. 110(1): p.
155-66.

42.

Fox, J.G., et al., Host and microbial constituents influence Helicobacter pylori-induced
cancer in a murine model of hypergastrinemia. Gastroenterology, 2003. 124(7): p. 187990.

43.

Nomura, S., et al., Spasmolytic polypeptide expressing metaplasia to preneoplasia in H.
felis-infected mice. Gastroenterology, 2004. 127(2): p. 582-94.

44.

Li, Q., S.M. Karam, and J.I. Gordon, Diphtheria toxin-mediated ablation of parietal cells
in the stomach of transgenic mice. J Biol Chem, 1996. 271(7): p. 3671-6.

45.

Goldenring, J.R., et al., Reversible drug-induced
Gastroenterology, 2000. 118(6): p. 1080-93.

46.

Nomura, S., et al., Alterations in gastric mucosal lineages induced by acute oxyntic
atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol,
2005. 288(2): p. G362-75.

47.

Huh, W.J., I.U. Mysorekar, and J.C. Mills, Inducible activation of Cre recombinase in
adult mice causes gastric epithelial atrophy, metaplasia and regenerative changes in the
absence of "floxed" alleles. Am J Physiol Gastrointest Liver Physiol, 2010. 299(2): p.
G368-380.

48.

Busuttil, R.A. and A. Boussioutas, Intestinal metaplasia: a premalignant lesion involved
in gastric carcinogenesis. J Gastroenterol Hepatol, 2009. 24(2): p. 193-201.

49.

Leung, W.K., et al., Factors predicting progression of gastric intestinal metaplasia:
results of a randomised trial on Helicobacter pylori eradication. Gut, 2004. 53(9): p.
1244-9.

50.

Liu, Q., et al., CDX2 expression is progressively decreased in human gastric intestinal
metaplasia, dysplasia and cancer. Mod Pathol, 2007. 20(12): p. 1286-97.

51.

Silberg, D.G., et al., Cdx2 ectopic expression induces gastric intestinal metaplasia in
transgenic mice. Gastroenterology, 2002. 122(3): p. 689-96.

52.

Raghoebir, L., et al., Disturbed balance between SOX2 and CDX2 in human vitelline duct
anomalies and intestinal duplications. Virchows Arch, 2013. 462(5): p. 515-22.

21

oxyntic

atrophy

in

rats.

CHAPTER 2: Tamoxifen induces rapid, reversible atrophy, and metaplasia in
mouse stomach

This chapter was published in Gastroenterology
Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach
Huh WJ, Khurana SS, Geahlen JH, Kohli K, Waller RA, Mills JC.
Gastroenterology. 2012 Jan;142(1):21-24.e7. DOI: 10.1053/j.gastro.2011.09.050. Epub 2011 Oct
14.
PMID: 22001866
WJH and SSK contributed equally to this manuscript.
Unless otherwise noted, SSK and WJH performed all the experiments in this chapter.
22

Abstract
Tamoxifen, a selective estrogen receptor modulator, is widely used in research and clinically in
patients. We find that treatment of normal mice with a single ≥ 3mg/20g body weight dose of
tamoxifen leads to apoptosis of > 90% of all gastric parietal cells and metaplasia of zymogenic
chief cells within 3 days. Remarkably, gastric histology returns to nearly normal by 3 weeks.
Tamoxifen toxicity occurs by oral and intraperitoneal administration, in both sexes, in multiple
strains, and does not depend on estrogen, though acid secretion inhibition is partially protective.
Thus, substantial gastric toxicity is a heretofore unappreciated tamoxifen side effect.
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Introduction
Tamoxifen is widely used to spatio-temporally delete mouse genes using the CreERT/loxP
system [1]. Tamoxifen is also used clinically as a selective estrogen receptor (ER) modulator, in
chemotherapeutic, anti-osteoporotic, and several other therapeutic regimens [2, [3] . Some
reports suggest tamoxifen also increases risk for subsequent gastric cancer [4, [5]. Most gastric
cancers occur in stomachs colonized by Helicobacter pylori [6]. Precancerous effects of
bacterial colonization include: death (atrophy) of acid-secreting gastric parietal cells (PCs),
differentiation changes (metaplasia) in the digestive-enzyme secreting zymogenic (chief) cell
lineage (ZC) and increased stem cell proliferation [7, [8].
Materials and Methods
Animals and injections- All experiments involving animals were performed according to
protocols approved by the Washington University School of Medicine Animal Studies
Committee. Mice were maintained in a specified-pathogen-free barrier facility under a 12 hour
light cycle. Wild type C57BL/6, BALB/c and FVB/N mice were purchased from The Jackson
Laboratory. To trace parietal cells (PCs), H+/K+ATPase-Cre mice [9] were crossed with a
reporter line, B6.129-Gt(ROSA)26Sortm1Joe/J (The Jackson Laboratory) [10], which expresses
floxed β-galactosidase in the nucleus under the control of the Rosa26 promoter. Tamoxifen (15mg/20g body weight, Sigma, St. Louis, MO; and in 1 experiment, 5mg/20g, Cayman Chemical
Company, MI) was injected intraperitoneally for one or three days to induce SPEM and mice
were dissected at 12 hours, 3 days, 7 days, 14 days, 21 days and 28 days after treatment.
Tamoxifen was dissolved in a vehicle of 10% ethanol and 90% sunflower seed oil (Sigma).
Tamoxifen stock concentrations ranged from 5mg/ml to 2mg/ml; 200μl/20g body weight was
injected intraperitoneally. Each mouse was orally gavaged with 4mg tamoxifen, prepared in the
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same vehicle described above, for 3 days and dissected at day 3. Fulvestrant (Sigma; 3mg/20g
body weight, dissolved in the same vehicle as tamoxifen) and17 β-estradiol (Sigma; 50µg /20g
body weight, dissolved in the same vehicle as tamoxifen to stock concentration of 100ng/100µl)
were injected subcutaneously every day for three days, with or without one injection of 5mg/20g
tamoxifen on the first day; stomachs were harvested 3 days after the first injection. Omeprazole
(Sigma; 1.5mg/20g body weight) was dissolved in 100 µl DMSO (Sigma) in 90 µl 1% methyl
cellulose (Sigma) and orally gavaged every day for four days, with or without one injection of
5mg/20g tamoxifen on the second day of gavaging, with harvesting at 3 days after tamoxifen
injection. Raloxifene (Sigma; 5mg/20g body weight) was dissolved in 10% DMSO and 90%
sunflower seed oil and injected into wildtype mice for 3 days and dissected on day 3.To evaluate
efficiency

of

recombination,

R26CreERT

[11]

mice

were

crossed

with

B6.129-

Gt(ROSA)26Sortm1Joe/J (The Jackson Laboratory) [10] and injected with 2mg/20g body weight
raloxifene for 5 days, dissected at day 14 and stained for LacZ.
Immunofluorescence- Stomachs were prepared, and stained, and imaged using methods modified
from Ramsey et al [12]. Primary antibodies used for immunostaining were: rabbit (1:10,000),
goat (1:2000) anti-human gastric intrinsic factor (gifts of Dr. David Alpers, Washington
University), rabbit anti-H+/K+ ATPase α subunit (1:10,000, Dr. Michael Caplan, Yale
University), goat anti-BrdU (1:20,000, Jeffrey Gordon, Washington University), rabbit antiCytochrome C (1:100, Cell Signaling Technology). Secondary antibodies, GSII lectin and BrdU
labeling were as described [12].
Genotyping- For PCR, tissue was lysed with 25mM sodium hydroxide (pH 12.0) at 95°C for 25
minute and neutralized with the same volume of 40mM Tris buffer (pH 5.0) For Cre, PCR was
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with RedTaq (Sigma), and KlenTaq (DNA Polymerase Facility, Washington University, St.
Louis, MO) was used for LacZ PCR. Primers: Cre forward: AGG GAT CGC CAG GCG TTT
TC and reverse: GTT TTC TTT TCG GAT CCG CC, LacZ forward: GTT GCA GTG CAC
GGC AGA TAC ACT TGC TGA and reverse: GCC ACT GGT GTG GGC CAT AAT TCA
ATT CGC.
LacZ staining- LacZ staining was modified from Lobe, et al, 1999 [13]. Tissue was fixed in
LacZ fix for 4 hours at 4°C and washed in LacZ wash buffer three times. Tissue was equilibrated
in 30% sucrose/PBS overnight at 4°C, was embedded in O.C.T. (Sakura, Torrance, CA) and was
frozen in dry ice. The frozen block was cryosectioned at 14 µm thickness. The section was fixed
again for 10 minutes in LacZ fix and washed in LacZ wash buffer three times. Then the section
was incubated in LacZ stain 6 hours at 30°C and washed in PBS three times. The section was
post-fixed in LacZ fix at room temperature for ten minutes, dehydrated through ethanol and
xylene, counter stained with nuclear fast red (Vector Laboratories Inc., Burlingame, CA) and
then mounted in Cytoseal XYL (Richard-Allan Scientific, Kalamazoo, MI).
Tunel Staining - Stomachs were inflated with freshly prepared formalin and suspended in
fixative overnight at 4°C, followed by multiple rinses in 70% Ethanol, arrangement in 2% agar in
a tissue cassette, and routine paraffin processing. Sections (5 μm) were deparaffinized and
rehydrated, and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining was performed using the ‘In Situ Cell Death Detection Kit, Fluorescein’ (Roche)
according to the manufacturer’s instructions. Sections were counter-stained with GS-II at 594nm
(1:2000, Invitrogen)
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Quantitative RT-PCR - For quantitative RT-PCR (qRT-PCR) analysis, total RNAs from stomach
tissue were extracted by RNAeasy Midi Kit (Qiagen, Valencia, CA). cDNA was synthesized
with Superscript III (Invitrogen) and random primers. qRT-PCR was performed with SYBR
Advantage qPCR Mix (Clontech, Mountain View, CA) and gene-specific primers (see table) on
an Mx3000P (Stratagene, La Jolla, CA). qRT-PCR analysis and standardization was as described
[14], every run was standardized to 18s rRNA primers: forward CAT TCG AAC GTC TGC CCT
ATC, reverse CCT GTG CCT TCC TTG GA.
Gene-specific primers used were as follows:
Sr.
No.

Gene

1.

Tff1

2.

Forward Primer
5’
3’

Reverse Primer
5’
3’

Ref.

AGCACAAGGTGATCTGTGTCC

GGAAGCCACAATTTATCCTCTCC

[14]

Atp4a

TCTGCTTTGCGGGACTTGTA

CGGCATTTGAGCACAGCAT

[14]

3.

Tff2

TGCTCTGGTAGAGGGCGAG

CGACGCTAGAGTCAAAGCAG

[14]

4.

Pgc

ATGAAGAGTATCCGGGAGACC

TGGGCTCATAGAGTACACTGTAG

[14]

5.

GIF

CCCTCTACCTCCTAAGTGTTCTC CTGAGTCAGTCACCGAGTTCT

[14]

6.

Gast

ACACAACAGCCAACTATTC

CAAAGTCCATCCATCCGTAG

[15]

7.

Mist1

GCTGACCGCCACCATACTTAC

TGTGTAGAGTAGCGTTGCAGG

[14]

8.

He4

AACCAATTACGGACTGTGTGTT

TCGCTCGGTCCATTAGGCT

[16]

9.

Lyz

GAGACCGAAGCACCGACTATG

CGGTTTTGACATTGTGTTCGC

[16]

Western blot - For Western blot analysis, stomach tissue was frozen in liquid nitrogen and
ground in urea buffer (8 M urea, 0.19 M Tris·HCl pH 6.8, 1% SDS) using PowerGen 700
homogenizer (Fischer Scientific). Proteins were separated on a 10% polyacrylamide gel
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(Invitrogen) and transferred to Nitrocellulose membrane (Amersham Hybond ECL). Primary
antibodies used for blotting were rabbit anti- H+/K+ ATPase α subunit (1:1000, gift from Dr.
Michael Caplan), rabbit anti-Gastric Intrinsic Factor (1:10,000 gift from Dr. David Alpers),
rabbit- anti-Chromogranin A (1:1000, DiaSorin, Stillwater, MN), rabbit anti-Cleaved Caspase 3
(1:1000, Cell Signaling Technology) and rabbit anti-α-tubulin (1:2,000, Cell Signaling
Technology). Secondary antibody was horseradish peroxidase (HRP)-conjugated donkey antirabbit IgG (1:2,000, Santacruz Biotenchnology, Inc.). Immobilon Western Chemiluminescent
HRP Substrate (Millipore) was used for detection.
Parietal cell (Atp4a+) and proliferating cell (BrdU+) counts – Cell counts were either by
immunofluorescence or from H&E. For immunofluorescence, stomach sections were costained
with GS-II, bisbenzimide, and either anti-H+/K+ATPase or anti-BrdU antibody. The numbers of
PCs or BrdU positive (proliferating) cells in every field were scored for five randomly selected
fields in the corpus of a single mouse, with three mice in every experimental set. PCs were also
counted in H&E-stained sections for every mouse used in the study. Fifty well aligned corpus
gastric units were selected at random from every mouse under study, the total number of PCs
determined and average PC/unit calculated. H&E counts were indistinguishable from
immunofluorescence-based counts.
Microscopy - Light and transmission electron photomicrographs were taken as described [17]
Graphing and statistics - All graphs and statistics were performed in GraphPad Prism, using oneway ANOVA with either Dunnett’s or Tukey’s post-hoc multiple comparison tests for cell count
data. qRT-PCR data significance was assessed by Student’s t test followed by Bonferroni post
hoc analysis to ensure against multiple comparison bias. Quantification of GSII and GIF
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immunofluorescent staining was performed using ImageJ software (http://rsbweb.nih.gov/ij/).
The GSII/GIF positive region of each unit was divided lengthwise into 10 equal sections. The
images were then thresholded (GSII 4-6 MFI; GIF 10-17 MFI) to subtract background. The
mean fluorescent intensities (MFI) above the threshold was multiplied by the area of pixels
above the threshold for both the GSII and GIF channel for each section. For tamoxifen treated
day 3 and day 21, the data from 20 units from 2 mice were quantified; in untreated mice, data
from 15 units from one mouse was quantified. The data for each section was averaged and
plotted.

Results and Discussion
In control experiments for tamoxifen induction of Cre-recombinase activity [14], we noticed that
tamoxifen injection (3 consecutive days, intraperitoneal, 5mg/20g mouse body weight) caused
dramatic rearrangement of the gastric mucosa with loss of > 90% of PCs, a 6-fold increase in
proliferation in stem/progenitor cells, and morphological changes in the ZCs in the bases of
gastric-units (Fig. 2.1A-D). By 14-21 days, the epithelium recovered (Fig. 2.1A).
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Fig. 2.1. Tamoxifen causes rapid, reversible gastric metaplasia in mice, which is highlighted
by parietal cell death, concomitant increase in proliferation and loss of differentiated cell

30

markers. A) H&E of wild-type mice following intraperitoneal (i.p.) injection of vehicle at day 7
or 5mg/20g body weight tamoxifen at 3, 7, and 14 days following injection. B)
Immunofluorescence (green: anti-ATP4A; red:anti-BrdU) at d3, quantified in C,D. E)
Quantification of mean PCs/unit/individual mouse by H&E; unless otherwise indicated, mice
were C57/B6 strain; “Tamoxifen II”: tamoxifen from another supplier. F) Whole stomach qRTPCR (expressed as Log2 scale. *P<0.05;**P<0.01;***P<0.001)

No other organs had marked phenotypes at this dose or time-schedule (Fig. 2.2). Even a single
dose of tamoxifen, by intraperitoneal injection or oral gavage, from two different commercial
suppliers in three different strains of mice caused similar effects in n>63 mice (Fig. 2.1E, 2.3AF). By qRT-PCR, PC-specific transcripts (Atp4a) and markers of ZC maturation (Mist1 aka
Bhlha15, Pgc, GIF) [17] were significantly reduced by d3, whereas the surface/foveolar lineage
marker (Tff1) and transcripts for gastrin were unchanged (Fig. 2.1F, see Fig. 2.3G for western
blots of GIF and ATP4A).
Increased progenitor cell proliferation and changes in ZC differentiation are characteristic of
spasmolytic polypeptide expressing metaplasia (SPEM) [14, [18]. In SPEM, expression of
mucous neck cell markers (like spasmolytic polypeptide, aka TFF2) occurs in the base of glands,
where ZCs normally reside [17, [18]. Tamoxifen increased two SPEM-specific transcripts, He4
and Lyz [8]; however, transcript levels for spasmolytic polypeptide(Tff2) itself were unchanged
(Fig. 2.1F). SPEM is usually diagnosed by histopathological criteria and not transcriptionally [7,
[8, [17, [18, [19], but we cannot rule out the possibility that the lack of increased Tff2 indicates
that tamoxifen-induced metaplasia is a SPEM variant.
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Fig. 2.2. Other organs are not affected by tamoxifen as severely as the stomach. Pancreas (A),
Liver (B), Heart (C), Spleen (D), Small Intestine (E) and Large Intestine (F) from vehicle treated
(top) and tamoxifen treated (bottom) wild-type mice 3 days following injection. Note that organs
exposed to tamoxifen do not differ substantially from those of control mice.
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Fig. 2.3. Tamoxifen induced SPEM is
dose dependent. Wild type mice injected
with 1mg/20g body weight (A), or
2mg/20g body weight (B) tamoxifen for 3
days did not show parietal cell death or
features of SPEM, whereas, mice treated
with 3mg/30g body weight (C) for 3 days
or a single injection of 5mg/20g body
weight (D) tamoxifen show complete
atrophy of parietal cells and SPEM
histology. Other strains of mice develop
SPEM

equivalently

on

tamoxifen

treatment as shown in BALB/c (E) and
FVB/N (F) strains after 3 days of
injection of 5mg/20g tamoxifen. G:
Western blot showing decrease in H+/K+
ATPase and Intrinsic Factor (GIF,
zymogenic cell marker) protein levels 3
days after tamoxifen treatment in mice,
when compared with controls. Chromogranin A levels are slightly higher post tamoxifen
treatment, which is consistent with previous reports of spasmolytic polypeptide expressing
metaplasia (SPEM).
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In humans and mice, metaplasia always occurs in the setting of PC atrophy [8, [17]. To assess
PC death, we crossed Atp4b-Cre mice, whose PCs constitutively express Cre [9], to nuclear lacZR26R mice. In these mice, all mature PCs had, as expected, nuclear lacZ expression (Fig. 2.4A).
Tamoxifen caused near complete loss of lacZ, indicating that PCs died and did not give rise to
other cells with different morphological or molecular characteristics. TUNEL-positive PCs were
not observed in the vehicle treated controls, whereas they were common within 12 hours after a
single injection of 5mg/20g tamoxifen (Fig. 2.4B). By 12h, cytochrome C staining could now be
found leaked into the cytoplasm of the majority of PCs, consistent with early aptoptosis; in
controls, distribution was still punctate, consistent with retention in the mitochondria (Fig. 2.4B).
By transmission electron microscopy, PCs showed neither vacuolization nor organellar swelling,
characteristics of necrotic death, but had apoptotic features like electron-dense inclusions in
mitochondria and peripheral chromatin condensation (Fig. 2.4D, E). Finally, only tamoxifentreated stomachs showed Caspase 3 cleavage (Fig. 2.4C).
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Fig. 2.4. Tamoxifen results in SPEM by causing death of parietal cells. A) Nuclear LacZ
labeled PCs following tamoxifen treatment. B) Top: TdT-mediated dUTP nick-end labeling
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shows dying PCs (arrowheads). Below: Cytochrome C staining is punctate, consistent with
mitochondrial localization in vehicle-treated (below left) and dispersed throughout the
cytoplasm tamoxifen-treated PCs (below right) C) Cleaved caspase 3 western blot with tubulin
loading control. D) At 2.5d following tamoxifen, PCs show chromatin condensation (arrows with
black outline), consistent with early apoptosis. E) Another degenerating PC exhibits
mitochondria ranging in morphology from normal (dashed arrow) to electron-dense-inclusioncontaining (white solid arrow) to electron-dense and degenerating (arrowheads).
Tamoxifen can function as both an estrogen receptor (ER) agonist and antagonist depending on
tissue type; however, neither treatment with the pure ER agonist 17-β-estradiol nor the specific
antagonist fulvestrant induced atrophy/metaplasia. And neither blocked tamoxifen effects (Fig.
2.5A, B). The sex of the mice also did not affect tamoxifen effects (Fig. 2.5C), nor did
ovarectomy of females to block endogenous estrogen production (Fig. 2.5C; data not shown).

36

Fig.

2.5.

SPEM

induction

by

tamoxifen is not estrogen receptor
(ER) or sex dependent. Mice treated
with ER agonist, 17-β-estradiol did
not develop SPEM (A) and neither did
estradiol rescue SPEM induced by
tamoxifen (right). Similarly, mice
treated

with

ER

antagonist,

Fulvestrant did not develop SPEM (B)
and neither did it rescue SPEM induced by Tamoxifen (right).
Ovarectomized (C) and female (right)
mice also developed SPEM like their
male counterparts (male mice used for
all other experiments in the current
study) on injection with tamoxifen. D:
Raloxifene does not show toxicity, like
tamoxifen, at the same dose and time
course. E: Cre-recombinase driven by
the R26 promoter, in a R26-Reporter
background, is induced by Raloxifene. Blue depicts LacZ staining in cells with Cre-recombinase
activity. The staining pattern is similar to what we see with tamoxifen in other experiments (not
shown) using R26-Cre: nearly all mesenchymal cells and many ZCs show induced.
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However, tamoxifen effects could largely be reversed by blocking the PC proton pump with
omeprazole (Fig. 2.6), suggesting a role for active acid secretion in tamoxifen toxicity to PCs.
Finally, another SERM family member, raloxifene, which also has both pro and anti-estrogenic
effects, did not cause atrophy up to a dose of 5mg/20g (Fig. 2.5D), indicating toxicity is not a
general feature of SERMs. On the other hand, intraperitoneal injection of raloxifene induced Cre
recombinase-mediated lacZ activation in mice expressing Rosa26-Cre fused with a modified ER
(Fig. 2.5E), indicating that raloxifene can be used to induce Cre recombinase activity to obviate
the off-target toxicity of tamoxifen in Cre-loxP inducible systems.
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Fig. 2.6. SPEM induction by tamoxifen is ameliorated by omeprazole treatment. A: Wild-type
mice injected with the proton pump inhibitor, omeprazole, in conjunction with tamoxifen (right)
are partially protected from SPEM induced by tamoxifen alone (center). Omeprazole, by itself,
does not have any effect on the stomach mucosa (left). B: Tamoxifen and omeprazole co-treated
mice show higher numbers of H+/K+ ATPase expressing parietal cells (right) when compared to
those treated with only tamoxifen (center). Omeprazole alone does not alter the number of H+/K+
ATPase (Atp4) expressing parietal cells (left). These results are quantified in (D). C: Tamoxifen
and omeprazole co-treated mice show lower numbers of BrdU positive proliferating cells (right)
when compared to those treated with only tamoxifen (center). Omeprazole alone does not alter
the number of BrdU positive proliferating cells (left). These results are quantified in (E).
Tamoxifen is a chemotherapeutic drug that has toxic effects on cancer cells from diverse tissues.
In osteoclasts (which, like PCs, are large, mitochondria- and proton pump-rich cells), toxicity is
caused by disrupting proton gradients and, thereby intracellular pH [20]. The drug DMP-777
causes PC death the same way [19]. Omeprazole is partially protective against both DMP-777
and tamoxifen toxicity, suggesting a similar mode of action [19]. The minimal dosing that causes
metaplasia in the current study is an order of magnitude more than the equivalent (40 mg/day)
used therapeutically in humans [21]. Acute loss of PCs in patients taking tamoxifen might be
beneficial for acid-reflux associated illness but could also predispose, long-term to gastric
cancer. Further experiments are clearly needed to address effects of tamoxifen on the human
stomach.
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CHAPTER 3: The hyaluronic acid receptor CD44 coordinates normal and
metaplastic gastric epithelial progenitor cell proliferation
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Abstract
The stem cell in the isthmus of gastric units continually replenishes the epithelium. Atrophy of
acid-secreting parietal cells (PCs) frequently occurs during infection with Helicobacter pylori,
predisposing patients to cancer. Atrophy causes increased proliferation of stem cells, yet little is
known about how this process is regulated. Here we show that CD44 labels a population of
small, undifferentiated cells in the gastric unit isthmus where stem cells are known to reside.
Loss of CD44 in vivo results in decreased proliferation of the gastric epithelium. When we
induce PC atrophy, by Helicobacter infection or tamoxifen treatment, this CD44+ population
expands from the isthmus towards the base of the unit. CD44 blockade during PC atrophy
abrogates the expansion. We find that CD44 binds STAT3, and inhibition of either CD44 or
STAT3 signaling causes decreased proliferation. Atrophy-induced CD44 expansion depends on
pERK, which labels isthmal cells in mice and humans. Our studies delineate an in vivo signaling
pathway,

ERK→CD44→STAT3,

that

regulates

normal

and

atrophy-induced

gastric

stem/progenitor-cell proliferation. We further show that we can intervene pharmacologically at
each signaling step in vivo to modulate proliferation.
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Introduction
Tumors of the stomach are the second leading cause of cancer-related death worldwide [1, [2].
Most of these tumors occur in the setting of chronic infection with the bacterium Helicobacter
pylori, which causes atrophy (death) of the acid-secreting parietal cells (PC). PC atrophy, in turn,
causes precancerous, metaplastic changes in other epithelial cells [3, [4, [5, [6]. In normal
corpus gastric units, PCs concentrate in the middle (neck) portion amongst mucous neck cells
(NCs) [7] and below the isthmus that houses the stem cell. Classical
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P-radiolabeling studies

indicate that one or a few cells in the isthmus constantly regenerate cells that undergo
bidirectional migration, up to the mucosal surface and down to the gland base, as they
differentiate into mature cells of the gastric unit [4, [8]. NCs migrate slowly from their birth
into the base, where they rapidly transition into digestive enzyme-secreting zymogenic cells
(ZCs).
PC atrophy in humans, mice and other model animals causes existing ZCs to re-express NC
markers [6, [9, [10, [11]. This aberrant ZC differentiation pattern is known as Spasmolytic
Polypeptide Expressing Metaplasia (SPEM) due to greatly increased expression of the NC
marker Spasmolytic Polypeptide (TFF2). PC atrophy also causes increased proliferation of
normal stem/progenitor cells in the isthmus [6, [7]. The pattern of chronic PC atrophy and
SPEM has been associated with 90% of resected gastric cancers and is thought to be a key
predisposing factor, but the molecular mechanisms causing SPEM as well as progenitor
expansion have not been elucidated [12, [13, [14]. Given that eradication of H. pylori seems to
cause only partial reversion of metaplasia and risk for cancer [15, [16, [17, [18], developing
additional treatment strategies that would encourage reversion of these lesions can potentially
greatly decrease the risk for gastric cancers worldwide.
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Our understanding of the molecular regulation of gastric corpus isthmal stem cell proliferation,
even under normal homeostasis, is still rudimentary despite considerable recent work having
elucidated gene products marking stem cells in the intestines (e.g. LGR5 [19], LRIG1 [20],
BMI [21]) and even in the more distal gastric antrum [19, [22]. A handful of molecular
pathways and markers [23, [24, [25] have been proposed for the gastric epithelium, but no
mechanistic studies revealing molecules that regulate proliferation of the canonical isthmal stem
cell either under normal conditions or in response to injury have been reported [4]. Furthermore,
the mechanisms underlying altered patterns of stem cell behavior during precancerous conditions
in any tissue are only beginning to be explored.
We have recently shown that a ≥3mg/20g body weight dose of tamoxifen is toxic specifically to
PCs, in an estrogen receptor independent manner, within the mouse stomach [26]. Nearly all
PCs atrophy by 3 days after a single intraperitoneal injection of tamoxifen, and death begins
within hours, leading to SPEM [26] that eventually reverses several weeks later if no more
tamoxifen is injected. PC death is accompanied by a rapid activation of stem and progenitor cells
in the isthmus region [26]. Thus, tamoxifen causes PC atrophy and isthmal stem cell activation
that is rapid, synchronous, and robust, affording us a novel tool to study the induction of stem
cell activity in response to PC atrophy within an animal model. Here, we report the signaling
mechanisms by which gastric corpus epithelial stem cells maintain homeostasis. We find that
CD44 labels undifferentiated, proliferating cells within the isthmus, which expand dramatically
during atrophy induced by Helicobacter infection and tamoxifen. Baseline isthmal progenitor
proliferation is reduced in Cd44−/− mice. Moreover, wild-type (WT) mice treated with PEP-1, a
peptide that blocks the interaction between hyaluronic acid (HA) and CD44, also show both
inhibited normal proliferation as well as blocked expansion during atrophy. We next show that,
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along with CD44, STAT3 phosphorylation is critical for isthmal cell proliferation in response to
injury and that STAT3 activation depends on CD44. We find ERK signaling is activated almost
immediately following PC damage and acts as the upstream modulator of Cd44 and the atrophy
induced proliferative response, as determined by a kinase activation screen. Finally, we show that
cells expressing pERK in their nuclei expand in the isthmus of mice during PC atrophy and in
atrophic and metaplastic lesions in human patients. Our results identify for the first time an in
vivo signaling pathway that mediates the response of the normal stem/progenitor cell
compartment to a metaplasia inducing injury.

Materials and Methods
Animals and injections- All experiments involving animals were performed according to
protocols approved by the Washington University School of Medicine Animal Studies
Committee. Mice were maintained in a specified-pathogen-free barrier facility under a 12 hour
light cycle. Wild-type C57BL/6 and CD44─/─ mice were purchased from The Jackson
Laboratory. Mice from all treatment groups were given an i.p. injection of a mixture of 5-bromo2’-deoxyuridine (BrdU, 120 mg/kg) and 5-fluoro-2’-deoxyuridine (12 mg/kg) 90 minutes before
sacrifice to label S-phase cells. Vehicles used for all injections are: sterile water, sterile saline,
ethanol in sunflower seed oil, or DMSO in sunflower seed oil; no phenotypes were induced by
injection of any of the vehicles alone.
Table 3.1: Mice treatments and injections
Treatment Dose
Vehicle
(body weight)
Tamoxifen 5mg/20g
10% ethanol +
90% sunflower
seed oil
U-0126
50mg/kg
10% DMSO
(Sigma) + 90%
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Injection
Source
Scheme
i.p. one day, Sigma
sacrificed
as
indicated
i.p. one hour Sigma
before
and

WP1066

2mg/20g

Hyaluronan 30mg/kg
(HA)
PEP-1
(5 week)

40mg/kg

PEP-1
(3 days)

40mg/kg

sunflower seed
oil
20% DMSO +
80% sunflower
seed oil.

every two hours
after tamoxifen
i.p. one hour
before
and
every 12 hours
after tamoxifen
0.9%
sterile i.p. twice a
saline
week
since
weaning, for 5
weeks
Sterile water
i.p. twice a
week
since
weaning, for 5
weeks
Sterile water

EMD
Millipore
Sigma

New
England
Peptide,
Gardner,
MA
i.p. once a day New
for 3 days, England
starting one day Peptide,
before
Gardner,
tamoxifen
MA
injection

H. pylori growth conditions and murine infection- The wild-type rodent-adapted cag+ H. pylori
strain PMSS1 was cultured on trypticase soy agar with 5% sheep blood agar plates (BD
Biosciences) for in vitro passage, as previously described [27]. It was then cultured in Brucella
broth (BB, BD Biosciences) supplemented with 10% fetal bovine serum (FBS, Atlanta
Biologicals) for 16 to 18 hours at 37°C with 5% CO2. Male C57BL/6 mice were purchased from
Jackson Laboratories and housed in the Vanderbilt University Animal Care Facilities in a room
with a 12-hour light-dark cycle at 21°C to 22°C. Mice were orogastrically challenged with either
Brucella broth (BB), as an uninfected (UI) control, or with the mouse-adapted wild-type cag+ H.
pylori strain PMSS1. Mice were euthanized at 4 and 8 weeks post-challenge and gastric tissue
was harvested for immunohistochemistry.
Human Tissues- Examination of human gastric pathological tissue specimens was approved by
the Institutional Review Board of Washington University School of Medicine, the Comité de
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Bioetica of Nicaragua for Universidad Nacional Autonoma De Nicaragua – Facultad De Ceincias
Medicas Managua, and the Research Ethics Board Manager for Health Sciences at the University
of Toronto. Serial sections (4–6 μm thick) obtained from paraffin-embedded tissue samples
(H&E and alcian blue–periodic acid–Schiff stains) were reviewed by two pathologists in Italy
(M.F., and M.R.) with specific expertise in gastrointestinal diseases, and a consensus on the score
for each pertinent histologic variable was reached. Diagnoses and selection of specific regions of
transitions among normal stomach, atrophic stomach, and intestinal metaplasia was performed
by a third pathologist in the US (JCM).
Immunofluorescence and Immunohistochemistry- Stomachs were prepared, and stained, and
imaged using methods modified from Ramsey et al [28]. Immunohistochemistry was performed
using ABC reagent and DAB substrate kits (Vector Labs) as per the manufacturer’s instructions.
For BrdU/Ki67 quantifications, positive cells were counted in >50 gastric units per mouse and
>3 mice per experiment. Total number of positive cells was divided by the total number of
gastric units for each mouse. Stomachs were prepared, and stained, and imaged using methods
modified from Ramsey et al [28]. Primary antibodies used for immunostaining are listed in
Table 3.2: Primary antibodies used for immunostaining
Serial No.

Antibody

Dilution

Source

1

Goat α-BrdU

1:20,000

Jeffrey Gordon, Washington University

2

Rabbit α-pERK1/2

1:100

Cell Signaling Technology, Danvers, MA

3

Rabbit α-Ki67

1:100

Abcam, Cambridge, MA

4

Rat α-CD44

1:50

BD Biosciences, San Jose, CA

5

Mouse α-E-cadherin

1:200

BD Biosciences, San Jose, CA

6

Rabbit α-Atp4a

1:10,000

Dr. Michael Caplan, Yale University
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Hyaluronan-binding protein staining was performed as described [29]. Secondary antibodies,
lectins and BrdU labeling were as described [28].
Western Blotting – Western Blotting –Western blot analysis was performed as described [26].
Antibodies used for blotting are listed in Table 3.3. Immobilon Western Chemiluminescent HRP
Substrate (Millipore) was used for detection.
Table 3.3: Primary antibodies used for Western blotting
Serial No.

Antibody

Dilution

Source

1

Rabbit α-Cyclin D1

1:1,000

Cell Signaling Technology, Danvers, MA

2

Rabbit α-pERK1/2

1:1000

Cell Signaling Technology, Danvers, MA

3

Rabbit α-p-p38MAPK

1:1000

Cell Signaling Technology, Danvers, MA

4

Rabbit α-SAPK/JNK

1:1000

Cell Signaling Technology, Danvers, MA

5

Rabbit α-pAKT

1:1000

Cell Signaling Technology, Danvers, MA

6

Rabbit α-PLCγ

1:1000

Cell Signaling Technology, Danvers, MA

7

Rabbit α-Egr1

1:1000

Cell Signaling Technology, Danvers, MA

8

Rabbit α-pSTAT3

1:1000

Cell Signaling Technology, Danvers, MA

9

Rabbit α-STAT3

1:2000

Cell Signaling Technology, Danvers, MA

10

Rat α-CD44

1:500

BD Biosciences, San Jose, CA

11

Goat α-HAS1

1:1000

Santacruz Biotechnology Inc., CA

12

Goat α-HAS2

1:1000

Santacruz Biotechnology Inc., CA

Secondary antibodies were horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG
(1:2,000, Santa Cruz Biotenchnology, Inc.), goat anti-rat IgG (1:1000, Santa Cruz Biotechnology,
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Inc.) and donkey anti-goat IgG (1:1000, Santa Cruz Biotechnology, Inc.).
Flourescence Activated Cell Sorting - Gastric corpora were collected, washed in PBS, dissected
into ~1mm2 pieces, suspended in 1mL HBSS, and mechanically disaggregated with two 20
second pulses in a Medimachine (BD). Tissue was incubated for 1h with vigorous shaking at 37°
C in 10mL HBSS supplemented with 1mM DTT and 5mM EDTA. The cell suspension was
filtered (50μm filter, Partek) and the filtrate incubated at 37° C, 5% CO2 until staining. The
remaining mucosa/tissue left on the filter was rinsed in 10mL RPMI, then incubated at 37° C
with vigorous shaking in 10mL RPMI containing 5% BSA and 1.5mg/mL Dispase II (Stem Cell
Technologies) for 1.5 h. This cell suspension was filtered, and the second filtrate pooled with the
first, washed, and surfaced labeled for flow cytometry. Cells were stained with Alexa Fluor™
647-conjugated with either anti-mouse Epcam (Cell signaling) or Alexa Fluor™ 647-conjugated
anti-mouse E-cadherin (for some experiments), and APC-Cy™7-conjugated anti-mouse CD44.
Labeled cells were analyzed with a FACScan (BD) flow cytometer. The use of high wavelength
fluorophores avoided considerable autofluorescence of living gastric epithelial cells.
Immunoprecipitation – Immunoprecipitation was performed using the Pierce Crosslink IP Kit
(Thermo Scientific, Rockford, IL) using the manufacturer’s instructions. Rabbit anti-Stat3
(1:200, Cell Signaling Technology) was used for pull down and western blots analysis was done
as described above.
Microscopy - Light and epifluorescence micrographs were taken as described [7].
Graphing and statistics - All graphs and statistics were performed in GraphPad Prism, using
Student’s t test (one-tailed or two-tailed, as appropriate) for comparison of two groups of data
and one-way ANOVA with either Dunnett’s or Tukey’s for multiple comparison tests.
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Results
CD44 is expressed in isthmal cells and regulates normal baseline proliferation
CD44 is a cell-surface adhesion molecule, widely described as a marker of cells with highest
proliferative capacity in cancers of the breast

[30, [31], colon [32, [33], and stomach [34].

CD44 is highly expressed in gastric cancer cell lines [34], Helicobacter pylori infected human
patient epithelia [34, [35], gastric carcinomas [36, [37], intestinal metaplasia [37, [38] and
dysplasia [39]. Though CD44 is expressed in gastric tumors [34, [35, [40], its expression has
not been characterized in normal mouse corpus gastric epithelial tissue [41], but it has been
observed in the antral epithelium [34] and at the squamous-corpus junction [42]. We found that
CD44 was expressed throughout the scant interglandular mesenchymal cells (Fig. 3.1A), but
CD44+ epithelial cells could also be found in epithelial cells within the isthmus (Fig. 3.2A) and
in the foveolar/pit region of wild-type mice (Fig. 3.1A, white bracket).

53

Fig. 3.1: The CD44+ cells expanding from the isthmus upon tamoxifen induced parietal cell
atrophy were epithelial. In vehicle treated mice, there was little overlap between CD44 (red) and
the epithelial marker, E-cadherin (green) (A, note only one isthmal cell with partial CD44partial E-cadherin label in magnified box at right), but this population expanded gradually over
3 days after tamoxifen treatment (B, C). Mesenchymal CD44+ cells are labeled with a white
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bracket, and CD44+ immune cells are marked by white arrowheads. Insets show magnified
images of the cells showing overlap between CD44 and E-cadherin (yellow).

CD44+ isthmal epithelial cells were small and undifferentiated, as they did not co-stain with
markers of differentiated cells, such as AAA and GSII (Fig. 3.2A). Since CD44 is known to
affect proliferation [43], we next investigated the requirement for CD44 signaling in gastric
epithelial stem cell proliferation. In mice lacking Cd44, the basal rate of proliferation was half of
the wild type (WT) controls (Fig. 3.2B, C; n=10), suggesting a role for CD44 in normal stem cell
homeostasis. CD44 can interact with multiple ligands in the extracellular matrix such as
osteopontin, collagen, fibronectin, laminin, and chondroitin sulfate, but its principal ligand is
hyaluronan (HA) [44]. HA activates CD44 by binding to its N-terminal functional domain [45].
To determine whether direct CD44 activation was required for isthmal cell proliferation, we next
treated adult mice with PEP-1 twice a week for 5 weeks. PEP-1 inhibits CD44-mediated
signaling by blocking the binding of its ligand, HA. Blocking the CD44-HA interaction with
PEP-1 caused statistically significant decrease in proliferation of normal stem cells to levels
phenocopying Cd44−/− mice (Fig. 3.2D n= 12 mice total, 3 mice per experiment, 50 gastric units
analyzed per mouse).
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Fig. 3.2: CD44 labels undifferentiated cells in the normal stem cell zone, i.e. the isthmus, of
the gastric unit, and its loss stunts basal rates of proliferation. In the normal mouse gastric
unit, CD44 labeled small, distinct cells in the isthmus region (A). Mice lacking the Cd44 gene
have about half the number of proliferating cells per gastric unit compared to WT controls (B,
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C). PEP-1 is a peptide inhibitor which blocks the interaction between hyaluronic acid and
CD44. Treatment with PEP-1 for 5 weeks reduces basal rates of proliferation (D), and results in
lower numbers of pit cells (E), similar to the Cd44−/− animals (E). In all figures: *P<0.05,
**P<0.01, ***P<0.001.

Cd44−/− gastric units also showed stunting of the gastric unit zone between the gastric lumen and
the isthmus, the pit/foveolar zone (Fig. 3.3A,B) and overall decreased census of pit cells (Fig.
3.2E), a phenotype that was recapitulated by 5-week treatment of WT mice with PEP-1 (Fig.
3.2E, 3.3C). Pit cells slough rapidly after emergence from the isthmal stem cell zone (half-life of
~3 days [46]) and would be expected to be most affected by decreased stem cell proliferation due
to their high turnover rate. We also treated mice for 5 weeks with HA, which caused statistically
significant increased isthmal cell proliferation (Fig. 3.3E, n=7) and pit/foveolar zones relative to
wild type (Fig. 3.2E), showing that injection of the CD44 activating ligand was sufficient to
induce increased proliferation and further confirming a direct role of CD44 signaling in
regulating isthmal stem cell proliferation. PCs and other non-pit cell epithelial lineages did not
differ in their baseline census whether CD44 was activated, inhibited or deleted (Fig. 3.3F).
Taken together, our data indicate that CD44 is expressed in undifferentiated epithelial cells
within the isthmus and regulates normal rates of gastric epithelial stem cell proliferation.

57

Fig. 3.3: Loss of functional CD44 caused abbreviated pit/foveolar regions. While wildtype mice
showed long pit regions (A) with ~11 pit cells per unit (Fig. 1D), Cd44─/─ mice showed shorter
pits with almost 2-fold reduced number of normal foveolar cells per unit (B, Fig. 1D). Mice
treated with PEP-1, showed a similar foveolar phenotype as Cd44─/─ (C), whereas, those treated
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with the CD44 ligand HA showed longer pit regions (D) with an average of ~13 foveolar cells
per unit (Fig. 3.2D) and almost twice the rate of proliferation of WT mice (E). None of the
conditions changed the parietal census significantly (F). In all figures: *P<0.05, **P<0.01,
***P<0.001.

Infection with Helicobacter pylori causes PC atrophy and expansion of CD44 into the base of
gastric units
We sought to determine whether CD44 expression in gastric epithelial cells was affected by PC
atrophy, which induces proliferation in mice and humans. Infection of humans with CagA+
strains of H. pylori is a major predisposing factor for the development of gastric adenocarcinoma
[47]. We infected WT mice with a CagA+ strain of H. pylori, PMSS1, for 8 weeks (n=5 mice). As
expected, in uninfected mice, there was no parietal cell death (Fig. 3.4A, left green arrowhead
indicates a PC), and CD44 was expressed in the epithelium in the isthmus (Fig. 3.4B, C, left;
orange arrowhead). In contrast, 8 weeks after H. pylori infection, most PCs were atrophic (Fig.
3.4A, right, note only rare residual PCs in a section of the gastric corpus, green arrowheads), and
CD44 expression was found diffusely in the base of gastric units (Fig. 3.4B, C) in zymogenic
cells which co-expressed the neck cell marker, GSII (yellow arrowheads), indicating they were
metaplastic.
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Fig. 3.4: Helicobacter pylori infection causes parietal cell atrophy and expansion of CD44
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expression. Hematoxylin and eosin stained sections of wild-type, uninfected mice show healthy
parietal cells (A, left, green arrowhead), whereas, those infected for 8 weeks with the cag+
PMSS1 strain of H. pylori show diffuse loss of parietal cells (A, right). The gastric unit is largely
replaced with metaplastic cells (A, right; brown arrowheads), and only a few parietal cells
remain (A, right; green arrowheads). CD44 also labels occasional immune cells infiltrating
interglandular regions (B, right; beige arrowheads). CD44 is expressed in the uninfected gastric
epithelium in the isthmus (B,C blue box; orange arrowheads) but expands to the base of the unit
upon infection with H. pylori (B, right, yellow box). In uninfected mice, the zymogenic cells do
not express CD44 (C, left, white arrowheads), however, upon infection, they become metaplastic
and express neck cell markers such as GSII (red) as well as CD44 (C, right, yellow arrowheads).
In mice infected with H. pylori for a shorter time period of 4 weeks, (D), CD44 expansion can be
seen to extend from the isthmus (purple box) and into the base (orange box) in some gastric
units. Exemplar CD44+ cells are marked with purple arrowheads (D, insets); gastric units are
outlined by dashed white line.

Tamoxifen induced parietal cell atrophy causes a burst of CD44+ progenitor cell proliferation
H. pylori infection in mice and humans is chronic and often focal and asynchronous across the
stomach. Elucidation of the molecular mechanisms underlying atrophy-induced proliferation in
the stomach requires a system for inducing atrophy that is synchronous, rapid, and global
throughout the whole stomach. We have shown that a single injection of 5mg/20g body weight of
tamoxifen causes dramatic rearrangement of the gastric mucosa, an effect that does not depend
on the estrogenic or anti-estrogenic effects of tamoxifen but instead causes direct PC toxicity
[26]. Fig 3.5 shows how within 3 days, over 90% of PCs atrophied, yet complete recovery of PC
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census occurred by 21 days (Fig. 3.5A and [26]). As PCs atrophied, proliferation accelerated in
the normal stem cell region, the isthmus, reaching 6-fold baseline levels by day 3 (Fig. 3.5B, C
and ref [26]). Even by 12h, almost half of the PCs had atrophied, and isthmal progenitor cells
could be seen expanding towards the base of the unit, the region vacated by dying PCs (Fig.
3.5B, C). Western blots showed that CD44 and the proliferation markers, PCNA and cyclin D1,
increased throughout the gastric corpus (Fig. 3.5D).
In short, tamoxifen causes PC atrophy, increased CD44 expression, and proliferation, similar to
infection with Helicobacter but has a rapid and synchronous timeframe for atrophy and injury
response across the whole stomach allowing for biochemical analysis of the process.
Furthermore, we have shown previously that tamoxifen treatment does not cause substantial
inflammatory cell infiltrate [26]. Unlike infection with CagA+ Helicobacter; the changes are
almost wholly confined to the mucosal cells already present at time of treatment, reducing
confounding variables in analyzing differences in global analysis of changes in signaling
pathways and gene expression.

62

Fig. 3.5: CD44 expands and labels proliferating cells upon parietal cell atrophy and is
required for this injury induced expansion of progenitor cells. Hematoxylin and eosin stained
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sections of wild-type mice at 3 days (A, left) following intraperitoneal (i.p.) injection of vehicle,
and, at 12 hours (A, middle) and 3 days (A, right) following i.p. injection of 5mg/20g body
weight of tamoxifen. Wild-type mouse stomach treated with vehicle shows normal stomach
epithelium, whereas, those injected with tamoxifen show a progressive loss of PCs. PC loss is
coupled with an expansion in proliferation, measured by BrdU incorporation (stained in red), at
12 hours (B, middle; C) and 3 days (B, right; C) after tamoxifen treatment, compared to vehicle
controls (B, left; C). Cyclin D1 and PCNA, which are markers of proliferation, are also
increased on PC atrophy at 12h and day 3 by western blot of whole corpus stomach regions (D).
The blot also shows that CD44 expression increases upon atrophy.

A CD44+ epithelial

population starts expanding from the time-point (6h) when PCs first begin to die (E) and reaches
the base of the unit by day 3 (E). The number of CD44+ epithelial cells expands ~3-5 fold during
this time, as shown by multiple FACS experiments (F). One of the FACS plots graphed in F is
shown in G. Many CD44 expressing cells co-stain with Ki67 after treatment with tamoxifen (H,
yellow box is magnified in inset at right).

We next set out to use tamoxifen-induced atrophy as a tool to determine the origin of CD44+
cells following PC atrophy. CD44+ isthmal cells began to expand as early as 6h after tamoxifen
injection (Fig. 3.5E). The initial increase in CD44-positive epithelial cells occurred in the isthmal
progenitor zone, from which they expanded into the base until there were CD44 and E-cadherin
double positive epithelial cells from isthmus to base by D3 (Fig. 3.5E, Fig. 3.1B,C). This pattern
was similar to the chronic CD44 labeling that occurred in the base of Helicobacter-infected
corpus units. By day 3, many of the CD44+ cells in the base labeled SPEM-type metaplastic
cells, co-labeling with GSII (Fig. 3.5E). We next decided to look at an earlier time point in our
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Helicobacter infected mice (4 weeks post infection) to determine whether, in certain units,
CD44+ cells could also be identified expanding from the isthmus as occurred shortly after
tamoxifen-induced atrophy. Fig. 3.4D shows that, whereas many units already show full
metaplasia with GS-II+/CD44+ cells only at the base, as in the 8-week post-infection animals,
some units showed CD44 extending from isthmus to the base.
We next quantified the expansion of CD44+ epithelial cells. Their census increased ~3 to 5-fold
over the course of the three day tamoxifen treatment, as determined by flow cytometry (n= 18
mice across 9 experiments) (Fig. 3.5F, G, Fig. 3.6).
Fig. 3.6: CD44+ epithelial cells
expand 5-7 fold upon parietal cell
atrophy as quantified by FACS. A
representative FACS graph from an
experiment

shows

that

CD44+

epithelial cells increase ~5-7 fold
upon treatment with tamoxifen for
12h and day 3 compared to vehicle
controls.
Furthermore, there was extensive co-labeling of the CD44+ population (at 12h) with the
proliferation marker Ki67 (Fig. 3.5H). CD44’s activating ligand, HA, was found in the
mesenchyme between gastric glands (Fig. 3.7A) and increased following atrophy, as did the
enzymes that synthesize it, HAS1 and HAS2 (Fig. 3.7B).
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Fig. 3.7: Hyaluronic acid (HA), a ligand of CD44, was
increased upon atrophic injury with tamoxifen. HA
(stained using Hyaluronan-binding protein; in green)
and CD44 (red) were increased in expression towards
the base of the gastric unit during tamoxifen induced
metaplasia (A, arrowheads). HAS1 and HAS2, enzymes
that synthesizes HA, were also increased by 12h of
tamoxifen treatment (B).
Thus, both CD44 and HA were increased in expression in tandem, following atrophy, with HA
present in the region of the basement membrane of the epithelial cells expressing CD44. During
response to PC atrophy, Cd44─/─ mice showed a statistically significant reduction in isthmal
proliferation compared to controls (n=6 mice, 2 experiments) (Fig. 3.8A), and a short, 3 day
pretreatment with PEP-1 was sufficient to nearly completely abrogate the proliferative response
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induced by PC atrophy (Fig. 3.9; n=5, 2 experiments).

Fig. 3.8: Cd44─/─ mice have compensatory mechanisms for increasing proliferation following
tamoxifen induced atrophy. When treated with tamoxifen, Cd44─/─ mice were able to increase
proliferation to almost normal levels (A; one-tailed, paired Student‟s t test), despite the defect in
basal levels of proliferation. Although there was a decrease in pSTAT3 in the Cd44─/─ mice (B),
similar to PEP-1 treatment (Fig. 6E), Cyclin D1 levels did not change in the Cd44─/─ mice (B),
suggesting that there might be a CD44-STAT3 independent compensatory mechanism in these
mice that regulates proliferation in the face of atrophy.
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Fig. 3.9: CD44 is necessary for elevating the
rate of progenitor cell proliferation upon
induction of atrophy. PEP-1 blockade of
CD44 activation halves atrophy induced
proliferation (B, C), measured by BrdU
incorporation (red, B), whereas parietal cells
still die upon PEP-1 inhibition of CD44 (A).

Thus, both stem cell normal homeostasis and response to PC atrophy are mediated by HA-CD44
interactions, though in mice null for Cd44 from conception, compensatory mechanisms allow for
some degree of non-CD44-mediated proliferation increase (note in Fig. 3.8B that atrophy still
caused an increase in cyclin D1 expression in Cd44−/− mice).
Therefore, our data show that CD44: (a) is expressed by cells in the normal stem cell
compartment; (b) marks proliferating progenitor cells during injury, and; (c) is necessary for
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maintaining the normal and injury-responsive proliferative capacity of the gastric units. We next
sought to determine the mechanism by which CD44 regulates progenitor cell proliferation.

CD44 regulates gastric progenitor cell proliferation through STAT3
Signal transducer and activator of transcription 3 (STAT3) controls diverse cellular functions,
such as growth, differentiation and apoptosis [48]. When activated by cytokines and growth
factors, STAT3 localizes to the nucleus and regulates transcription of target genes that control
proliferation and apoptosis [34, [48, [49]. STAT3 increases normal and cancer stem cell
proliferation [50] by inducing its targets survivin and cyclin D1 [51, [52] and is activated by
cagA+ strains of H. pylori in host cells, in vitro and in vivo [53]. CD44 increases cyclin D1
expression by directly interacting with active STAT3 [54]. As we observed increased
proliferation and cyclin D1 expression in the CD44-dependent response of the gastric unit to PC
atrophy, we hypothesized that the mechanism of CD44 action might be via STAT3-cyclin D1.
Consistent with our hypothesis, we found that while activated STAT3 (STAT3 phosphorylated on
Tyr 705) was at low levels in normal mucosa, there was abundant p-STAT3 during atrophy (Fig.
3.10A). We then checked whether STAT3 bound CD44 by co-immunoprecipitation and found
indeed that there was more CD44 associated with STAT3 in response to atrophy (Fig. 3.10B)
when compared to controls. Immunoprecipitated STAT3 was phosphorylated only in tamoxifen
treated samples and not in control or Cd44─/─ stomachs (Fig. 3.10B). STAT3 phosphorylation
was also decreased in the absence of CD44 or when CD44-HA interactions were blocked by
PEP-1 (Fig. 3.10C, 3.8B). CD44 expression was also reduced by PEP-1 blockade of its HA
ligand (Fig. 3.10C). When we blocked STAT3 activation by injecting its specific inhibitor,
WP1066 [55], with and without tamoxifen, we found that STAT3 inhibition greatly reduced
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atrophy-induced cyclin D1 expression and stem cell proliferation (Fig. 3.10D,E), without
affecting CD44 expression (Fig. 3.10E). Hence, we conclude that STAT3 is activated upon injury
in the gastric epithelium, and CD44 binds to STAT3 to regulate the injury-induced burst of
proliferation of progenitor cells.

Fig. 3.10: CD44 regulates gastric progenitor
cell proliferation through STAT3. STAT3 is
activated by tyrosine phosphorylation after
atrophy induction with tamoxifen (A).
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IP with antibody against STAT3 followed by Western blot for CD44 shows increased association
between CD44 and STAT3 during tamoxifen-induced atrophy, compared to controls; also
phosphorylated STAT3 was pulled down only during tamoxifen induced atrophy (B). Inhibition of
STAT3 and CD44 functions (using WP1066 and PEP-1 respectively) causes decreased Cyclin D1
expression (C, E) and proliferation as quantified in tissue using BrdU (D); “D1”= 1 day post
tamoxifen; “D2” = 2 days. CD44 levels were not affected by STAT3 inhibition, whereas, pSTAT3
was significantly reduced upon CD44 inhibition with PEP-1 (C, E). CD44 expression is reduced
upon blocking interaction with its HA ligand by PEP-1 (C).

ERK signaling regulates progenitor cell proliferation through CD44
To determine the upstream signal causing CD44 expansion and increased proliferation, we
surveyed multiple signaling pathways known to affect proliferation, such as the MAP kinases
(p38MAPK, ERK, and JNK), AKT, and PLCγ in tamoxifen-induced atrophy. Whereas most
proliferation mediators were either not substantially or only marginally increased, there was a
dramatic increase in active ERK at the time of peak atrophy (Fig. 3.11A). ERK is known to
increase proliferation in normal [56] as well as neoplastic cells [56, [57], though its role in
gastric stem cell homeostasis has not previously been assessed. Accordingly, ERK was strongly
activated as early as 6 hours after treatment with tamoxifen (Fig. 3.11B), which was further
confirmed by the concomitant increase in expression of its downstream target, EGR1 as well as
CD44 (Fig. 3.11B) [58]. If ERK signaling was indeed involved in regulating proliferation in the
gastric epithelium following PC atrophy, blocking it should block atrophy-induced proliferation.
ERK phosphorylation can be blocked with the kinase-specific inhibitor of MEK, U-0126 [59].
We co-injected mice intraperitoneally with U-0126 along with tamoxifen. Fig. 3.11C shows that
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U-0126 successfully blocked ERK phosphorylation in the stomach during tamoxifen-induced
atrophy and prevented a downstream increase in ERK’s transcriptional target EGR1 [60, [61].
Confirming our hypothesis that pERK mediates PC-atrophy induced CD44, U-0126 injection
into mice blocked the increase in CD44 (n= 10 mice across 3 experiments) (Fig. 3.11C). We
observed similar results with another inhibitor of ERK activation, PD 98059 [62] (unpublished
data; n= 3 mice, two experiments). As expected, ERK inhibition also blocked the proliferative
response to atrophy (Fig. 3.11D, E), much like loss or inhibition of CD44. BrdU incorporation
per gastric unit, at 12h post tamoxifen treatment, was reduced by 56 ±5% (n=3 mice; 50 gastric
units counted per mouse) in mice treated with U-0126 compared to those receiving tamoxifen
and vehicle.
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Fig. 3.11: ERK signaling is activated early upon
induction of injury and is required to induce CD44.
Western blots of candidate signaling pathways that might
be involved in increasing the proliferative response after
PC atrophy by tamoxifen (A). Of the pathways analyzed,
only ERK signaling shows a dramatic increase in
activation after tamoxifen, compared to vehicle controls.
ERK1/2 are tyrosine phosphorylated soon after PC
damage ensues (6 hours after tamoxifen treatment);
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EGR1 and CD44, downstream targets of ERK signaling, are already increased in expression at
this early time point (B). Co-injection of tamoxifen with U-0126, a specific inhibitor of ERK
phosphorylation, mutes the metaplastic induction of pERK along with downstream targets, EGR1
and CD44 by western blot (C), and mutes the proliferative response shown by BrdU
immunostaining in red (D), quantified in (E).

ERK signaling is increased in multiple models of gastric metaplasia and labels isthmal cells
If ERK activation mediates the expansion of stem/progenitor cells, then phosphorylated ERK
should be identifiable within those cells. In agreement, Fig. 3.12A, B show that, whereas control
mice showed no detectable pERK, 6 hours following induction of atrophy, we identified 2-3
undifferentiated cells per unit with nuclear pERK within the canonical isthmal stem cell zone
(Fig. 3.12A, B). pERK could also be detected in multiple cell nuclei per unit in tox176 mice
[63] that show constitutive PC atrophy due to PC-specific expression of attenuated diphtheria
toxin (unpublished data) and in mice 8 weeks after infection with Helicobacter (Fig. 3.14A, right
panels) whereas pERK was completely absent in uninfected controls (Fig. 3.14A, left panels).
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Fig. 3.12: pERK labels metaplasia-associated cells in mice and humans. pERK labels nuclei of
isthmal progenitor cells (orange arrowheads) at 6 hours of tamoxifen treatment (A, B), whereas,
there is no pERK signal in vehicle treated controls. PCs do not stain positive for pERK in either
vehicle or tamoxifen treated mice. Gastric units of human patients showing focal intestinal
metaplasia (C, right) in a region with mixed gastric and intestinal differentiation (magnified in
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E), indicating transitional/early metaplasia (goblet cell is marked with a yellow arrowhead)
stain positive for pERK (green arrowheads). Quantification of pERK expression in human IM
patients (n=3) displaying such a transitional epithelium by counting the number of pERK + cells
in the „intestinal metaplasia (IM)‟ regions and in residual gastric-differentiation regions
„adjacent to IM‟ epithelium vs. those in normal humans, shows a dramatic increase in pERK+
cells in IM regions, with a significant increase in pERK+ cells even in gastric regions adjacent to
IM when compared to normal human patients (D).
Serial histological sections immunostained with anti-pERK and anti-CD44 from mice injected
with tamoxifen for 12h showed a population of positive cells in the same location in the isthmus
(Fig. 3.13).

Fig. 3.13: CD44 and pERK label the same population of cells as they start expanding from the
isthmus during tamoxifen induced metaplasia. Immunohistochemical staining of serial sections
of mouse stomachs treated for 12h with tamoxifen show that CD44 (yellow arrowhead) and
pERK (green arrowheads) label a similar, overlapping population of isthmal cells during
atrophy.
Finally, we examined a small cohort (n=3) of human gastric resection specimens for pERK
staining [10]. pERK+ cells were almost never observed in normal control stomach specimens
(Fig. 3.12C) or in regions without atrophy. However, pERK+ epithelial cells could be found in
regions of gastric differentiation neighboring or contiguous with intestinal metaplasia (Fig.
3.12C, magnified in 3.12E). pERK+ cells were also particularly prominent in intestinal
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metaplasia lesions that neighbored regions of gastric differentiation. To test this pattern of pERK
staining in regions of transition between normal and metaplastic differentiation in a broader
cohort of samples, we extended our study to include ten more gastric specimens with chronic
parietal cell atrophy and inflammation caused by infection with Helicobacter pylori.
The specimens were acquired in collaboration with an international consortium studying gastric
carcinogenesis in Nicaragua (http://gcbiomarkers.org/). 8/10 of these specimens showed the
same pattern of pERK staining, with high pERK staining in transition regions adjacent to
metaplastic tissue. One specimen did not display metaplasia nor did it stain with pERK. The
remaining sample did not stain with pERK even though it displayed intestinal metaplasia. We
took 3 random pERK stained patient slides and quantified regions showing transitions between
gastric and intestinal differentiation. In regions of intestinal metaplasia with residual gastric
epithelium, there were 11±3.46 pERK+ cells per high power field of 60X magnification
(quantification from n=3 different patient specimens, representative of staining patterns observed
in 9/11 specimens; p<0.01). In the gastric epithelium adjacent to intestinal metaplasia, pERKpositive cells were also increased significantly (3.67±1.15 per hpf, p<0.05) compared to regions
in the same specimens that had residual normal differentiation patterns with preserved parietal
cells (~0.33 pERK+ cells per hpf) (Fig. 3.12D; Fig. 3.14B,C).
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Fig. 3.14: ERK signaling is activated after parietal cell atrophy in both, humans and mice.
Immunohistochemical staining for pERK showed numerous positive nuclei of metaplastic cells in
mice infected with the PMSS1 strain of H. pylori (A; green arrowheads), whereas uninfected
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controls did not stain positive for pERK (A). pERK staining was also observed in gastric tissues
of human patients undergoing intestinal metaplasia (B, C; green arrowheads) in regions of
transition between normal gastric tissue and glands developing early intestinal metaplasia with
appearance of goblet cells (yellow arrowhead).

Given the data in humans and mice, we posit that activation of ERK signaling plays a key role in
the cell proliferative response to PC atrophy and is the upstream regulator of the CD44-STAT3
proliferation axis.

Fig. 3.15: Model for stem/progenitor cell renewal during normal and atrophic injury
conditions. The isthmal stem cell (SC) is self-renewing and also gives rise to acid-secreting
parietal cells (PCs), among other cell-types within the stomach. Upon atrophy of PCs, by toxins
or H. pylori infection, the SCs activate ERK to ramp up proliferation. ERK activation is required
for expanded CD44 expression and the association between CD44 and pSTAT3, which in turn,
upregulates Cyclin D1 to drive proliferation.
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Discussion
Here we demonstrate that parietal cell atrophy, which increases the risk for gastric cancer [64],
causes increased isthmal stem/progenitor cell proliferation, which depends on activation of ERK.
ERK induces CD44, which is critical for both normal proliferation and the atrophy-induced
expansion. CD44 signaling maintains normal proliferation and increases proliferation following
PC atrophy via interaction with its ligand HA. STAT3 binds CD44 and is phosphorylated only
when CD44 is present and can interact with its ligand HA. Inhibition of STAT3 phosphorylation
inhibits atrophy-induced stem cell proliferation but does not affect increased expression of
CD44.

Thus,

we

conclude

that

atrophy-induced

proliferation

depends

on

an

ERK→CD44→STAT3 axis.
To our knowledge, this is the first report delineating an in vivo mechanism for isthmal cell
expansion almost immediately after PC damage and atrophy. We utilize tamoxifen treatment as a
rapid, synchronous, and inducible model for PC atrophy that recapitulates what we observe in
mice in chronic Helicobacter pylori infection. Soon after PC atrophy begins, there is a dramatic
increase in activation of ERK in isthmal cells, possibly due to release of a damage-induced proproliferative signal or loss of a proliferation-inhibiting signal from the surrounding PCs. Our
finding that ERK is critical for inducing stem cell proliferation is consistent with other reports. In
the juvenile rat, premature weaning also induces isthmal proliferation that depends on ERK
signaling [65]. In patients infected with H. pylori, it has been proposed that bacterial CagA
activates the ERK cascade in gastric epithelial cells, which initiates the development of gastric
cancer [66]. It has also been shown that systemic constitutive activation of the K-ras oncogene,
which is upstream of ERK in the ERK-MAPK pathway, causes gastric hyperplasia and increased
proliferation [67]. It appears that ERK is a consistent injury-induced proliferative signal in
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precancerous lesions of the gastrointestinal tract, such as esophageal dysplasia [68], Barrett’s
adenocarcinoma cells [69] and pancreatic ductal adenocarcinoma [70].
Once active, ERK increases the expression of its target CD44. CD44 expression expands from
the isthmus soon after PC damage. CD44 is a well-known cancer stem cell marker and co-labels
proliferating cells in the gastric epithelium upon injury. CD44 labels a population of cells that
includes the LGR5+ population in the bases of the pyloric glands [19] (unpublished data);
however, we show here it also labels occasional, small epithelial cells in the corpus gastric unit
isthmus. Lack of CD44 signaling, in Cd44−/− mice and in mice treated with PEP-1, stunts stem
cell proliferation. Cd44−/− mice display a defect in the numbers of pit cells possibly due to faster
turnover rate of these cells compared to parietal and other epithelial cells, which leads to an
accumulation of the deficit over time. Another explanation for this observation could be that
CD44 might regulate pit cell progenitor proliferation selectively, since we do observe
mesenchymal CD44 accumulation adjacent to pit cells.

When subjected to PC injury by

tamoxifen, the PEP-1 mice are unable to elicit the same proliferative response as control mice,
whereas Cd44 nulls are better at coping with PC atrophy, probably due to compensatory
mechanisms established during lifelong lack of CD44. This is confirmed by the fact that while
PEP-1 treated mice do not show an expansion in cyclin D1 expression following injury, the
Cd44−/− mice are still able to elevate cyclin D1 to control levels, suggesting they have developed
other ways of responding to injury that are independent of the normal CD44-dependent
mechanism. Both PEP-1 treated and Cd44−/− mice, when injured with tamoxifen, undergo PC
atrophy, establishing that the proliferative response is downstream of the initial attack of
tamoxifen, i.e. the ablation of PCs (note in Fig. 3.9C, PEP-1 treated mice have lower
proliferation, even though there are almost no PCs remaining). It will be interesting to see
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whether loss of CD44 in Cd44−/− or PEP-1 inhibited mice affects the course of H. pylori
infection. In addition to its role in proliferation, CD44 has recently been shown to impart cells
with resistance against reactive oxygen species (ROS) [71]. As most gastric pathology involves
inflammatory responses, and inflammation induces the release of ROS, CD44 might play a dual
role in overcoming such injurious stimuli – by increasing proliferation and protecting the
dividing cells from the surrounding toxicity, thereby increasing their lifespan.
CD44 induces cyclin D1 by associating with active STAT3 [54]. Abolishing STAT3 activity
decreases proliferation in spite of PC atrophy, without affecting Cd44 expression. Tamoxifen
treated Cd44−/− and PEP-1 injected mice show reduced pSTAT3, establishing a role for CD44 in
STAT3 activation in a feed-forward proliferation circuit. Interestingly, Cd44−/− mice are able to
increase cyclin D1 without the presence of active STAT3, confirming that the CD44-independent
mechanism regulating proliferation in cases of acute PC injury is also STAT3-independent. As
PEP-1 has a more dramatic effect on atrophy induced proliferation than loss of CD44, it is
possible that HA signaling through its other receptors, such as TLR4 [72], which would be
blocked by PEP-1 but would still function in Cd44−/− mice, might compensate loss of CD44.
However, treating Cd44−/− mice with PEP-1 does not further reduce the rate of proliferation in
uninjured mice (unpublished data), suggesting that HA receptors other than CD44 might not play
key roles in maintaining normal stem cell turnover.

Taken together, it appears that the

ERK→CD44→STAT3 axis is involved in expansion of proliferating isthmal stem/progenitor
cells under conditions of acute injury.
There is only a scant literature on the intracellular signaling pathways that regulate nonneoplastic turnover of progenitor cells in the corpus [4]. On the other hand, some of the signals
regulating stem cell response extrinsically have been identified. For example, Sonic hedgehog
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and BMP2/4/7 are critical for regulation of normal stem cell turnover because deficiencies in
those factors cause increased isthmal proliferation [73, [74], though those effects might be
indirect via loss of PCs causing decreased acid and increased gastrin, which is a known corpus
stem cell mitogen [75, [76]. Gastrin works in part by stimulating histamine release by
enterochromaffin cells, which also regulates proliferation of isthmal stem cells [77, [78, [79].
EGFR stimulating factors like EGF, TGFα, and Amphiregulin work through ERK and other
downstream signaling pathways; all cause increased proliferation [80, [81].
It is unclear which ligand stimulates activation of ERK in the responsive isthmal cells. It might
be derived from neighboring dying PCs. We do not believe the early stem cell response to
atrophy we observe depends on gastrin, as gastrin transcript levels are unchanged until at least 3
days following tamoxifen treatment [26]. Signaling through the EGFR receptor tends to cause
pit/foveolar cell specific proliferation as opposed to stimulation of the multipotent, isthmal stem
cell [82]. Thus, EGF family ligands are less likely candidates.
Inhibition of the ERK pathway decreases proliferation and CD44 expression. Though regulation
of biological processes like proliferative response to injury in vivo is undoubtedly complex, we
posit three possible, non-mutually exclusive mechanisms by which ERK could mediate increase
in CD44. First, ERK activation could increase CD44 transcriptionally leading to an increase in
CD44+ cell proliferation. Second, ERK could increase proliferation of CD44+ isthmal cells,
without increasing CD44 expression directly. Third, ERK signaling could increase HA in the
basement membrane/mesenchyme by directly activating HAS, which in turn would increase
CD44-dependent proliferation. Our data support the first interpretation. The second mechanism
does not seem plausible because if it were true, then blocking CD44 action would not affect
proliferation, yet our data show that CD44 is necessary for atrophy-induced increase in
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proliferation. The third interpretation seems less likely because we observe pERK in isthmal
cells in the epithelium as early as 6h after atrophy induction, just before CD44+ cells start
expanding from the same region. We do not observe pERK in the mesenchyme, so there are
likely to be other mechanisms leading to upregulation of HAS.
It is intriguing to speculate that the resident CD44+ epithelial population in wild-type mice might
mark a normal corpus stem cell, as these cells are isthmal, occasional, have high N:C ratio under
normal conditions and expand greatly upon injury. CD44+ cells also co-label with LGR5+ cells in
the antrum/pyloric region of the stomach, which can regenerate the entire pyloric unit, consistent
with multipotency.
One seeming paradox in our CD44 data is that loss of CD44 under homeostatic conditions
decreases census of surface/pit cells, whereas, during response to parietal cell atrophy, it affects
proliferation of cells expanding away from the pit zone and into the base.

One explanation is

that in homeostasis, pit cells turnover far more rapidly than any other cells in the gastric unit, so
defective CD44 signaling manifests as decreased census of those cells. During parietal cell
atrophy, there is rapid turnover of parietal cells, deeper in the unit, so CD44 mediates expansion
of cells towards the base of the unit to replace the lost parietal cells.
Lifetime risk for development of gastric cancer has been reported to be decreased only partially
by eradication of Helicobacter pylori [15, [16, [17]. It is likely that aberrant epithelial
differentiation patterns, such as atrophy, metaplasia and increased proliferation, persist after
treatment and must also be treated to reduce cancer risk substantially. The experiments in the
current study identify both the novel role of a specific signaling pathway involved in the
proliferative response to PC atrophy and show, as a proof of principle, that those pathways can
be pharmacologically inhibited at multiple steps. Ultimately, the identification of clear
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pharmaceutical targets in the metaplasia/atrophy sequence might be critical for reversing the risk
for cancer progression from precursor lesions.
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CHAPTER 4: Metaplasia in the stomach is induced by cytokines produced by
macrophages
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Abstract
Atrophy of acid secreting parietal cells in the stomach is the first step towards developing
metaplasia, which eventually progresses to gastric cancer. Gastric cancer is the second largest
cause of cancer related deaths worldwide. Parietal cell death is accompanied by a rapid
remodeling of the gastric epithelium, characterized by stem cell activation, dedifferentiation of
post-mitotic zymogenic cells and their re-entry into the cell cycle. However, the origin of parietal
cell atrophy and metaplasia remain obscure.
We have previously established that the breast cancer treatment drug, tamoxifen, causes prompt
parietal cell death within 3 days of administration. Atrophy is accompanied by an increase in
stem cell proliferation by activation of the ERK→CD44→STAT3 signaling cascade.
Nevertheless, the upstream signal that leads to parietal cell death and the communication
between damaged parietal cells and the neighboring stem cells that lead to their activation are
unknown. Here we find that, within a few hours, there is a dramatic increase in the levels of
circulating IL-6 in the sera of mice treated with tamoxifen. Although inflammation is absent,
there is an increase in F4/80+ macrophages in the mesenchymes of tamoxifen treated mice. When
challenged with tamoxifen ex vivo, primary macrophages secrete IL-6.

Depletion of

macrophages in tamoxifen treated mice blocks parietal cell atrophy and associated expansion in
stem cell proliferation. Factors secreted by macrophages lead to the activation of ERK in stem
cells and increase in iNOS in parietal cells. ERK causes a burst of stem cell proliferation,
whereas, iNOS activates the parietal cell death cascade. When iNOS signaling is blocked,
parietal cell atrophy and proliferation expansion are rescued. In conclusion, we propose a
mechanism by which the innate immune system signals to the gastric epithelium to initiate
parietal cell death and metaplasia.
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Introduction
When acid-secreting parietal cells (PCs) in the gastric epithelium atrophy (die) by genetic
ablation [1], infection with Helicobacter pylori [2] or by chemical means such as treatment with
tamoxifen [3], it causes a stereotypic response in the remaining epithelial cells known as
spasmolytic polypeptide expressing metaplasia (SPEM). SPEM is characterized by expanded
stem cell proliferation and dedifferentiation of enzyme secreting zymogenic cell (ZCs)s. The ZC
dedifferentiation is characterized by re-expression of markers like TFF2 (spasmolytic
polypeptide) that are usually expressed only during the ZC precursor stage [4]. Healthy PCs
secrete a number of factors, such as amphiregulin, transforming growth factor α (TGF-α),
heparin binding-epidermal growth factor-like growth factor (HB-EGF), Sonic hedgehog (Shh),
that aid in differentiation of other mucosal lineages [4]. It is not clear which, if any, of the
known growth factors normally elaborated by PCs might regulate the dedifferentiation of ZCs
into SPEM cells. Presumably, loss of the PC-elaborated signal might affect ZC differentiation
either directly or via an intermediary cell type. Alternatively, injured or dying PCs might
elaborate a stress signal that causes metaplasia of ZCs.
H. pylori infection related PC atrophy is associated with inflammation, which makes
mesenchyme to epithelial signaling fairly complicated. Hence, we utilize the tamoxifen induced
PC atrophy model to determine signals from them mesenchyme to the epithelium that cause PC
stress and eventual death. Tamoxifen does not cause inflammation, but displays all the epithelial
changes of H. pylori SPEM. Therefore, we analyzed circulating cytokines that were elevated
upon tamoxifen treatment that could signal to the epithelium and lead to PC atrophy and stem
cell expansion.
Several cytokines are implicated in mediating PC death upon infection with H. pylori.
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Interleukin-1β (IL-1β), IL-6, tumor necrosis factor alpha (TNF-α), IL-8, IL-21, gamma interferon
(IFN-γ), and transforming growth factor β (TGF-β) are found at increased levels in the gastric
mucosa of patients with H. pylori-associated gastritis compared with levels in healthy controls
[5]. Antigen presenting cells (APCs) such as dendritic cells and macrophages are present in H.
pylori infected mucosa and are likely involved in secreting some of the above mentioned
cytokines [5]. Along with the function of eradicating the bacterial infection, these APCs might
release cytokines that lead to epithelial remodeling and metaplasia. Most studies focus on the
role of immune cells and cytokines in eliminating H. pylori. Here we are interested in
determining the effect of these cytokines on PC death and stem cell expansion.
Our study shows that macrophages are increased in the mesenchymes of tamoxifen treated
mouse stomachs and these macrophages secrete IL-6 when challenged in vivo and ex vivo with
tamoxifen. We also find that depletion of macrophages rescues tamoxifen induced PC death and
stem cell expansion and this occurs by blocking iNOS expression and ERK activation
respectively. Increasing nitric oxide (NO) by injecting NO donors increases proliferation,
whereas blocking NO with scavengers reduces PC death and proliferation.

Materials and Methods
Animals and injections- All experiments involving animals were performed according to
protocols approved by the Washington University School of Medicine Animal Studies
Committee. Mice were maintained in a specified-pathogen-free barrier facility under a 12 hour
light cycle. Wild-type C57BL/6 and iNOS─/─ mice were purchased from The Jackson Laboratory.
Mice from all treatment groups were given an i.p. injection of a mixture of 5-bromo-2’deoxyuridine (BrdU, 120 mg/kg) and 5-fluoro-2’-deoxyuridine (12 mg/kg) 90 minutes before
sacrifice to label S-phase cells. Vehicles used for all injections are: sterile saline, ethanol in
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sunflower seed oil, or DMSO; no phenotypes were induced by injection of any of the vehicles
alone. Table 1 enumerates the treatments given to mice.
Table 4.1: Mice treatments and injectionsTreatment
Dose
Vehicle
(body weight)
Tamoxifen
5mg/20g
10% ethanol +
90% sunflower
seed oil
Clodronate
100µL
Solution from
manufacturer

Injection
Scheme
i.p. once a day,
sacrificed
as
indicated
i.p. twice a day
until sacrifice

Source
Sigma

Encapsula,
Nano
Sciences
Control
100µL
Solution from i.p. twice a day Encapsula,
Liposomes
manufacturer
until sacrifice
Nano
Sciences
Aminoguanidine 400mg/kg
0.9% saline
s.c. once a day Sigma
until sacrifice
SNAP
20mg/kg
20% ethanol + i.p. 3 times a Sigma
80% sunflower day
until
seed oil
sacrifice
DetaNONOate
0.4mg/kg
0.9% saline
i.p. once a day Sigma
until sacrifice
Curcumin
100mg/kg
25% ethanol + i.p. 3 times a Sigma
75% sunflower day
until
seed oil
sacrifice
Human Tissues- Examination of human gastric pathological tissue specimens was approved by
the Institutional Review Board of Washington University School of Medicine, the Comité de
Bioetica of Nicaragua for Universidad Nacional Autonoma De Nicaragua – Facultad De Ceincias
Medicas Managua, and the Research Ethics Board Manager for Health Sciences at the University
of Toronto. Serial sections (4–d6 μm thick) obtained from paraffin-embedded tissue samples
(H&E and alcian blue–periodic acid–Schiff stains) were reviewed by two pathologists in Italy
(M.F., and M.R.) with specific expertise in gastrointestinal diseases, and a consensus on the score
for each pertinent histologic variable was reached. Diagnoses and selection of specific regions of
transitions among normal stomach, atrophic stomach, and intestinal metaplasia was performed
by a third pathologist in the US (JCM).
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IL-6 ELISA- Wildtype mice were injected i.p. with either vehicle (10% ethanol + 90% oil; n=3)
or tamoxifen (n=3) and blood was collected by retro-orbital bleeding. Blood was allowed to clot
at 37°C for 30 minutes, centrifuged at 2000g for 10 minutes at 4°C and aliquoted and stored at 20°C. Aliquots were shipped to the Cytokine Core Laboratory of the University of Maryland for
performing IL-6 ELISAs.
Macrophage collection and culture- Peritoneal macrophages were isolated and cultured as per
[6]. Briefly, wildtype mice were each injected with 4mL thioglycollate medium 5 days prior to
sacrifice. 10mL of ice cold DMEM was injected into the peritoneal cavity immediately after
sacrifice, and collected into the same syringe. Media along with suspended macrophages were
centrifuged at 1200 rpm for 10 minutes at 4°C. Supernatant was discarded and the pellet was
suspended in DMEM/F12-10 media and plated into a 6-well plate at the concentration of 2*106
cells per well. Cells were allowed to adhere to the plate overnight at 37°C, 5% CO2 in an
incubator. Media was changed the following day to discard dead cells and debris. The wells were
treated with either DMSO alone or tamoxifen in DMSO (2mg/mL) for 1hr. at 37°C.
IL-6 RT-PCR- Cultured and treated macrophages were washed with PBS and mRNA was
extracted using the Qiagen RNeasy Mini Kit using the manufacturer’s instructions. RNA was
quantified using Biotek ELISA plate reader and Gen5 software. 1µg RNA was synthesized to
cDNA using the protocol described in [3] and PCR was performed using the primers for IL-6
(Forward

Primer

5’→3’

CCAAGAGGTGAGTGCTTCCC;

CTGTTGTTCAGACTCTCTCCCT)

and

18S

Reverse

(Forward

Primer
Primer

5’→3’
5’→3’

CATTCGAACGTCTGCCCTATC; Reverse Primer 5’→3’ CCTGTGCCTTCCTTGGA [3].
Immunofluorescence and Immunohistochemistry- Stomachs were prepared, and stained, and
imaged using methods modified from Ramsey et al [7]. For BrdU/Ki67 quantifications, positive
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cells were counted in >50 gastric units per mouse and >3 mice per experiment. Total number of
positive cells was divided by the total number of gastric units for each mouse. Stomachs were
prepared, and stained, and imaged using methods modified from Ramsey et. al. [7]. Primary
antibodies used for immunostaining are listed in Table 4.2:
Table 4.2: Antibodies used for immunostaining
Serial No.

Antibody

Dilution

Source

1

Goat α-BrdU

1:20,000

Jeffrey Gordon, Washington University

2

Rabbit α-pERK1/2

1:100

Cell Signaling Technology, Danvers, MA

3

F4/80

1:100

BD Biosciences, San Jose, CA

4

Rabbit α-GIF

1:20,000

David Alpers, Washington University

5

Rabbit α-iNOS

1:100

Abcam, Cambridge, MA

Secondary antibodies, lectins and BrdU labeling were as described [7].
Western Blotting – Western Blotting –Western blot analysis was performed as described [3].
Antibodies used for blotting are listed in Table 4.3. Immobilon Western Chemiluminescent HRP
Substrate (Millipore) was used for detection.
Table 4.3: Primary antibodies used for Western blotting
Serial No.

Antibody

Dilution

Source

1

Rabbit α-pERK1/2

1:1000

Cell Signaling Technology, Danvers, MA

2

Rabbit α-Tubulin

1:2000

Cell Signaling Technology, Danvers, MA

3

Goat α-HAS2

1:1000

Santacruz Biotechnology Inc., CA

Secondary antibodies were horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG
(1:2,000, Santa Cruz Biotenchnology, Inc.), goat anti-rat IgG (1:1000, Santa Cruz Biotechnology,
Inc.) and donkey anti-goat IgG (1:1000, Santa Cruz Biotechnology, Inc.).
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Microscopy - Light and epifluorescence micrographs were taken as described [8].
Graphing and statistics - All graphs and statistics were performed in GraphPad Prism, using
Student’s t test (one-tailed or two-tailed, as appropriate) for comparison of two groups of data
and one-way ANOVA with either Dunnett’s or Tukey’s for multiple comparison tests.

Results
IL-6 is produced and secreted into the serum immediately after treatment with tamoxifen
High levels of circulating IL-6 are associated with advanced gastric cancer [9]. IL-6 is a major
mediator of inflammation and activator of STAT3, which enhances proliferation and helps cells
progressing towards neoplastic growth [10]. In chapter 3, we have shown increased STAT3
activation associated with increased stem cell proliferation following treatment with tamoxifen.
Accordingly, we find an increase in circulating IL-6 in sera of mice treated with tamoxifen
within 6 hours of injection (Fig. 4.1A). Activated peritoneal macrophages frequently secrete IL-6
in other disease models such as endometriosis [11], stress [12], treatment with LPS [13], and so
on. Therefore, we isolated peritoneal macrophages from mice, cultured and treated them with
tamoxifen ex vivo. While IL-6 transcripts were absent in mice treated with DMSO control, we
found IL-6 mRNA expression in macrophages treated with tamoxifen for 1h (Fig. 4.1C). In
inflammatory diseases of the gastrointestinal tract, such as ulcerative colitis and Crohn’s disease,
there is enhanced secretion of IL-6 by mononuclear cells of the lamina propria [14]. Although
tamoxifen does not produce classical inflammation in our model of gastric metaplasia, we
observed an increase in F4/80+ macrophages in the mesenchyme adjacent to the base of the
gastric units (Fig. 4.1B). These macrophages presumably secrete IL-6, along with other
cytokines and factors that increase STAT3 activation and proliferation of cells at the base of the
unit.
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Fig. 4.1 Tamoxifen increases IL-6 secretion by macrophages. In mice treated with vehicle,
there was undetectable IL-6 in the sera, whereas tamoxifen treated mice showed a dramatic
increase in IL-6 concentration in their sera (A). Macrophages are important secretors of IL-6
and are increased in the mesenchymes of tamoxifen treated mouse stomachs, labeled in green
with F4/80 (B). Arrowheads point to green macrophages in the mesenchyme and dashed lines
outline gastric units (B). When cultured peritoneal macrophages are treated with tamoxifen, they
increase their expression of Il-6 transcripts, shown in (C) by RT-PCR, when compared to DMSO
treated controls.

Macrophages secrete IL-6 when treated with tamoxifen ex vivo and are necessary for
developing metaplasia
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IL-6 is typically secreted by either T-cells or macrophages. To rule out the possibility of the
involvement of T-cells, we treated Rag1─/─ mice with tamoxifen and found that they developed
metaplasia like the wildtype controls (data not shown). Therefore, we focused our next
experiments on macrophages. In order to determine the role of macrophages in inducing
metaplasia, we depleted macrophages using clodronate before treating mice with tamoxifen.
Mice that received clodronate in addition to tamoxifen had a blunted proliferative response when
compared with those that received tamoxifen alone (Fig. 4.2A). Moreover, clodronate also
blocked PC death and dedifferentiation of ZCs at the base of the unit (Fig. 4.2B). In Fig. 4.2B,
the orange bracket shows dedifferentiated ZCs expressing both neck and ZC markers (purple and
red overlap) in the tamoxifen treated mice whereas the clodronate + tamoxifen treated mice show
distinct regions of neck cells (white bracket) and ZCs (yellow bracket).
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GSII (Neck Cells)

Fig. 4.2 Depletion of macrophages by treatment with clodronate rescues SPEM development
induced by tamoxifen. Pre-treatment of mice with clodronate before inducing atrophy with
tamoxifen blocks the proliferative expansion of stem cells (A) as measured by counting BrdU+
proliferating cells per gastric unit. Clodronate pretreated mice also show lower degree of GSII
(neck cell marker) and GIF (zymogenic cell marker) overlap signifying lesser dedifferentiation of
zymogenic cells in these mice compared to tamoxifen treated positive controls (B).
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Macrophages induce ERK activation and iNOS expression following treatment with
tamoxifen
We next determined at what stage clodronate affected the ERK-CD44-STAT3 proliferation
cascade outlined in Chapter 3. We performed western blots for each signaling intermediate and
found that ERK activation was affected by macrophage depletion by clodronate (Fig. 4.3).
Clodronate treatment did not affect HA production as its synthesizing enzyme HAS2 remained
unchanged (Fig. 4.3). Since we have shown earlier that macrophages secrete IL-6 upon treatment
with tamoxifen (Fig. 4.1) and IL-6 is known to activate STAT3, we expected a block in STAT3
phosphorylation in presence of clodronate. However, pSTAT3 levels remained unchanged (Fig.
4.3) suggesting that there might be IL-6 independent methods of activating STAT3. Another
possible explanation is that IL-6 might activate STAT3 by phosphorylating Ser727 [15] while we
have analyzed phosphorylation at the Tyr705 residue.

Fig. 4.3: Clodronate blocks ERK
activation and iNOS expression

+

in tamoxifen induced SPEM.
Western blots show that while
STAT3 activation and HAS2
expression are unchanged upon
clodronate treatment, pERK and
iNOS expressions are blocked by
depletion of macrophages.
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These data show that depletion of macrophages blocks ERK activation, which explains the
decrease in proliferation. However, we also observe a decrease in PC death with clodronate
treatment. Therefore, we assayed for the stress signal, i.e. expression of iNOS and found that
while iNOS was increased in tamoxifen treated mice, clodronate inhibited the expression of
iNOS (Figure 4.3). Expression of iNOS could be the source of the parietal cell atrophy signal
downstream of factors secreted by macrophages.

iNOS is expressed in damaged parietal cells of mice and humans
Nitric oxide (NO) is an endogenous mediator of a number of physiological functions and stress
responses. It is a vasodilator that protects gastric mucosa by reducing acid secretion and
increasing blood flow and epithelial alkaline secretion [16]. NO is a short-lived molecule that
can cause local effects in cells, including proliferation, apoptosis, migration, invasion and
angiogenesis [17]. The literature on the role of NO in cancer tumorigenesis is dichotomous, with
some reports arguing about its pro-tumorigenic functions and others suggesting that it is antitumorigenic [17]. NO is generated by three isoforms of NOS (nitric oxide synthase) enzymes:
neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS) [17]. eNOS and
nNOS produce low concentrations (nanomolar) of NO for short durations, wheras iNOS is
capable of producing large amounts (micromolar) of NO over hours or days [17]. At low
concentrations, NO acts as a signal transmitter and aids maintenance of homeostasis; whereas, at
higher concentrations, such as those produced during injury by iNOS, it is cytoprotective against
pathogens and tumors [17]. In humans, H. pylori infection is associated with higher levels of
iNOS and NO [18]. Moreover, increased risk of developing gastric cancer has been reported in
populations with higher consumption of nitrate and nitrite from animal sources, which
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decompose in the stomach to give rise to reactive nitrogen species such as NO [19]. Furthermore,
tamoxifen increases iNOS expression and NO production by myoepithelial cells when they are
co-cultured with conditioned media from or breast carcinoma cells [20]. Therefore, we tried to
elucidate the role of iNOS and NO in parietal cell death and stem cell proliferation upon
induction of metaplasia by tamoxifen.
While iNOS is normally absent in the gastric mucosa, we found an increase in iNOS expression
in PCs of mice injected with tamoxifen (Fig. 4.4). iNOS labeled individual PCs which is in
accordance with the trend of asynchronous PC death.

Figure 4.4: iNOS labels parietal cells in tamoxifen treated mice. While vehicle control
stomachs do not show any iNOS expression (red; left panel), mice treated with tamoxifen start
expressing iNOS as early as 6 hours after treatment with tamoxifen (middle panel) and continue
expressing iNOS at 12 hours of treatment (right panel). The expression of iNOS is limited to
parietal cells, shown in insets.

We also observed an increase in iNOS staining in human gastrectomy samples that exhibited
SPEM (Fig. 4.5A, right). In tox176 mice, where PCs are killed by diphtheria toxin as soon as
they differentiate, we saw rare iNOS staining in pre-parietal cells (Fig. 4.5A, left). iNOS staining
by immunohistochemistry was prominent in parietal cells of metaplastic human stomachs (Fig.
4.5B).
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Fig. 4.5: iNOS is expressed in pre-parietal
cells of tox176 mice and in PCs of humans
with gastric metaplasia. Pre-parietal cells of
tox76 mice express iNOS (A, left), as do
parietal cells of humans with metaplasia (A,
right; B, right and below). Normal human
stomachs do not express iNOS (B, left)
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Nitric oxide signaling is necessary and sufficient for inducing parietal cell death and
expansion of proliferation
In order to delineate the role of NO in inducing or protecting from PC atrophy and stem cell
expansion, we performed loss of function and gain of function experiments, using NO donor and
NO scavenger injections in mice. We injected SNAP (S-Nitroso-N-acetyl-DL-penicillamine) and
DetaNONOate NO donors into mice and observed a slight increase in proliferation at Days 1 and
3 respectively (Fig. 4.6A, B).

Figure 4.6: Effect of nitric oxide donors on epithelial proliferation. While administration of the
NO donor, DetaNONOate, for 3 days did not significantly increase proliferation (A), treatment
with another NO donor, SNAP, caused a doubling of proliferating cells within a day of treatment
(B).
We then injected mice with tamoxifen in the presence of an iNOS specific inhibitor,
Aminoguanidine, and found a decrease in the expansion of proliferation induced by tamoxifen
alone (Fig.

4.7A). When treated with an NO scavenger, curcumin, we observed a more

substantial decrease in proliferation compared to tamoxifen alone (Fig. 4.4B).
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Figure 4.7: Blocking iNOS activity and scavenging nitric oxide inhibits the expansion of
proliferation during metaplasia. Mice pre-treated with the iNOS inhibitor, aminoguanidine,
before injury with tamoxifen showed a blunting of the proliferative response (A), as did mice pretreated with the NO scavenger, curcumin (B).
However, multiple experiments with treatment of iNOS─/─ mice with tamoxifen did not
consistently show a decrease in proliferation or parietal cell protection compared to WT mice
treated with tamoxifen (Fig. 4.8) and we reckon this defect is due to compensation by other NOS
enzymes (eNOS and nNOS) in these mice. Also, since curcumin affects multiple signaling
pathways, including ERK, we believe that part of the proliferation dampening effect of curcumin
might be due to blocking of ERK signaling, which we have proved earlier to be involved in stem
cell proliferation (Chapter 3). In conclusion, NO produced by iNOS in parietal cells might be
necessary and sufficient in causing stem cell expansion upon metaplasia.
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Fig. 4.8: iNOS─/─ mice treated with
tamoxifen display a threshold
phenomenon whereby they either
lose all their parietal cells or none.
Parietal cell counts show that
wildtype mice lose all their PCs

upon tamoxifen treatment, whereas
iNOS─/─ mice either lose PCs or
completely rescue their loss.

Discussion
Here we demonstrate that signaling initiated by macrophages leads to parietal cell death and
development of metaplasia, which is a known precancerous lesion [4]. In the presence of
tamoxifen, macrophages secrete IL-6 and other factors which begin the cascade of parietal cell
death and expansion of proliferation. Parietal cell death is mediated by the expression of iNOS.
Inhibition of macrophages and iNOS decrease parietal cell death, stem cell proliferation and
associated metaplasia. Hence, we conclude that the initiation of metaplastic changes in the
gastric epithelium is brought about by factors released by elicited macrophages.
Infection with Helicobacter pylori, which is the main predisposing factor for developing gastric
cancer, results in inflammatory infiltration in the gastric mesenchyme [5]. Patients with H. pylori
infection show myeloid antigen presenting cells, such as macrophages and dendritic cells, in
their gastric mucosa [5]. H. pylori infected monocytes in vitro secreted more proinflammatory
cytokines such as IL-12p40, IL-23, IL-1β, IL-6, and IL-10 compared to uninfected controls [5].
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Our model of tamoxifen induced parietal cell atrophy displays all the hallmarks of metaplasia
associated with H. pylori infection, except the development of classical inflammation [3].
However, we do observe the presence of CD45+/F4/80+ myeloid cells in the mesenchymes of
mice treated with tamoxifen, while these cells are absent in vehicle treated samples (Fig. 4.1).
Moreover, of all the cytokines assayed, we observe an increase in circulating levels of IL-6 in
tamoxifen treated mice compared to controls (Fig. 4.1). Isolated and cultured macrophages
express IL-6 when treated with tamoxifen, whereas vehicle treated macrophages fail to do so
(Fig. 4.1). Therefore, even in the absence of inflammation, factors secreted by macrophages,
including IL-6, are increased in the sera of mice treated with tamoxifen.
Macrophages regulate injury induced stem cell proliferation by modulating the activation of
ERK. We have shown in Chapter 3 that ERK activation initiates a CD44-STAT3 proliferation
signaling cascade. Loss of ERK activation in mice lacking functional macrophages is responsible
for the inhibition of stem cell proliferation and we predict that this is accomplished by a block in
the CD44-STAT3 signaling downstream of pERK. We do not observe any change in the
expression of HAS2, an enzyme that synthesizes hyaluronic acid, upon macrophage depletion.
Therefore, hyaluronic acid activated CD44 is not a critical modulator of proliferation
downstream of macrophage signaling. It is intriguing that even though macrophages secrete IL-6
ex vivo and in vivo, and that IL-6 is the main upstream activator of STAT3, we do not find
deactivation of STAT3 upon macrophage depletion. This could either be due to an IL-6 and
macrophage independent mechanism of STAT3 activation or due to its activation via
phosphorylation or acetylation of a different amino acid reside of STAT3 that we did not test for.
Another very interesting observation is that macrophage depletion blocks parietal cell death,
which is the first response of the gastric mucosa to injury. Our data show that this blockage
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occurs by inhibition of iNOS signaling by clodronate. iNOS is expressed in parietal cells of mice
treated with tamoxifen and humans with gastric metaplasia. Nitric oxide release is necessary and
sufficient to cause PC death and expansion of proliferation as shown by NO donors and
scavengers. iNOS─/─ mice showed variability in loss of PCs upon tamoxifen treatment, perhaps
due to a threshold effect of NO concentration on PC loss or due to compensation by eNOS and
nNOS in producing sufficient amounts of NO to cause PC atrophy.
Our observations delineate an interplay between circulating factors, mesenchymal signals and
epithelial responders that lead to all aspects of metaplasia development, i.e. parietal cell loss,
expansion of proliferation and dedifferentiation of ZCs. Future studies identifying the specific
factors that cross talk from the mesenchyme to the epithelium to initiate the metaplastic cascade
will prove critical in understanding the source of stem cell activation in the stomach.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
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Conclusions
The goal of my thesis has been to understand mechanisms that regulate gastric epithelial stem
cell proliferation during normal homeostasis and preneoplastic metaplasia. The main
predisposing factor for developing gastric metaplasia and cancer is infection with Helicobacter
pylori. H. pylori infection leads to parietal cell atrophy and an associated expansion in progenitor
cells. However, there is a large amount of inflammation associated with infection, which makes
it difficult to separate the individual signals responsible for atrophy and increase in proliferation
respectively. Hence, to analyze different signaling pathways that are induced early following
atrophy of parietal cells, we first identified a model for inducing atrophy in a rapid and
synchronous manner, without a substantial inflammatory component.

In Chapter 2, we showed that a single injection with a high dose of the breast cancer
chemotherapeutic drug, tamoxifen, induces rapid parietal cell atrophy within three days of
administration [1]. Moreover, tamoxifen induced atrophy is not accompanied by substantial
inflammation but does cause an expansion in the proliferative progenitor cell compartment,
along with dedifferentiation of zymogenic cells [1]. Parietal cell loss is reversible within two
weeks of cessation of tamoxifen treatment [1]. Although the mechanism of tamoxifen toxicity on
parietal cells in unknown, treatment with the proton pump inhibitor, omeprazole, partially
rescues atrophy; suggesting that tamoxifen may act by disrupting the proton gradient [1].
In Chapter 3, we utilized the ability of tamoxifen to kill parietal cells and remodel the gastric
epithelium to determine mechanisms that modulate progenitor cell expansion. We found that the
proliferating isthmal cells label with the cell surface receptor, CD44 [2]. CD44 is normally
expressed in the immune cells and mesenchyme, but also labels small, undifferentiated isthmal
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cells in the normal, uninjured gastric epithelium [2]. Upon treatment with tamoxifen, CD44+
cells from the isthmus start expanding towards the base of the unit until day 3 of the treatment,
when all cells in the gastric unit label with CD44 [2]. We found that loss of CD44, either by
deletion of the Cd44 gene or by blocking its activation using PEP-1, reduced the number of
proliferating cells at baseline when compared to wildtype controls [2]. Accordingly, Cd44─/─ and
PEP-1 treated mice were unable to dramatically increase proliferation when challenged with
tamoxifen. Conversely, when CD44 was activated by treating mice with its ligand hyaluronan,
there was an increase in proliferation [2]. Thus, CD44 interaction with its normal extracellular
matrix binding partner is necessary and sufficient for proliferation under normal and injury
conditions. We then determined the mechanism by which CD44 regulates proliferation. We
found that CD44 binds to pSTAT3 and regulates the transcription of the proliferation gene,
CyclinD1 [2, [3]. When STAT3 activation is blocked pharmacologically and challenged with
tamoxifen, there is a dampening of the proliferative response and expression of CyclinD1 [2].
Therefore, CD44 enhances progenitor cell proliferation following injury by binding to STAT3
and controlling the expression of CyclinD1. Since we found CD44 is induced at the
transcriptional level, we then determined which signaling pathway might induce Cd44 gene
expression. We found that ERK was activated by phosphorylation early upon treatment with
tamoxifen, and blocking of ERK activation inhibited proliferation and Cd44 expression [2].
Hence, we concluded that atrophy-induced CD44 expansion depends on pERK, which,
accordingly, also labels the proliferating isthmal cells that respond to atrophy.

We have shown that even though we inject mice systemically with tamoxifen, the stomach is
specifically sensitive to injury when compared to other organs [1]. Therefore, in Chapter 4, we
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analyzed signals from the circulation, which could cause parietal cell death and increased
proliferation. We found that mice that were treated with tamoxifen showed a dramatic increase in
IL-6 in their sera. Since IL-6 is generally secreted by T-cells and macrophages, we looked for the
presence of these cells in the stomachs of mice treated with tamoxifen. While control mice did
not show cells labeling with the macrophage specific marker, F4/80, we found scant F4/80+
macrophages in the mesenchymes of tamoxifen treated stomachs. When cultured and treated
with tamoxifen, peritoneal macrophages showed an increase in the expression of Il-6. Depletion
of macrophages with clodronate not only reduced the proliferative response to tamoxifen, but
also blocked atrophy of parietal cells. Therefore, we next identified the signal from the
macrophages to the parietal cells that causes atrophy upon tamoxifen treatment.

iNOS expression is increased in parietal cells upon treatment with tamoxifen and in humans with
intestinal metaplasia. When treated with nitric oxide donors, the mice showed parietal cell
damage and a concomitant increase in proliferation, reminiscent of tamoxifen treatment.
Blocking of iNOS with its pharmacological inhibitor or scavenging of nitric oxide rescued the
increase in proliferation. Hence, we conclude that factors secreted by macrophages upon
tamoxifen challenge are sufficient to induce parietal cell atrophy by increasing the expression of
iNOS. Nitric oxide (NO) is a diffusible gas that can signal to cells locally. Depending upon the
concentration of NO, it is capable of inducing proliferation in stem cells via the MAPK pathway
independent of EGFR [4]. Furthermore, NO causes dedifferentiation of articular chondrocytes by
increasing ERK signaling and inhibiting p38MAPK [5]. Therefore, NO serves as an ideal
signaling intermediate released by PCs during injury that can signal to adjacent stem cells to
proliferate and zymogenic cells to dedifferentiate and re-enter the cell cycle.
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In conclusion, in this thesis, we have outlined a tamoxifen induced mechanism by which parietal
cells undergo atrophy and initiate the development of metaplasia. Metaplasia is associated with
an expansion in stem cell proliferation brought about by an ERK→CD44→STAT3→cyclin D1
signaling cascade. Once challenged with tamoxifen, macrophages secrete cytokines that induce
parietal cell death, in a mechanism that depends on parietal cell induction of iNOS, and stem cell
proliferation, through the activation of ERK signaling.
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Future Directions
I)

Determining the role of the CD44 ligand, hyaluronan, in regulating CD44 expression
and proliferation of isthmal cells

Hyaluronan (HA) is a component of the extracellular matrix and is found in connective,
epithelial and neural tissues, forming large networks in the extracellular compartment [6]. Each
HA molecule consists of on average 10,000 repeating disaccharide units of D-glucuronic acid
and N-acetylglucosamine, synthesized by the action of three HA synthesizing enzymes (HAS1, 2
and 3) [6]. HA accumulates at sites of inflammation and tumor progression [6]. Although HA
accumulation is not a universal characteristic of all tumors, many cancers contain increased
amounts of HA compared to normal tissues [7]. It is also believed that HA surrounding cancer
cells helps in increasing their spread and migration [8].The stroma surrounding gastric tumors
shows increased staining of HA relative to normal gastric mesenchyme [7]. We found that HA
staining was found in the mesenchyme surrounding the gastric unit in normal wildtype mice [2].
However, there was also an increase in HA in the mesenchyme of tamoxifen treated mice
(Chapter 3 [2]). The expression of HA synthesizing enzymes, HAS1 and HAS2 was also
increased (Chapter 3 [2]). Fig. 5.1 (adapted from Chapter 3) shows the expression of HA and
HAS1, 2 in normal and tamoxifen treated mice.

116

Fig. 5.1: Hyaluronic acid (HA), a ligand of CD44, was
increased upon atrophic injury with tamoxifen. HA

(stained using Hyaluronan-binding protein; in green)
and CD44 (red) were increased in expression towards
the base of the gastric unit during tamoxifen induced
metaplasia (A, arrowheads). HAS1 and HAS2, enzymes
that synthesizes HA, were also increased by 12h of
tamoxifen treatment (B).
Moreover, we observed an increase in HA staining in human biopsies of patients who had
developed intestinal metaplasia (Fig. 5.2). In normal human stomachs, HA stained the
mesenchymes in between gastric units; however, in humans with intestinal metaplasia, these
regions of HA staining in the mesenchyme were greatly expanded (Fig. 5.2).
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Fig. 5.2: Hyaluronic acid (HA) is increased in human patients with gastritis and intestinal
metaplasia. HA (stained using Hyaluronan-binding protein; in green) and GSII (red) were
increased in expression in the mesenchyme surrounding the gastric unit during intestinal
metaplasia (yellow bracket).

Since atrophy and metaplasia are accompanied by a surge in proliferation that are regulated by
the HA receptor, CD44 (Chapter 3), we next looked at whether HA was sufficient to induce
proliferation. We injected 3-week old mice with HA twice a week for 5 weeks and found that
they had increased proliferation, with increased pit cell census (Chapter 3) compared to wildtype
controls. Since the mouse gastric epithelium continues to develop and differentiate for a few
weeks after birth, our data show that HA is an important regulator of proliferation during this
developmental period. To assess whether HA is involved in adult gastric epithelial proliferation,
we injected adult wildtype mice with HA every day for 3 days and 10 days and found a
significant increase in proliferation (Fig. 5.3).
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Fig. 5.3: HA is sufficient to induce
expansion of stem cell proliferation.
Mice treated every day with HA for 3 days
and 10 days showed significant increase
in proliferation, stained with BrdU,

compared to vehicle treated control mice.
We then tested for sufficiency of HA in inducing proliferation, by blocking the interaction of HA
with its receptors using the peptide PEP-1 (Fig. 5.4 and Chapter 3).

Fig. 5.4. HA is necessary for normal and injury induced expansion of proliferation. Mice
treated with the HA blocking peptide, PEP-1, for 5 weeks showed half the number of
proliferating cells compared to wildtype controls (A). When PEP-1 treated mice were injected
with tamoxifen, they were able to expand proliferation to only half of that of mice treated with
tamoxifen alone (B).
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Since HA is necessary and sufficient for inducing proliferation but does not lead to parietal cell
death or zymogenic cell dedifferentiation (data not shown), stem cell proliferation must be
uncouplable from parietal cell death. While pERK induced CD44 expansion and interaction with
HA appears to be the mechanism adopted by injured stem cells to increase proliferation, HA
induced proliferation even in the absence of pERK can modulate normal proliferation in the
gastric epithelium. Thus, if we can understand the mechanisms that regulate HA synthesis, we
should have a strong foothold into the pathways that feed into both normal cell turnover and
atrophy induced expansion of gastric stem cells.

II)

Determining the factors secreted by activated macrophages that lead to parietal cell
atrophy and proliferation expansion

We have shown in Chapter 4 that macrophages secrete IL-6, among other factors, which increase
parietal cell death and associated expansion of proliferation. However, it is unlikely that IL-6 is
the only factor responsible for rescuing the metaplastic changes in the epithelium during injury.
Our collaborative work with Dr. Richard DiPaolo, as well as the work of others [9], has shown
that IL-11 is involved in inducing PC injury during autoimmune gastritis, along with IL-6 [10].
Moreover, loss of EBI3, which forms have the heterodimeric cytokines IL-27 and IL-35,
accelerates the development of metaplasia in mice with autoimmune gastritis (DiPaolo lab,
unpublished data). To identify factors responsible for PC atrophy and stem cell proliferation, we
will first determine whether macrophage secreted factors are sufficient for development of
metaplasia. For this, we will isolate peritoneal macrophages, culture and treat them with
tamoxifen, and then adoptively transfer them into clodronate treated or irradiated mice and assess
whether the recipient mice develop metaplasia. Once we have established sufficiency, we can
determine which proteins and cytokines have higher expression in tamoxifen treated macrophage
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cultures using qRT-PCR. Finally, we can test sufficiency of individual factors by injecting
recombinant versions of these factors into mice or transducing them using adenovirus vectors
and assessing whether they undergo PC atrophy or expansion in proliferation or ZC
dedifferentiation or all of the aforementioned processes.

III)

Determining the mechanism by which zymogenic cells undergo dedifferentiation
following parietal cell atrophy

Along with proliferation expansion, another epithelial remodeling process associated with
parietal cell death is the dedifferentiation of zymogenic cells. Zymogenic cells are largely postmitotic and normally do nothing but their physiological duty of elaborating enzymes critical for
digestion. Upon parietal cell atrophy, zymogenic cells start re-expressing markers of their
precursors, i.e. neck cells, such as TFF-2, represented by GSII in Figure 5.5 [1].
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Fig. 5.5 Tamoxifen induces spasmolytic polypeptide-expressing metaplasia (SPEM). A:
photomicrographs of basal and neck zones of gastric units with mucous neck cells (green, GS-II
lectin) and zymogenic cells (red, GIF) taken 3 days after vehicle treatment (above); 3 days
(middle) and 21 days (below) after tamoxifen treatment. B: Neck and base zones of gastric units
were analyzed for expression of neck and zymogenic cell markers as a function of distance
(0=first cell positive for neck/zymogenic markers; 100 = basal-most neck/zymogenic cell). For
each unit, distance was normalized into bins representing 10% of total distance. Plotted are the
products of the mean fluorescent intensity and the total area that is either GS-II (neck cell) or
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GIF (zymogenic cell) positive (means±SD, across all gastric units). Note how normal neck cell
differentiation peaks, then falls off toward the base, whereas, zymogenic cells are found in the
base and not the neck. Tamoxifen treatment causes neck cell marker expression in the base. The
changes in neck cell (C) and zymogenic cell (D) markers for all conditions are plotted on the
same axes.

Blocking of PC atrophy inhibits the dedifferentiation of ZCs. This could be caused by one of
three mechanisms:
i.

Healthy PCs constantly engage in homeostatic signaling with ZCs, the loss of
which during atrophy leads to ZC dedifferentiation

ii.

Injured PCs release stress signals that cause ZCs to dedifferentiate

iii.

A common upstream stress signal leads to death of PCs and dedifferentiation
of ZCs

While the nature of signaling between PCs and ZCs is not extensively elucidated, our data with
blocking iNOS and macrophage activation show that either the PC stress signals or common
activators or both might be involved in orchestrating epithelial remodeling during injury.
Whatever the nature of the PC to ZC signaling might be during atrophy, it results in ZC
dedifferentiation. We observe an increase in CD44+ cells at the base of the gastric units during
atrophy (Fig. 3.1). These CD44+ cells could either originate from CD44+ isthmal cells that
proliferate and occupy the base and/or from the dedifferentiation of ZCs which causes them to
reduce their size, express the stem cell marker, CD44, and enter the cell-cycle. It is technically
challenging to establish the relative contribution to the CD44-positive cells from expanded
isthmal stem cells vs. dedifferentiating ZCs. Once CD44 is expressed, it imparts the ZCs with

123

proliferative (and potentially stem/progenitor) cell capabilities, because it has been well
established that. ZCs act as cryptic progenitors during atrophy and give rise to metaplastic cells
[11].

An important developmental pathway that regulates dedifferentiation is the Hippo pathway [12].
Inactivation of the hpo kinase cascade in drosophila larval eye imaginal dics increases the rate of
cell duplication, protects cells from apoptosis, and delays the cell cycle exit of the uncommitted
cells [13]. The Hippo pathway restricts organ growth and size by phosphorylating and
inactivating the transcription factor YAP (Yes-Associated Protein). Inactivation of the tumor
suppressors of the Hippo pathway or activation of the oncogene YAP results in massive tissue
overgrowth characterized by increased cell proliferation and diminished cell death [14]. YAP1
dephosphorylation is a reliable metric for assessing Hippo activation. Hence, we determined the
status of YAP1 phosphorylation in our model of tamoxifen induced atrophy in Figure 5.6. We
found a decrease in pYAP1 at Day 3 of tamoxifen treatment, which coincides with the highest
number of proliferating cells during tamoxifen induced atrophy, as well as the appearance of
proliferating ZCs [1]. Therefore, to reiterate, we find an increase in YAP1 activation and Hippo
signaling coinciding with increased proliferation and ZC dedifferentiation in our model of
tamoxifen induced atrophy.

Fig. 5.6. YAP1 is activated upon treatment with
tamoxifen. Phosphorylation of YAP1, which
deactivates it, is decreased 3 days after treatment
with tamoxifen, which coincides with maximum
parietal cell atrophy and CD44 expression
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CD44 has been shown to interact with merlin, a product of the Nf-2 gene, which is a component
of the Hippo tumor suppressor pathway and interacts with cytoskeletal components [15]. In
schwannoma cells, merlin binds to the cytoplasmic tail of CD44 and this binding inhibits the
association between CD44 and HA [15]. It will be interesting to determine whether CD44
increase in ZCs during atrophy causes ZC dedifferentiation and proliferation via the Hippo
pathway. This can be studied using null mutants of the Hippo kinases Mst1 and Mst2. Pdx1-Cre
driven Mst1─/─ X Mst2fl/fl mice have shown to cause dedifferentiation in pancreatic acinar cells
[9]. In order to adapt these mice to our system, we can generate β-actin-Cre; Mst1─/─/Mst2fl/fl
mice or Mist1-Cre; Mst1─/─/Mst2fl/fl mice which should over-activate the Hippo pathway in the
entire epithelium or zymogenic cells, respectively. If these mice show dedifferentiation of
zymogenic cells and increase their proliferation, it will confirm the role of Hippo in developing
metaplasia.

A recent study in Drosophila larval imaginal discs showed a link between Hedgehog (Hh)
signaling and the Hippo pathway in regulating cell proliferation [16]. The authors showed that
the Hh inhibitory receptor, Patched (PTCH1) acts as a tumor suppressor, and loss of Ptch1 leads
to hyperactivation of YAP1, resulting in excess proliferation [16]. In humans, PTCH1 is highly
expressed in the gastric epithelium and especially in the membrane compartment of ZCs (Human
Protein Atlas). In the stomach, Shh is expressed highly, though recent studies using Shh-Cre
lineage tracing have shown that all major corpus lineages express Shh [17]. Hedgehog signaling
is frequently associated with advanced gastric adenocarcinomas [18]. Although, during
metaplasia there is a loss of Shh due to death of parietal cells, there is an increase in the
expression of the Hh target, Gli1, when compared to controls (data not shown). This indicates
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that either other cell lineages increase expression of Shh during PC atrophy or that Shh
molecules are released by dying PCs which enables signaling to other cells in the unit, including
ZCs. Increased Gli1 expression is a readout of increased Shh signaling and mirrors the result of
loss of Ptch1. I hypothesize that increased Hh signaling results in hyperactivation of YAP1 and
increased proliferation via the Hippo pathway. This is an unexplored area of research and can be
beneficial in understanding mechanisms that lead to ZC dedifferentiation and entry into the cell
cycle.

VII. Determining the role of CD44 in Helicobacter pylori niche establishment
Helicobacter pylori infection in humans is the major risk factor for developing gastric cancer
[19]. Once H. pylori colonizes the stomach, it persists for the lifetime of the host. Although
infection is associated with inflammation, it typically does not clear the bacteria [19]. In mice,
the CagA+ strain of H. pylori, PMSS1, colonizes the antrum of the stomach [20], which is devoid
of acid secreting parietal cells. This enables H. pylori to evade the harsh acidic environment of
the stomach corpus and phenocopies the way infection is thought to occur in humans. The
bacteria survive as two major populations: first, freely swimming in the mucus gel and using its
motility, chemotaxis and stress responses to survive and swim towards the shelter of the
epithelium; and second, adhered to epithelial cell surface through various adhesins [20]. Howitt
et. al. [21] found that H. pylori utilizes a novel family of chemotactic proteins called ChePep for
colonizing the stomach. ChePep is necessary for H. pylori flagellar rotation, which enables it to
evade acidic regions within the stomach, which act as chemorepellants [21]. ChePep also
regulates its ability to colonize deeper into antral glands [21]. Thus, H. pylori is presumably
attracted to some moiety on the surface of gastric epithelial cells, eventually attaches to the cell
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surface and establishes a colony. H pylori preferentially adhere to intercellular junctions between
epithelial cells [20]. Tan et. al. found that the bacteria adhered to the intercellular junctions were
able to undergo several rounds of replication while being adhered to their original point of
attachment [20]. Moreover, H, pylori colonization is typically adjacent to a dividing cell (Manuel
Amieva, Stanford University; personal communication). It is unclear whether bacterial
attachment promotes epithelial cell proliferation or whether H. pylori is chemically attracted to
dividing cells within the gastric unit. Either scenario presents interesting, addressable questions
in order to understand the nature of host-pathogen interactions.

Once attached to the host cell, H. pylori deliver the cytotoxin-associated gene A (CagA) protein
into the host cell [22]. CagA is one of the most important links between infection and
development of gastric cancer [22]. Once inside the host cell, CagA localizes to the plasma
membrane and interacts with host cell junctional complex machinery, such as ZO-1, Jam and Ecadherin [22]. Moreover, kinases from the host cell, such as c-Src/Lyn and Abl, phosphorylate
tyrosines on the CagA protein and activate a receptor tyrosine kinase signaling cascade [22].
These events lead to loss of host cell polarity and increased invasiveness [22]. Recent studies
have shown that in an attempt to protect host cells from the infection, intracellular CagA is
degraded by autophagy induced by accumulation of reactive oxygen species (ROS) [23]. The
accumulation of CagA is restricted to cells deficient in autophagy [23]. Tsugawa et. al. found that
cells expressing CD44 (specifically, the variant CD44v9) were resistant to ROS and, therefore,
deficient in autophagic degradation of CagA [23]. This observation is important in understanding
the relation between H. pylori infection and CD44 in gastric metaplasia, since presence of both
leads to gastric cancer.
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We have shown in Chapter 3 that CD44 labels proliferating cells, normally and during parietal
cell atrophy by tamoxifen and H. pylori infection [2]. The human Cd44 gene contains 20 exons
[24]. Exons 1-5 and 16-20 are typically spliced together to form standard CD44 or sCD44, which
forms a 37kDa protein and is ubiquitously expressed [24]. Exons 6-15 can be variably spliced
into the standard exons to give rise to CD44 variants in the N-terminal extracellular domain [24].
Certain CD44 isoforms, such as CD44v6 and CD44v9, are overexpressed in gastric cancer [25].
As mentioned before, CD44v9 enables resistance to ROS and promotes H. pylori infection in
hosts [23].
These observations raise a number of interesting questions:
1. Is H. pylori chemically attracted to CD44+ cells in the normal gastric epithelium, by
virtue of specific sugar moieties on the CD44 extracellular domain?
2. Does attachment of H. pylori to potentially CD44+ stem cells lead to an increase in stem
cell proliferation?
3. Does H. pylori attachment selectively increase expression of CD44v9 over CD44s?
4. Are Cd44─/─ mice resistant to H. pylori colonization and persistence?
5. Is ROS induction sufficient to induce CD44+ stem cell proliferation?
Addressing these questions will provide key insights into the mechanisms by which H. pylori
modulates the host epithelium to establish its niche. Moreover, since host cell changes persist
after eradication of the bacterium, understanding the role of CD44 will facilitate devising
therapeutic strategies post H. pylori clearance in patients.
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APPENDIX 1: The Gastric Mucosa: Development and Differentiation
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Abstract
The development and differentiation of the gastric mucosa are controlled by a complex interplay
of signaling proteins and transcriptional regulators. This process is complicated by the fact that
the stomach is derived from two germ layers, the endoderm and the mesoderm, with the first
giving rise to the mature epithelium and the latter contributing the smooth muscle required for
peristalsis. Reciprocal epithelial–mesenchymal interactions dictate theformation of the stomach
during fetal development, and also contribute to its continuous regeneration and differentiation
throughout adult life. In this chapter, we discuss the discoveries that have been made in different
model systems, from zebrafish to human, which show that the Hedgehog, Wnt, Notch, bone
morphogenetic protein, and fibroblast growth factor (FGF) signaling systems play essential roles
during various stages of stomach development.

132

Introduction
Evolutionarily, the stomach as a functional organ, with its acid and digestive enzyme-secreting
properties, emerged well after the development of the intestine, and was more or less
concomitant with the evolution of jaws. Its final, adult form is similarly slow to develop,
occurring, for example, several weeks after birth, in rodents. Like the rest of the epithelium of
the luminal gastrointestinal (GI) tract, the gastric epithelium exhibits continual cell loss
throughout adult life [1]. To replace the lost cells, resident stem cells continually differentiate
into multiple cell lineages. Thus, in terms of cell fate specification decisions, developmental
processes never stop in the stomach. In this chapter, we examine the embryonic specification of
the stomach from the luminal GI tract, its subsequent development into a mature organ, and,
finally, the differentiation processes that continue into adulthood. More specifically, we examine
the development of cell lineages and the role of signaling pathways at each step.

I.

Early Foregut Development

We first briefly review early development, to put the emergence of the stomach in its proper
context. In the mouse embryo, gastrulation begins at E6.25, with the formation of a thickening
on the posterior side of the epiblast, called the ―
primitive streak‖. Epiblast cells ingress through
the primitive streak and the node, and undergo an epithelial-to-mesenchymal transition (EMT) to
gradually form the endoderm and the mesoderm. During the formation of the vertebrate GI tract,
the endoderm and mesoderm undergo extensive regionalization and elongation to give rise to
organs with specific structures and functions. The vertebrate embryonic GI tract consists of an
endodermally derived epithelium and a mesodermally derived mesenchyme. Eventually, the gut
tube is patterned along the anterior–hindgut (which forms the distal transverse, descending, and
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rectosigmoid segments of the colon) [2]. After this initial patterning, the fate of the endoderm,
although broadly determined, is still only partially specified and depends on patterning factors
secreted by the underlying mesoderm. As we will discuss, the fact that factors from the
mesenchyme direct epithelial fate decisions remains relevant, to some degree, throughout adult
life. Key regulatory pathways that are developmentally critical, such as the Hedgehog, Wnt, bone
morphogenetic protein (BMP), and FGF systems, send signals across the epithelial–
mesenchymal boundaries throughout the nascent luminal GI tract and thus contribute toward
patterning of the gut tube along the left–right, A–P, dorsal–ventral, and radial axes.

II.

Specification of the Stomach as a Separate Organ: An Overview

Following gastrulation, the primitive gut tube is formed from the endoderm, and it encircles the
inner leaflet of the lateral plate mesoderm, which then forms the visceral mesoderm [2]. The
formation of a solid gut tube at the dorsal midline by the convergent-extension of the sheet of
endodermal cells requires both the vascular endothelial growth factor (VEGF) and Wnt/PCP
(planar cell polarity) pathways, as studied in zebrafish [3]. The transcription factor HNF1b/Tcf2
aids in the formation of a single gut tube lumen by inducing genes whose expression results in
apical fluid secretion into the developing luminal space [4]. The primitive gut tube endoderm is
broadly partitioned antero-posteriorly, with the anterior half of the embryo expressing the
transcription factors Hhex, Sox2, and Foxa2 and the posterior half expressing Cdx1, 2, and 4 [5].
The anterior half forms the foregut while the posterior half forms the hindgut. Between E8.0 and
E9.5, broad foregut and hindgut territories become divided into organ-specific zones and
lineages in the mouse embryo. Gastric epithelial cytodifferentiation is initiated around E13.5.
Unlike humans—who have entirely glandular stomachs—mice have a stomach in which the
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proximal third is lined by a stratified, keratinized squamous epithelium (the region known as the
forestomach). By E16.5, the morphological differences between the forestomach and glandular
epithelia are evident in mice. Recombination experiments have shown that the presumptive
stomach endoderm might have some plasticity until E11.5/E12.5, but at E14.5, the endoderm no
longer requires mesenchymal instructive signals for its A–P patterning [6]. This finding is
corroborated by studies in the chick, which also show that most of the endoderm is capable of
self-differentiation even from the early stages of development and that it does not require
mesodermal inputs to do so. However, mesodermal signals are crucial for early specification and
patterning [7].

III.

Morphogenetic Codes Involved in Stomach Specification

In the 1960s, Lewis Wolpert hypothesized that molecules could affect target tissues by traveling
over distances in a gradient, much like the color gradients on the French Flag (thus called the
French Flag model). Morphogens are such molecules, which originate in a specific tissue, and
travel over some distance to act on specific receptors with progressively decreasing signal
strength. The dose or strength of the ligand molecule binding to its receptor determines the
output of gene expression in the target tissue, and it is, therefore, the decisive factor in
establishing positional information. A limited number of morphogenetic signaling pathways that
play crucial roles in determining the different axes during development of an organ have been
identified. The four principal signaling pathways are the Hedgehog, Wnt, transforming growth
factor (TGF), and receptor tyrosine kinase (such as fibroblast growth factor (FGF), epithelial
growth factor (EGF), and platelet derived growth factor (PDGF)) systems. These four pathways
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coordinate the spatiotemporal expression of transcription factors that impart foregut or hindgut
identity to the GI tract [5].
A. The Hedgehog Signaling Pathway – Early Events
1. Left-Right Axis Formation
Correct patterning of the left-right axis is essential for the proper development of gut-derived
organs such as the pancreas and liver and for leftward looping of the gut tube. During
gastrulation, a group of ciliated cells at the anterior end of the primitive streak form a notch
called the node, which is believed to regulate left-right axis formation of the gut, by generating a
leftward flow of the extraembryonic fluid [8]. Hedgehog signaling is involved in gut tube
formation as Smo and Shh/Ihh mutant mice fail to close the midgut, probably due to leftward gut
malrotation [9]. Shh is expressed at E7.75 in the anterior endoderm [10, [11] and later expands to
the posterior part of the gut, whereas Ihh is expressed in the posterior endoderm and spreads
anteriorly [12, [13]. Shh and Ihh play redundant roles in left-right axis formation, and both
mutants lack Nodal expression in the left lateral plate mesoderm and fail to specify the left side
program. It has been proposed that hedgehog has an indirect role in this process in that it
becomes distributed asymmetrically to one side of the embryo secondary to impaired nodal flow
[13, [14]. This asymmetrical flow of Hh is thought to be dependent on FGF signaling [14].

2. Anterior-Posterior Endodermal Patterning in the Gut
Patterning of the endoderm along the A-P axis occurs after gastrulation, as early as E6.7. The
first endodermal cells to exit the primitive streak move anteriorly and express the Hex gene,
whereas later-exiting endodermal cells express FoxA2 (Hnf3β), and those exiting last form the
posterior endoderm and express Cdx2 [15, [16]. However, the timing of the exit of cells from the
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primitive streak is not the only determinant early of A-P patterning. At this stage, patterning
factors secreted by the mesenchyme are essential to provide hindgut. Hex, FoxA2 and Sox2 are
required for foregut development, while Cdx1, 2 and 4 are required for hindgut development and
defining the foregut-hindgut boundary [5, [17]. At later stages of development, the endoderm
plays an instructive role in patterning the mesoderm [18].

3. Hedgehog in Stomach Development
Shh is expressed at high levels in the forestomach epithelium and at low levels in the glandular
part of the stomach epithelium from E11.5 to 15.5 [19]. Ihh has a reciprocal expression pattern to
that of Shh, in that it is highly expressed in the glandular stomach and to a lesser extent in the
forestomach [20]. The expression of Ptc1, which is both the receptor for and a target of
Hedgehog signaling, in the underlying mesenchyme closely follows the expression of Shh [20].
Ihh mutants do not show any gross abnormalities in glandular stomach development [9], which
suggests that in spite of high amounts of message in the glandular stomach, Ihh might not be
translated or active, or may be compensated by Shh. Ihh expression in the hindstomach depends
on the mesenchymal/epithelial signaling brought about by FGF10 binding to the FGFR2b
receptor (Spencer-Dene et al., 2006). Inhibition of Shh signal in the glandular epithelium in these
earlier stages is blocked by FGF10 through Gata4 [18, [20]. At later stages of development, i.e.
E18.5, Shh expression expands to include the glandular stomach epithelium and results in
signaling within the epithelium itself and to the mesenchyme [9]. Shh null mice display a small,
malformed forestomach which is in accordance with its early expression pattern. Shh apparently
does not play a major role in governing development of gastric epithelial cell lineages, and
glands form normally in the posterior stomach, though with reduced gland branching [18]. Shh
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and Ihh double null embryos arrest shortly post-gastrulation, and as Shh and Ihh may have
redundant functions, single null alleles do not yield an accurate analysis of overall Hh signaling
during gastrointestinal morphogenesis. To fully understand the function of Hedgehog signaling
in the developing GI tract, Mao and coworkers [21] used conditional gene targeting to ablate
both Shh and Ihh at E9.5, and found that Hh signaling plays a critical role in promoting the
survival and proliferation of mesenchymal progenitors underlying the gastric epithelium.

B. The Wnt Signaling Pathway
Wnt ligands are secreted glycoproteins and have been shown to govern important developmental
processes such as cell fate determination, tissue patterning, cell proliferation and morphogenesis
[22]. Wnt signaling occurs by two pathways, the canonical Wnt/β-catenin signaling pathway
(Wnt1, 3 and 8) which brings about activation and nuclear translocation of β-catenin, and the
non-canonical Wnt/Ca2+ and Wnt/Fz planar cell polarity pathways (Wnt 5a and 11). Wnt
signaling is also regulated by various secreted Wnt antagonists, the Soluble Frizzled Related
Proteins (Sfrps), which bind to and block Wnt ligands from binding to Frizzled receptors [23],
the WIF-1 protein, which has a similar mechanism of action as SFRPs but is structurally
different and has been studied extensively in Drosophila and Xenopus [24], and Cerberus, a Wnt
antagonist similar to SFRP and WIF-1 that has been studied principally in Xenopus. At present,
it is not clear whether the mouse Cerberus like protein, mCer1, funtions as a true orthologue of
Cerberus [25]. Finally, there are the Dickkopf (Dkk1-4) proteins that act by binding to the Wnt
co-receptors LRP5/6 rather than by interacting with the Wnt ligands directly [21, [26, [27].
At stage E12.5 of mouse embryonic development, Wnt4, 5a and 11 exhibit specific and partially
overlapping expression patterns in the stomach: Wnt11expression is strong in the esophageal-
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pyloric junction and in part of the forestomach around the lesser curvature; Wnt5a is expressed
in the entire forestomach and part of the corpus; Wnt4 expression is confined to the pyloric
region of the stomach epithelium and is weakly present in the esophagus. Wnt5b and 6 might be
expressed in the esophageal epithelium at this stageas well [28]. The non-canonical Wnt5a is
diffusely expressed in the mesenchyme at E12.5 and more specifically in the ectomesenchyme
just underlying the epithelium at E14.5. Decreasing Wnt5a expression results in repression of the
intestinal marker Cdx2 and posterior expansion of Sox2, the foregut marker [29]. In the chick
embryo, Wnt5a is expressed in the presumptive stomach mesenchyme, and overexpression of
Wnt5a causes increased and ectopic expression of some of the marker genes of the luminal and
glandular epithelial cells, the former characterized by the expression of Spasmolytic Polypeptide
and thus analogous to neck cells in the mammalian gastric corpus, and the latter marked by by
the expression of pepsinogen, analogous to the zymogenic or chief cells in mammals. In
particular, the overexpression of Wnt5a markedly enhances the expression of ECPg (Embryonic
Chicken Pepsinogen), indicating its role as a mesenchymal factor that regulates the
differentiation of the proventricular epithelium [30]. Wnt/β-catenin signaling is necessary and
sufficient to promote hindgut development of the endoderm and repress foregut formation in frog
and zebrafish embryos [31].
Given the interdependence of Wnts and their receptors, it is also important to understand the
spatio-temporal expression of Sfrps and other inhibtors when evaluating Wnt signaling in the
developing stomach. Recent studies have shown that Sfrp1, Sfrp2 and Sfrp5 are redundant in
function and required for forestomach morphogenesis [22]. Sfrp1 expression starts in the
splanchnic mesoderm around E10.5, extending from the caudal region of the presumptive
stomach up to the midgut. Sfrp1 and 2 are targets of Barx1, a homoeodomain transcription
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factor, which is specifically expressed in the presumptive stomach mesenchyme from E9 until
E15, with a peak at E13.5 [32]. Barx1 acts by inhibiting the canonical Wnt pathway in the
stomach. Using TOP-GAL reporter mice, the authors showed that canonical Wnt signaling is
active in the presumptive intestine but not the presumptive stomach endoderm. Wnt signaling
initiates around E9.5, persists through E12.5, and is attenuated by E14. Barx1 upregulates the
expression of Sfrp1 and 2 in the mesoderm, which in turn compete with the Wnt ligands,
blocking signaling to the epithelium. The attenuation of Wnt is required for specification of the
stomach-specific program in the epithelium. Since Barx1 is not expressed in the intestinal
mesenchyme, Wnt signaling in the intestinal epithelium is not attenuated and the epithelium
continues to follow the default intestinal specific program [32]. That the intestinal program is in
fact, the default pathway, has also been suggested by studies in chick embryos [33]; although in
these studies, Wnt involvement was not specifically addressed. Barx1 also regulates the
expression of Bapx1 (Nkx3.2) in the mesenchyme, which is required for the formation of the
pyloric sphincter [34]. Overall, the literature indicates that Wnt signaling promotes posterior
fates in the gut endoderm, with inhibition of Wnt promoting foregut marker expression
posteriorly and overexpression leading to intestinal differentiation (posteriorization) of the
stomach.

C.

The FGF pathway:

FGFs (through FGF receptors) have been shown to signal across epithelial-mesenchymal borders
to promote cell proliferation, migration, and differentiation during the development of the lung,
intestine, and stomach [35, [36, [37]. The mouse and human FGF families consist of 23 members
that are structurally related and are either secreted or act as intracellular ligands. Nyeng and
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colleagues analyzed the expression of all 23 FGF ligands in later stages of the developing
stomach (E14.5-E18.5) on the messenger RNA level and found that FGF1-3, FGF7, FGF9 and
FGF10 were expressed above a baseline control gene [36]. Earlier, Bhushan and coworkers [38]
had shown that FGF10 was expressed in the posterior part of the stomach mesenchyme at E11.5,
before cytodifferentiation had occurred. FGF10 is a ligand for FGFR2-IIIb, which is expressed
on the epithelium. During these later stages of embryonic gastric morphogenesis, FGFR2b
expression in the corpus and antrum was more or less constant over time with a slight increase at
E15.5, coinciding with the timing of the highest expression of FGF10 and, interestingly, was
more prominent in newly forming glands.
In chick embryos, overexpression of FGF10 in the presumptive stomach mesenchyme results in
excessive cell proliferation of the overlying epithelium and affects its differentiation, leading to
the expression of cSP (spasmolytic polypeptide – luminal marker) as well as Smad8 (a glandular
marker) in epithelial cells [7]. In mouse and chick embryos, FGF4 is expressed in the mesoderm,
and signals to the endoderm to promote the expression of Cdx genes in the presumptive hindgut
region and to repress the expression of Hhex and Foxa2 in the presumptive foregut [39, [40, [41].

D.

The BMP/TGF Signaling pathway

Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the
transforming growth factor beta (TGFβ) superfamily. BMPs have been shown to play critical
roles in heart, neural, cartilage, postnatal bone development and other organs such as kidney,
lung, liver, limb, amnion, eye, teeth, pituitary, and testes. Smad1, 5 and 8 are the immediate
downstream signaling molecules of BMP receptors. BMP signaling promotes posterior
endoderm development [5]. Danesh and colleagues studied the expression patterns of different
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BMP ligands in the early developing murine embryo (E7.25-E10.5) (Danesh et al., 2009). They
found that BMP2 is absent from the gut tube at this time. At E8.25, BMP4 is expressed in the
posterior lateral plate mesoderm; whereas at E10.5, it extends to dorsal gut mesoderm [42].
BMP7 is expressed at low levels in the foregut endoderm at E8.75, and by E10.5, its expression
in the posterior stomach is highly intensified. BMP2 is expressed in the mesenchyme of the
developing proventricular mesenchyme of the chick. Overexpression of BMP2 leads to an
increase in the number of glands expressing ECPg (embryonic chicken pepsinogen), whereas
overexpression of Noggin (a BMP antagonist) completely inhibits gland formation [7]. On the
other hand, overexpression of BMP4 does not lead to any change in gland formation [7].

E.

The Retinoic Acid Signaling pathway

Retinoic Acid (RA), the active derivative of Vitamin A, is a diffusible embryonic signaling
molecule that has a wide array of target molecules in a variety of different organs. In the GI tract,
RA signaling is important in establishing the foregut-hindgut boundary [5]. Retinoic Acid
activity depends on the RA-synthesizing enzyme, retinaldehyde dehydrogenase (RALDH).
Raldh1 is weakly expressed in the stomach epithelium at E12.4-14.5; whereas Raldh2 has a
stronger expression in the stomach mesenchyme at E10.5-E12.5 [43]. Raldh2-/- mouse fetuses
exhibit a smaller, rudimentary stomach than wild type littermates, with a columnar epithelium
lacking squamous or glandular differentiation [44]. These knockout mice have lower FGF10
expression in the mesenchyme, but Hoxa5 expression is unaffected. It has been proposed [45]
that Hoxa5 regulates FGF10 expression, but the above results indicate that there might be other
upstream players controlling FGF10.
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F.

The Notch Signaling System

While Notch signaling has been shown to play important roles in controlling cell fate decisions
during development of various tissues, including the intestinal epithelium, its role in the
development of the mammalian stomach has not been fully explored, although it has been shown
that the differentiation of multiple enteroendocrine cell lineages in the stomach is dependent on
the transcription factor Ngn3, and important effector of the pathway [46] In the developing
chicken proventricular epithelium, Notch signaling acts as a binary switch between choosing the
luminal (cSP expressing) or glandular (Smad8/ECPg expressing) cell fate [47]. Nyeng and
colleagues [36] studied the cross talk between Notch and FGF signaling in the mouse embryonic
gut development and found Notch1, its downstream bHLH transcription factor Hes1, and its
ligand Jagged2 to be expressed in the gastric epithelium in the corpus and antrum at high levels.
and in the forestomach at a basal level from E14.5 through E18.5 [36]. They also found that
Hes1 expression was upregulated in response to FGF10, thus implying that FGF10 positively
regulates Notch signaling in the developing stomach epithelium [36].

IV.

Transcription Factors

In an attempt to identify marker genes for the development of each organ of the GI tract in
chicks, Yasugi and Mizuno identified groups of genes expressed in the epithelium at different
times around gland formation, i.e. when the epithelium invaginates into the mesenchyme to form
gastric glands [7]. The first group includes genes which are expressed prior to and during gland
formation, i.e. foxa2, cSox3, cfos and junD. The second group of genes, cSox2, Shh, cSP,and
PPARγ, are expressed prior to but not after gland formation . The last set of genes is expressed
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specifically after gland formation, i.e.

Smad8 and Gata5. Delta and Notch are expressed

sporadically. ECPg is expressed after gland formation and specifically in the gland epithelium.
A. The Hox Genes
The Hox transcription factors share a common DNA-binding motif called the homeodomain.
These proteins are involved in regional specification along the A–P axis during embryonic
development and are expressed in lateral plate mesoderm.48 As the gut derivatives are locally
specified along the A–P axis, it is expected that the Hox genes will play a role in establishing
regional identities. Kawazoe and coworkers48 examined the expression of the different Hox
genes in the developing GI tract at E12.5. Among the HoxA cluster, in situ hybridization studies
showed that Hoxa-4 and Hoxa-5 were expressed in the distal part of the stomach, whereas Hoxa6 is expressed in the entire stomach mesenchyme. Hoxb-4 also has a distal stomach expression
pattern, whereas Hoxb-5 and Hoxb-7 are expressed over the entire stomach. No expression of
Hoxc-4, Hoxc-5 and Hoxd-4 was observed in the stomach at E12.5. The authors hypothesize that
a different Hox code exists in different regions of the gut, which regulates regional specification,
with the HoxA cluster predominating the foregut domain. Hoxa-5 is expressed as early as E9.0 in
the caudal segment of the foregut and by E15.5 its expression follows a gradient, with highest
levels in the hindstomach mesenchyme. Hoxa-5 expression vanishes after birth, around P15 in
mice. Hoxa5-/- mice, at age P15, display a thinner stomach epithelium and hypertrophied
submucosa. Aubin and colleagues proposed that Hox5a acts by negatively regulating Fgf10
expression in the hindstomach mesenchyme, which then decreases Ihh in the hindstomach
epithelium and increases Shh in the forestomach epithelium [45]. Hoxa5 also increases Tgfb1
and Tgfb3 in the mesenchyme. Overall, Hoxa5 appears to provide a posteriorization signal to the
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gastric epithelium and mesenchyme. Finally, a study on Hoxb1 expression in the gut
mesenchyme revealed that it is regulated by retinoic acid signaling [48].
B. COUP-TFII
COUP-TFs (COUP-TFI or NR2F1 and COUP-TFII or NR2F2) are highly conserved nuclear
orphan receptors that are expressed in the mouse embryonic stomach mesenchyme [49].

At

E12.5, COUP-TFII is expressed in the mesenchyme adjacent to the endoderm but not distally,
and regulates radial and A-P patterning of the stomach

[50]. Ablation of COUP-TFII

specifically in the mesenchyme leads to the formation of a thicker epithelium, an anterior shift of
the limiting ridge that divides the fore- and hind-stomach, reduction in the size of the
forestomach, and expansion of the hindstomach. COUP-TFII may be regulated by Hh signaling
from the overlying epithelium and it, in turn, might regulate the expression of Bmp4 in the
mesenchyme [50]. Since COUP-TFII may be downstream of Shh, it acts as an anteriorization
signal like Shh. In the adult, COUP-TFII is expressed in the gastric epithelium, specifically in the
parietal cells and the base of the gastric unit [50].
C. Sox2
Sox2 is a transcription factor that is important to maintain pluripotency of the epiblast and
embryonic stem cells. At E9.5 in the mouse embryo, Sox2 is expressed in the endoderm of the
entire foregut. However, its expression is gradually localized to the esophageal endoderm as the
embryo develops. In the stomach, Sox2 is initially expressed in the stomach epithelium as
distally as the pylorus but is later downregulated in the glandular corpus and antrum and
expressed only in the forestomach by E18.5 (Que et. al., 2007). Hypermorphic Sox2 allele
expression causes the forestomach epithelium to resemble that of the glandular stomach due to
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the expression of mucin and trefoil factor genes [51]. This suggests that Sox2 might act in the
developing fetus by inhibiting the expression of the hindstomach genes in the forestomach.
D. Barx1:
Barx1 is a mouse homeodomain transcription factor, a member of the Bar subclass of
transcription factors, which is expressed in restricted areas of the head and neck mesenchyme
and that of the developing stomach from E9.5 to E16.5 [52]. Kim and coworkers [32] observed
that Barx1 had a high enrichment of RNA message in the stomach mesenchyme as compared to
the intestine in E12 mouse embryos. Inbred Barx1-/- embryos and outbred Barx1-/- neonates
(since inbred Barx1-/- embryos die at E12.5) show stomach defects, with much smaller stomachs
than wild type littermates and lack of leftward rotation [32, [53]. Moreover, the mucosa is
highly thickened and disorganized and the posterior 3rd of the Barx1-/- neonate stomach
undergoes intestinal homeotic transformation, showing expression of intestinal markers and true
villus morphology [53]. As outlined above, Barx1 acts by upregulating the expression of soluble
Wnt antagonists Sfrp1 and Sfrp2, which in turn bind to Wnt ligands and limit their availability to
engage Frizzled receptors on endodermal cells of the presumptive stomach. Since Barx1 is not
expressed in the presumptive intestinal mesenchyme, Wnt signaling is not inhibited in this region
and it follows an intestinal specific program [53]. Thus, Barx1 acts as an anteriorizing signal and
in its absence, the gastro-duodenal boundary are shifted anteriorly.
E. Bapx1
Bapx1 is a homeodomain transcription factor that specifies gut smooth muscle in Drosophila
[54]. In the chick embryo, Bapx1 is expressed in the gizzard mesenchyme and inhibits the
expression of Bmp4 and Wnt5a [55]. Bapx1 is presumed to be regulated by Shh and controls the
patterning of the gizzard [55]. Studies in mouse embryos show Bapx1 to be activated at E8.5 in
146

the lateral plate mesoderm adjacent to the endoderm [34]. Embryos lacking Bapx1 show a defect
in the expansion and morphogenesis of the antral-pyloric segment, rendering it an important
factor for pyloric sphincter development [34].
F. Forkhead-box (FOX) family:
Forkhead transcription factors belong to the winged helix family of factors and are so named due
to the appearance of their DNA binding motifs when bound to DNA
colleagues

[56]. Kaestner and

[57] identified Fkh6 (forkhead homologue 6, now termed FoxL1) as being

specifically expressed in the gastrointestinal mesoderm just underlying the endoderm. FoxL1-/mice show an expanded glandular epithelium, extensive branching within the mucosa and
vacuolated pit cells [57] Absence of FoxL1 caused decreased Bmp2 and Bmp4 expression. The
phenotype implies a role for FoxL1 in epithelial proliferation [57]. Another interesting study
done by Fukamachi and colleagues [58] suggested a role for FoxL1 in the differentiation of
oxynticopeptic cells (which are cells combining the separate roles of parietal cells and
zymogenic cells that characterize mammalian stomachs) into parietal cells, since eliminating
FoxL1 in mice caused parietal cells to stain positively for pepsinogen.
In evolution, the first species to display two different cell types, i.e. the parietal cell and
zymogenic cell, for the secretion of hydrochloric acid and digestive enzymes may be found in the
elasmobranch Hexanchus griseus, but the molecular mechanism governing this lineage
differentiation (e.g., whether a FoxL1 ortholog plays a role) during evolution is unknown [59].
Loss of FoxL1 severely abrogates basal and histamine-stimulated gastric acid secretion without
affecting the cellular canaliculi architecture [58]. A related transcription factors, FoxF1, is coexpressed with FoxL1 in the developing gut mesoderm, and both are direct targets of Hedgehog
signaling through Gli2 and Gli3 [60]. In the adult, FoxL1 indirectly targets Wnt/β-catenin
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signaling by upregulating extracellular matrix heparin sulfate proteoglycans, which in turn
increase the local concentration of Wnt ligand for binding to Frizzled receptors which are
expressed in the epithelium [61]. Wnt signaling provides a positive signal for cell proliferation,
suggesting that FoxL1 may have opposing roles in the fetus and the adult.

Fig. A1.1. Epithelial-mesenchymal interactions during early foregut/stomach development in
the embryo. The gut tube is formed by the juxtaposition of an endodermally derived epithelial
later and a mesodermally derived mesenchymal later. Post-gastrulation, important signaling
interactions occur bidirectional across the epithelial-mesenchymal boundary, which help in
specifying the different organs of the gut tube along the different axes. Depicted is a schematic of
the cross talk occurring between the two tissue layers during the specification of the stomach.
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V.

Postnatal Gastric Development

The source of nutrients for an embryo is obviously different from that of a neonate. Until birth,
the developing embryo procures its nourishment from the placenta and substances from
swallowed amniotic fluid, which also might contain factors that aid in development [62]. As the
newborn develops, maturation and gland formation of the gastrointestinal tract continue, peaking
its rate of growth at around three weeks in rodents. The stomach grows at a more rapid rate just
after birth as compared to the rest of the body [63]. Gastric epithelial cells differentiate into and
establish different lineages – the pit, zymogenic, enteroendocrine and parietal cell lineage [64].
At birth, gastric acid secretion capacity is low, but it rapidly increases about three-fold during the
first three days post partum [65], coupled with a proportionate increase in the number of parietal
cells per unit volume of gastric mucosa (Xu et. al., 1992). The low pH of the stomach
immediately after birth equips the neonates with the first line of defense against ingested
microorganisms as the pups change their environment from a sterile to an open one [66]. Gastric
acid secretion is responsive to levels of the hormone gastrin (secreted by G-cells of the antrum).
Gastrin expression increases shortly after birth, in correlation with the observed increase in acid.
Gastrin gene expression responds to EGF via cAMP activation [67]. Interestingly, there is
>1,000 times more EGF in colostrum and milk consumed by neonates as compared to plasma
levels, and ingested EGF might act as the trigger for gastrin release, subsequent parietal cell
proliferation, and acid secretion immediately after birth [68].
Studies in neonatal rats have shown that changes in suckling of new born pups, such as weaning,
have an impact on proliferation of gastric mucosal cells [69]. Gama and Alvarez showed that if
pups are early-weaned, the basal proliferation in the gastric mucosa is higher, suggesting that
milk plays an important role in maintaining the desired proliferative rate and homeostasis.
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Indeed, the mitogen TGFβ is found in rat milk and its concentration decreases towards weaning
[70]. TGFβ receptors I and II are also expressed in the gastric epithelial cells at E20 until
weaning [71]. This timing coincides with the proliferation of the cells in the developing gastric
unit. Post-weaning, the proliferative zone of the unit is restricted to the isthmus region where the
stem cell is believed to reside.
Ghrelin is a growth-hormone-releasing peptide released by the endocrine cells of the rat fetal
stomach from E18 onward, and its expression peaks during the second and third weeks after
birth [72]. Ghrelin is also released by other tissues in the pregnant mother (such as the brain,
hypothalamus, pituitary, immune cells, ovary, placenta and others), in the fetus during
development (such as in the stomach, intestine, pancreas, lungs), and in the neonate (such as the
stomach and lungs) [73]. For the newborn, the sources of circulating ghrelin include secretion
by the stomach mucosa and the maternal contribution in colostrum and milk [74]. Ghrelin may
play a role in postnatal gut development as it leads to an increase in total body weight and the
weight of the stomach (Hayashida et. al., 2002).
VI.

Adult Gastric Homeostasis

The gastric epithelium undergoes continuous renewal throughout the life span of the animal [1].
This renewal occurs due to the proliferation and differentiation of multipotent stem cells that are
present in the isthmus region of the adult gastric unit. The stem cell gives rise to precursors that
move bidirectionally (towards the lumen and towards the base) in the unit, giving rise to three
main lineages with eleven cell types, i.e.
1. Pit (also known as surface-associated/foveolar) cell lineage – Pre-pit cell precursors,
Pre-pit cells, Pit cells
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2. Zymogenic cell lineage – Pre-neck cell precursors, Pre-neck cells, Neck cells, Prezymogenic cells, Zymogenic cells
3. Parietal cell lineage - Pre-parietal cell precursors, Pre-parietal cells, Parietal cells
In addition to these lineages, endocrine cells are also scattered throughout the gastric unit. Even
though there is emerging literature on the mechanisms by which the different cell types are
formed, many gaps remain. For example, even though the location of the stem cell within the
gastric corpus has been well established by ultrastructure and turnover analysis, its molecular
identity has not been well characterized (Huh et. al., 2006).

Fig. A1.2. Normal architecture and organization of different cell types in the gastric unit of
the adult mouse. The corpus (body) of the adult stomach consists of repeating invaginations
called gastric units, each of which can be divided into four regions characterized by the presence
of specific cell types in each region. Depicted is an H&E stained slide of the adult mouse
stomach showing a single gastric unit outlined in white, with each region labeled: 1, Pit region,
which lines the stomach lumen, consists of mucus-secreting pit aka foveolar cells, and narrows
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deeper in the unit into the isthmus region; 2, the isthmus region, characterized by the presence of
multipotent gastric stem cell; 3, neck region, where mucus-secreting neck cells and most of the
acid-secreting parietal cells reside; and 4, base region, where enzyme producing zymogenic cells
are present.
1. The Pit cell lineage: The stem cell in the isthmus region gives rise to a pit cell precursor,
which is devoid of secretory granules. The precursor then differentiates into pre-pit and
ultimately into pit cells, which migrate into the pit region. Pit cells contain mucous
granules (characterized by Muc5AC, Gkn1, Tff1) and degenerate upon reaching the
luminal surface. This entire process takes place over three days [75, [76, [77, [78]. Verzi
and colleagues showed that the forkhead transcription factor FoxQ1 is expressed
specifically in the stomach in the adult GI tract and within the stomach, its expression is
limited to pit cells [79]. However, this finding is controversial as another report claims
that FoxQ1 is expressed exclusively in parietal cells [80]. Verzi and coworkers find that
FoxQ1 is required for the expression of Muc5AC but not Gkn1 in pit cells [79]. FoxQ1
mutant stomachs also have dysregulation of genes involved in assembly and function of
membranous organelles, such as Rpgrip, Sec22 and Stk25, suggesting that it may play a
crucial role not only in the expression of Muc5AC, but also in imparting this cell with its
specific architecture [79]. Gastrin has been implicated in increasing proliferation of pit
cells, leading to an extended pit region

[81]. Ihh may also play a role in pit cell

differentiation and maintenance [82].

2. The Zymogenic cell lineage: The pre-neck cell precursors that arise from the stem cell in
the isthmus give rise to mucus-secreting neck cells, which eventually mature to form
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enzyme-secreting zymogenic cells (ZC), which occupy the base of the unit. Neck cells
are characterized by the expression of TFF2 (also known as spasmolytic polypeptide) and
the expression of TFF2 is expanded during SPEM (spasmolytic polypeptide expressing
metaplasia) [83]. The journey of the neck cell to the base to form zymogenic cells takes
around 14 days, and zymogenic cells at the base of the gland have a half life of 194 days
[84]. The improbability of a terminally differentiated, post-mitotic mucus secreting neck
cell maturing into an enzyme secreting zymogenic cells was highlighted by Hanby and
colleagues

[85]. However, Ramsey and co-workers presented the first molecular

evidence that zymogenic cells, in fact, arise from neck cells, and that this maturation is
controlled by the bHLH transcription factor, Mist1 [86]. Recent studies by Tian and
colleagues show that Mist1 facilitates structural maturation of zymogenic cellsin part by
regulating the expression of Rab proteins, which control the formation of serous secretory
granules [87]. Another pathway that expands the zymogenic cell population is the
retinoic acid pathway [88].

3. The Parietal cell lineage: Parietal cells (PCs) arise from pre-parietal cells in the isthmus
region, function in acid secretion, and contain a highly dense canalicular network [89].
Aside from their acid secretion function, parietal cells also produce growth factors that
maintain normal patterns of cell differentiation and proliferation within the gastric unit
[90]. Most of the PC transcriptional machinery is centered around regulating the
expression of genes that keep the cell functional, such as Arf1, Sod2, Mucdhl, Fads1,and
Calm2 [90]. The PC also elaborates growth factors such as Igfbp2 and Pthlh that can
have an effect on the differentiation and proliferation status of other cell types in the
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gastric unit [90, [91]. The aforementioned transcription factor FoxQ1 appears to be
unique in that it controls gastric acid secretion, but not the development of parietal cells,
and FoxQ1-/- mice show a defect in the development of canaliculi and are less responsive
to gastrin [80].
Hormonal regulation of gastric acid secretion is performed by peptides such as gastrin (secreted
by the G-cells of the antrum), ghrelin (produced by Gr cells), natriuretric peptides (produced in
the central nervous system), orexins (neuropeptides), histamine and others, either alone or in
combination

[92]. Gastrin is the main stimulant for acid secretion after a meal, and its

mechanism of action is via the activation of the CCK-2 (cholecystokinin) receptor, which in turn
activates the PLC and/or MAPK pathways, causing the release of histamine from ECL cells
(endocrine cells) of the stomach [93]. Histamine diffuses to parietal cells, where it binds to H-2
receptors and activates cAMP production, ultimately resulting in the recruitment of the
H+/K+ATPase to the canalicular membrane to enable acid secretion [94].

VII.

Morphogenetic pathways in maintaining adult gastric homeostasis:

A. The Hedgehog Pathway
Studies by Van den Brink and colleagues first catalogued Shh expression in the adult gastric
fundus [95]. Ptc-1, a target of hedgehog signaling, is also expressed in parietal cells and
epithelial cells at the base of the unit. There are contrasting observations relating to the
expression of Shh in the pit region, and it is not yet certain if Shh is, in fact, expressed in these
cells [96]. Within the epithelium, the targets of hedgehog signaling are parietal cells at the
cellular leve,l and FoxA2, Isl-1, the H+/K+ATPase, and BMP4 at the molecular level [18, [95,
[97]. Shh is in turn regulated by EGF signaling [97]. While FoxA2, Isl-1 and H/KATPase are
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expressed in the epithelium, BMP4 is expressed in the interstitial myofibroblast like cells [95].
However, studies by Fukaya and coworkers showed that Ptc-1 expression was absent from the
isthmus region suggesting that hedgehog does not act directly on stem/progenitor cells [82]. In
contrast, Ihh is expressed in differentiated pit cells and may play a role in the differentiation and
maintenance of this lineage [18, [82].
B. The BMP signaling system
As discussed earlier, BMP4, but not BMP2, is a target of Shh in the stomach. Nitsche and
coworkers showed that BMP4 regulates the expression of H+/K+ATPase-α subunit, through the
activation of Smad-1, in an isolated canine parietal cell culture system

[98]. There are

contrasting observations regarding the cellular identity of BMP4-producing cells. Van den Brink
and colleagues found BMP4 solely in fibroblasts in-vivo [95], whereas, Nitsche and coworkers
recently showed that it is also expressed in parietal cells in-vitro [98]. EGF acts by inhibiting
H+/K+ATPase expression in parietal cells and this effect can be reversed by BMP4

[98].

Therefore, BMP4 may be a crucial regulator of differentiation and functional maturation in
parietal cells. Indeed, inducible ablation of the Bmp4 gene in mice leads to hyperplastic polyp
formation in the antral mucosa, indicative of a sustained role for BMP4 in suppressing antral
proliferative response [99, [100].
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Fig. A1.3. Interplay between developmental signaling pathways coordinating differentiation
and maintenance of different cell lineages within the gastric unit. The gastric epithelium is
constantly renewing which requires replenishment of the various differentiated cell types (each
having a different life span), from multipotent stem cells. The schematic shows signaling
intermediates involved in the maintenance of cell lineage homeostasis and phsysiology in the
gastric unit.

Conclusion
In conclusion, multiple transcriptional regulators and spatially controlled signaling pathways
contribute to the development of the stomach during fetal life, and to the continuing
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differentiation of the gastric mucosa throughout adult life. The relatively recent evolutionary
appearance of a separate stomach provides an interesting model system to study
mesenchymal/epithelial signaling, which may provide information on similar processes
elsewhere in the body. Given the high incidence and mortality of gastric cancer, discussed in
detail elsewhere in this volume, an understanding of how these factors control epithelial biology
is a prerequisite for improving diagnosis and treatment.
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APPENDIX 2: Autoimmune gastritis mediated by CD4+ T cells promotes the
development of gastric cancer.
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Abstract
Chronic inflammation is a risk factor for cancer, including gastric and other gastrointestinal
cancers. For example, chronic inflammation caused by Autoimmune Gastritis is associated with
an increased risk of gastric polyps, gastric carcinoid tumors, and possibly adenocarcinomas.
This study details the progression of gastric cancer in a mouse model of Autoimmune Gastritis
(AIG). Disease is caused by CD4+ T cells which express a transgenic T cell receptor specific for
a peptide from the H+/K+ ATPase proton pump, a protein expressed by parietal cells in the
stomach. Here, we show that autoimmune gastritis causes epithelial cell aberrations that mimic
most of those seen during progression to gastric cancer in humans. These include: chronic
gastritis followed by oxyntic atrophy, mucous neck cell hyperplasia, spasmolytic polypeptideexpressing metaplasia (SPEM), dysplasia, and ultimately gastric intraepithelial neoplasias (GIN).
These studies provide direct evidence that autoimmune gastritis supports the development of
gastric neoplasias. This AIG model should be useful for studying inflammation induced gastric
cancer.
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Introduction
Autoimmune gastritis (AIG) is one of the most common autoimmune conditions in humans, and
is caused when the adaptive immune system (T and B cells) targets self-antigens expressed by
parietal cells and chief cells in the gastric mucosa. AIG may persist in an asymptomatic form for
many years. A subset of individuals will eventually develop Pernicious Anemia (PA). PA is the
major cause of vitamin B12 deficiency. AIG and PA have respective prevalence of 2 and 0.15–
1% in the general population [1, [2], which is increased 3- to 5-fold in individuals with other,
concomitant autoimmune diseases, such as type 1 diabetes [3, [4] and autoimmune thyroid
disease [5, [6]. Gastric carcinoid tumors, evolving from enterochromaffine-like (ECL) cell
hyper/dysplasia induced by hypergastrinemia, develop in 4–9% of patients with AIG/PA [7, [8,
[9]. Gastric carcinoid tumors are relatively benign lesions, metastasizing in less than 10% of
cases [10]. Several studies have examined whether individuals with AIG/PA also have a higher
risk of developing gastric adenocarcinomas, which is the second leading cause of cancer related
deaths in the world. Two recent studies, one with 4.5 million retired male veterans in the USA
and the other with included 9 million individuals from Sweden, reported that individuals with PA
had an increased risk of developing not only gastrointestinal carcinoids, but also stomach
adenocarcinomas, small intestinal adenocarcinomas, squamous cell carcinomas (SCC), and
esophageal SCCs [11, [12].
Gastric cancer is the fourth most common cancer and the second most deadly malignant
neoplasia in the world. A model, referred to as the Correa pathway, describes the development
of gastric adenocarcinomas in humans from a histological perspective [13]. This model details
the progression of gastric cancer through a series of pathological steps the epithelium undergoes
starting with chronic inflammation (gastritis), followed by atrophy (especially loss of parietal
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cells), metaplasia, dysplasia, and eventually neoplasia.

A better understanding of how

inflammation induces gastric epithelial cell changes could provide potential therapeutic strategies
for diagnosing and preventing gastric cancer [14]. To gain a better understanding of the
progression of gastric cancer from a cellular and molecular perspective, numerous groups have
developed animal models, mouse models in particular, to study gastric carcinogenesis. Such
strategies have included chronic infection with Helicobacter [15], chemical depletion of parietal
cells [16, [17], and several different lines of genetically modified mice. While these models
have increased our understanding of the roles of infection, parietal cell loss, and genes involved
in regulating epithelial cell biology, none have directly examined the role of chronic
inflammation as the primary inducer of epithelial cell change, which would be useful for
understanding the roles of cytokines and immune cells in promoting gastric cancer and for
addressing the potential link between AIG and gastric cancer.
We investigated the potential link between AIG and gastric cancer using a T cell receptor (TCR)
transgenic mouse model of AIG [18]. These transgenic CD4+ T cells recognizes a peptide from
the parietal cell specific antigen H+/K+ ATPase, which is also the major autoantigen targeted by
the immune system in humans with AIG/PA [19]. All mice developed chronic gastritis that
resulted from large numbers of CD4+ T cells that infiltrated the gastric mucosa and produced
large amounts of IFN-γ and smaller amounts of IL-17. Mice developed severe oxyntic atrophy
and metaplasia by 2 to 4 months of age. At this stage of disease, mice also developed several
molecular features associated with the progression of gastric cancer in humans, including
spasmolytic polypeptide expressing metaplasia (SPEM), increased levels of mRNA for gastric
cancer biomarkers (HE4, OLFM4, TFF2), and increased levels of phosphorylated STAT3
compared to non-transgenic control mice. Finally, by 12 months of age, all mice with AIG
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developed high grade dysplasia consistent with gastric intraepithelial neoplasia (GIN).

In

summary, we report a new mouse model demonstrating that inflammation associated with AIG
induces many of the pathologic and molecule features of gastric carcinogenesis, including the
development of severe dysplasia/GIN. These studies support a link between AIG and gastric
cancer and highlight the importance of localized inflammation in the development of stomach
cancer. This new, immune-system-induced model of gastric cancer will be useful for studying
important host factors that influence inflammation induced adenocarcinomas.

Material and Methods
Mice - TxA23 TCR transgenic mice have been previously described, and have been bred >15
generations onto the BALB/c background [18]. The BALB/c control mice described in these
experiments are TCR transgene negative littermates that were co-housed with the TxA23 TCR
transgenic mice. All mice were maintained under specific pathogen-free conditions and cared
for in our animal facility in accordance with institutional guidelines. Our colony tested negative
by PCR for the following: Helicobacter bilis, Helicobacter hepaticus, Helicobacter rodentium,
Helicobacter sp., Helicobacter trogontum, and Helicobacter typhlonius.
Histopathology - Stomachs were removed from mice, rinsed in saline, immersion fixed in 10%
neutral-buffered formalin (Thermo Scientific), paraffin embedded, sectioned, and stained with
hematoxylin and eosin. Pathology scores were assigned using methods modified from Rogers et.
al. [20]. Slides were blinded and sections from individual mice were assigned scores between 0
(absent) and 4 (severe) to indicate the severity of inflammation, oxyntic atrophy, mucinous
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hyperplasia/metaplasia, and dysplasia. Scores were validated by an independent second
pathologist blinded to experimental conditions.
Immunofluorescence - Stomachs were fixed for 20 minutes with methacarn (60% methanol, 30%
chloroform and 10% glacial acetic acid (all from Fisher)), washed with 70% ethanol, embedded
in paraffin and sectioned into 0.5µm thick sections. Slides were deparaffinized, rehydrated,
stained, and imaged using methods modified from Ramsey et. al. [21]. The primary antibodies
used for immunostaining were rabbit anti-human gastric intrinsic factor (gifts of Dr. David
Alpers, Washington University), rabbit anti-Ki67 (Abcam), and mouse anti-Ecadherin (BD
Bioscience).

Secondary antibodies and GSII lectin (Molecular Probes) labeling were as

described [21].
A gastric unit is defined as an invagination of the gastric mucosa that is lined by a single layer of
columnar epithelium.

Each gastric unit is lined by foveolar cells at the luminal end and

zymogenic cells at the base. Ki67 staining was quantified by counting each Ki67+ nucleus per
gastric unit for >50 units per mouse and classified into <10, 10-20 and >20 positive nuclei per
unit. Percentages were calculated by dividing the number of gastric units in each category by
total number of gastric units analyzed in that mouse stomach sample.
Immunohistochemistry - Tissue was deparaffinized and rehydrated. Endogenous peroxidase was
blocked using a 0.3% H2O2 in methanol for 15 minutes. Antigen retrieval was done in a pressure
cooker with Diva (Biocare: DV2004MX). Avidin/biotin kit (Biocare) was used to block
endogenous biotin. The antibody pStat3 (D3A7) from Cell Signaling was diluted in Davinci
(Biocare) and incubated over night at 4°C. The secondary antibody, biotinylated goat anti-rabbit
and streptavidin-HRP from Jackson Labs were each applied for 1 hour at room temperature.
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Visualization was done with Biocare's Betaziod DAB and slides were counterstained in
hematoxylin.
Immunoblot - A section from the stomach was homogenized with an electric pestle tissue
homogenizer. Cells were then lysed in .5 ml of lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM betaglycerophosphate , 1 mM Na3VO4, 1 µg/ml leupeptin (Cell Signaling) and a protease inhibitor
cocktail (Sigma)). Lysates were vortexed for 1 minute and sonicated for 15 seconds followed by
centrifugation for 10 min at 4°C. Lysates were ran on a NuPAGE 4-12% BIS-TRIS gradient gel
(Novex) and transferred to a nitrocellulose membrane. Membrane was blocked for 1 hour with
5% non-fat dairy milk. Primary antibodies (all from Cell Signaling) were stained for 1 hour
(rabbit mAB-β-Actin-and rabbit mAB-STAT3) or overnight (rabbit mAB-Phospho-STAT 3) in
5% bovine serum albumin in 4˚C. HRP-Linked secondary antibody (anti-rabbit IgG) was stained
for 1 hours at room temperature in 5% non-fat dairy milk.

Protein was detected by

chemiluminescence using LumiGLO (Cell Signaling) on CL-XPosure X-Ray film (Fisher).
Flow cytometry - Cell surface staining was performed according to standard procedures using
monoclonal antibodies against CD4, CD19, CD11b and Ly6G. Intracellular cytokine staining
was performed using monoclonal antibodies against IFNγ and IL-17A. All antibodies were
purchased from BD Pharmingen. All flow cytometry was performed on a BD LSRII or BD
FACSCalibur and analyzed using FlowJo (TreeStar). For intracellular cytokine staining, cells
were stimulated with PMA (Calbiochem) and Ionomycin (Calbiochem) for 4 hours at 37°C.
Golgi-stop (BD Bioscience) was added after 1 hour. Cells were then washed, fixed in 4% formyl
saline, washed, and permeabilized (0.5% BSA, 0.1% Triton, and 2mM EDTA in PBS) for 1 hr at
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room temperature.

After washing, cells were incubated overnight with the anti-cytokine

antibodies, washed and analyzed by flow cytometry.
Isolation of cells from the gastric lymph nodes and gastric mucosa - The method for isolating
cells from the stomach tissue has been described previously [22, [23]. Briefly, the gastric lymph
nodes (gLN) were removed from the stomachs, homogenized, and passed through a 40-μM pore
nylon filter. Stomachs were opened with an incision from the antrum to the fundus, and rinsed in
PBS to remove food. Cells were flushed from the gastric mucosa using a syringe with a 25
gauge needle. PBS containing 5% FCS and penicillin/streptomycin (Sigma) was repeatedly
injected within the mucosa causing the tissue to swell and rupture. Single cell suspensions were
collected, gently vortexed, and passed through a 40-μM nylon filter. Cells were counted, stained
with antibodies, and analyzed by flow cytometry. To detect secreted cytokines, 1x10 6 cells were
culture in vitro in 24 well plates containing 2 mL of supplemented RPMI. Supernatants from
cell cultures were collected after 48 hours and cytokines and chemokines were measured using
Milliplex (Millipore).
Quantitative Real Time PCR - Total RNA was prepared using the RNeasy Mini Kit system
(Qiagen).

The quantity and quality of RNA was determined using a NanoDrop 2000

spectrophotometer (Thermo Scientific) and 0.5 µg of the RNA was used to generate a first strand
cDNA copy according to the manufacturer’s instruction (High Capacity cDNA Reverse
Transcription Kit, Applied Biosystems). Quantitative PCR was performed using TaqMan®
Gene Expression Assays systems (Applied Biosystems). GAPDH served as an internal reference
standard. PCR was ran on the 7500 Real-Time PCR System (Applied Biosystems).
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Statistical Analysis - Data are expressed as means of individual determinations +/- standard error.
Statistical analysis was performed using the Mann-Whitney Test (*P<.05; **P<.01; ***P<.001)
using GraphPad Prism 5.

Results:
Inflammation in TxA23 mice is characterized by CD4+ T cells secreting IFN-γ and IL-17. Our
first goal was to characterize the cell types and cytokines of TxA23 mice. Cells were isolated
from the gastric mucosa and gastric lymph nodes of 2 month old mice and analyzed by flow
cytometry. The majority (>85%) of the hematopoietic derived cells isolated were either CD4+ T
cells or CD19+ B cells (Figure 1A). As expected, the majority of the CD4+ T cells that infiltrated
the stomach expressed the transgenic TCR (TCRVα2/TCRVβ2) specific for the H+/K+ ATPase
peptide (Figure 1B). Macrophages (CD11b+Ly6G-) and neutrophils (CD11b+Ly6G+) and a subset
of dendritic cells (CD11b+CD11c+, data not shown) comprised the rest of the cells found in the
gastric mucosa (Figure 1C). Next, cells were re-stimulated and cytokine production by CD4+ T
cells was determined by intracellular cytokine staining. The majority of cytokine producing
CD4+ T cells isolated from the stomachs and gastric lymph node produced IFN-γ, and fewer
produced IL-2, and IL-17. IL-4 secretion by CD4+ T cells was not detected (Figure 1D). Finally,
total cells isolated from the gastric lymph node were cultured immediately after isolation. The
amounts of several cytokines secreted into the supernatants were determined after 48 hours. The
most abundant cytokines secreted by cells were IFN-γ and IL-17 (Figure 1E). Lower levels of
IL-6, IL-2, IL-10, and IL-4 were also detected. Thus the inflammatory cell infiltrate within the
gastric mucosa consists primarily of a mixture of Th1 (IFN-γ+) and Th17 (IL-17+) CD4+ T cells,
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and B cells. This type of inflammation is consistent with the types of inflammation described in
humans infected with H. Pylori and with autoimmune gastritis [24, [25].

Fig. A.2.1. Inflammation in TxA23 mice. Representative flow cytometric plots of cell types and
cytokines from a TxA23 mice (n = 21). A, flow cytometry was used to identify T cells (CD4+)
and B cells (CD19+). B, the majority of CD4+-gated T cells express the transgenic TCR
(TCRVα2/TCRVβ2) that recognizes a peptide from H+/K+ ATPase. C, macrophages
(CD11b+Ly6G−) and neutrophils (CD11b+Ly6G+) make up a large proportion of the
remaining cells. D, intracellular cytokine staining showing IL-17, IFN-y, IL-2, and IL-4
production by CD4+ T cells combined from the gastric mucosa and lymph node. E, cytokines
secreted by cells isolated from the gastric lymph nodes of TxA23 mice were measured by beadbased ELISA. Data are the mean ± SE of 7 mice from 3 independent experiments.
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TxA23 progress through a series of pathological changes associated with the development of
gastric cancer.
In humans, the progression of intestinal-type gastric cancer is thought to evolve through a series
of discrete steps known as the Correa pathway

[13].

The first step in this pathway is

inflammation (gastritis), then loss of parietal cells (oxyntic atrophy) and the development of
mucinous metaplasia, followed by dysplasia and finally cancer. We examined the pathological
features of gastric disease in TxA23 mice. At 2 months of age, TxA23 mice had moderate
degrees of inflammation, oxyntic atrophy and mucosal hyperplasia/metaplasia, but little or no
evidence of dysplasia (Figure 2A). By 4 months of age, inflammation, oxyntic atrophy, and
mucosal hyperplasia/metaplasia were significantly more severe compared to 2 month old mice
(Figure 2A). Lesions in the stomachs of 4 month old TxA23 mice comprised large areas in
which parietal cells were either reduced in number or absent from the gastric units, and the
remaining mucosa was dominated by large, hyperplastic mucus-containing cells that expanded to
the bases of gastric units (Figure 2B-C). Four of the 19 mice had developed mild focal dysplasia
(Figure 2D). For comparison, Figure 2E is representative of the normal pathology observed in 11
individual control mouse, which are transgene negative BALB/c mice that were co-housed with
TxA23 littermates. Disease severity was similar in male and female mice at all ages. These data
demonstrate that chronic inflammation resulting from autoimmune gastritis induced the
development of preneoplastic lesions in the gastric mucosa of TxA23 mice with many
pathological features in common with the Correa pathway.
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Fig. A.2.2. Preneoplastic lesions in TxA23 mice. A, pathology scores of stomach sections from
2-month-old (n = 9) and 4-month-old TxA23 mice (n = 19). B–D, representative images of
pathology observed in TxA23 mice illustrating inflammation, oxyntic atrophy, and mucosal
hyperplasia (B). C, extensive parietal cell loss accompanied by moderate levels of mucinous
metaplasia (red bracket). D, focal regions of mild dysplasia (blue bracket). E, normal
morphology in a BALB/c control mouse with healthy parietal cells and basal nonmetaplastic
zymogenic chief cells at base of unit (red bracket, base region). Arrows point to healthy parietal
cells. Statistics were conducted using the Mann–Whitney U test (**, P < 0.01; ***, P < 0.001).
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Increased epithelial cell proliferation, phosphorylated STAT3, IL-6, and expression of gastric
cancer-associated biomarkers in TxA23 mice. Next, we used immunofluorescence to compare
the extent of gastric epithelial cell proliferation in 2 and 4 month old TxA23 mice compared to
BALB/c control mice (Figure 3A-C). In wild type BALB/c mice, the number of proliferating
(marked by Ki67+ immunoreactivity) epithelial cells (marked by E-cadherin+) per individual
gastric unit was always less than 10. However, in TxA23 mice almost 70% of 2-month old
gastric units had 10 or more proliferating cells, and by 4 months, more than 75% had more than
10 with about a third of those having 20 or more (Figure 3D).
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Fig. A.2.3. Increased epithelial cell proliferation in the gastric mucosa of TxA23 mice. A–C,
images are representative of 2-month-old (A) and 4-month old (B) TxA23 mice and 4-month-old
(C) BALB/c stomach sections. E-Cadherin (green) stains epithelial cells, Ki67 (red) stains
proliferating cells, and Hoechst (blue) was used to stain nuclei. D, a quantitative analysis of the
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percentage of gastric units containing proliferating epithelial cells (E-cadherin+Ki67+) in
BALB/c and 2- and 4-month-old TxA23 mice.

Increased levels of the active (phosphorylated) signal transducer and activator of transcription 3
(pSTAT3) was involved in cellular transformation in numerous cancers of epithelial origin,
including gastric cancer [26]. A recent study suggested that pSTAT3 is a significant prognostic
factor in gastric cancer in humans [27]. To determine whether the level of pSTAT3 was
increased in the stomachs of TxA23 mice, we performed western blots on gastric tissue lysates
between age matched TxA23 and healthy BALB/c control mice. Compared to BALB/c mice,
TxA23 mice expressed slightly higher levels of total STAT3 and a much higher level of pSTAT3
(Figure 4A).

Immunohistochemical analysis revealed a large number of pSTAT3 positive

epithelial cells present in the gastric mucosa of TxA23 mice, and nearly undetectable levels in
gastric tissue from BALB/c controls (Figure 4B), in agreement with the results observed by
Western blot.

Several members of the IL-6 cytokine family, including IL-6 and IL-11, activate STAT3 [28].
IL-6 and IL-11 have important roles in maintaining gastric homeostasis by regulating mucosal
proliferation, inflammation, angiogenesis, and apoptosis [29, [30]. We performed quantitative
real time PCR analysis using mRNA isolated from gastric tissue from 2 month old TxA23 and
BALB/c mice to measure the relative levels of IL-6 and IL-11. The levels of IL-11 mRNA were
equivalent between the two genotypes; however, the levels of IL-6 mRNA were ~40 fold higher
in TxA23 mice compared to BALB/c mice (Figure 4C).
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Fig. A.2.4 Increased levels of cancer associated markers in TxA23 mice. A, representative
Western blotting of STAT3, pSTAT3 and β-actin on whole stomach lysates of 2-month-old TxA23
(n = 9) and BALB/c mice. B, immunohistochemistry staining for pSTAT3 in gastric pits of
BALB/c and TxA23 stomachs (magnification, ×20). C, the relative expression of IL-6 and IL-11
in mRNA extracted from the stomachs of TxA23 and BALB/c mice. D, the relative expression of
genes (HE4, TFF2, and OLFM4) that serves as biomarkers for the SPEM and preneoplastic
progress was compared between mRNA isolated from the stomachs of TxA23 mice and BALB/c
controls.

A number of genes have been described as biomarkers for precursor lesions like SPEM that are
predisposing for gastric cancer. Some of these genes include Human Epididymis 4 (HE4) [16],
Trefoil Factor 2 (TFF2) and Olfactomedin 4 (OLFM4) [31]. HE4 is absent in normal stomach
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and expressed in humans and mice with SPEM [16]. Increased levels of OLFM4, also known as
GW112, have been observed in gastric cancers, including 58% of stage III/IV gastric cancers
[31]. TFF2 is also known as spasmolytic polypeptide, and, by definition, increases when SPEM
is present. We performed quantitative real time PCR analysis using mRNA isolated from
sections taken from the body of the stomachs of TxA23 mice. All of the TxA23 mice expressed
higher levels of HE4 and OLFM4, and a majority, 5 out of 7 mice, expressed higher levels of
TFF2 compared to age-matched BALB/c control mice (Figure 4D).

Together these data

demonstrate that disease in TxA23 mice shares many of the molecular features of gastric cancer
that have been reported in humans, including increased epithelial cell proliferation, increased
levels of pSTAT3 protein, and higher levels of IL-6, HE4, OLFM4, and TFF2 mRNA.

SPEM is present in the gastric mucosa of TxA23 mice.

Intestinal-type gastric cancer

predominantly develops in the setting of oxyntic atrophy and mucous cell metaplasia [13].
Spasmolytic polypeptide-expressing metaplasia (SPEM), is a metaplasia in the gastric fundus
resembling deep antral gland cells, and recent studies have indicated that SPEM may be directly
linked to gastric neoplasia [25, [32]. We used immunohistochemistry to determine whether 4
month old TxA23 mice developed SPEM. A representative section from a TxA23 mouse is
shown in figure 5A. In gastric units in which parietal cells have not yet been destroyed, chief
cells are found at the base of the unit and are identified by staining with antibodies to gastric
intrinsic factor (GIF). Of note, the antrum/pyloris of TxA23 mice were indistinguishable from
BALB/c control mice. In the corpus region, neck cells are found above and identified by lectin
GSII staining (Figure 5B). However, we also observed multiple gastric units in which the
majority or all of the parietal cells had been lost (Figure 5B, C). In these parietal cell depleted
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units, there was an expansion of GSII-positive cells (mucous neck cell hyperplasia) and an
emergence of cells expressing both neck cell specific and chief cell specific markers (GIF) in the
base of the units, whereas in regions with parietal cell preservation, the normal basal marker
expression pattern was maintained (Figure 5D). Thus, GSII-positive GIF-positive cells in the
base of gastric units that lack parietal cells also stained positive for TFF2 (data not shown),
demonstrating13 that TxA23 mice developed regions of SPEM by 4 months of age.
Fig. A.2.5. TxA23 mice have distinct
regions of parietal cell loss coupled with
the emergence SPEM. Representative
immunostains of the corpus region of the
stomach of TxA23 transgenic mice. A, the
lamina propria is separated from the
glandular mucosa by the white dotted lines
wherein parietal cells are stained with
VEGFB (teal) and nuclei with Hoechst
(blue). Note the distinct regions of parietal
cell loss as highlighted by solid white
lines. B, the area highlighted by the yellow
box in A was stained with GSII (green,
neck cells), GIF (red, ZC), and Hoechst
(blue, nuclei). The yellow box on the left
indicates a region of SPEM where cells coexpress GSII and GIF (white arrowheads).

180

This region of the stomach has shown considerable parietal cell destruction. Higher
magnification of this region is shown in C. White arrows indicate areas of relatively normal
gastric epithelial cell differentiation that correlate with regions where parietal cell numbers are
normal. Further magnification of this region is shown in D.

TxA23 Mice Develop Gastric Intraepithelial Neoplasia (GIN). In the next set of experiments we
allowed a cohort of TxA23 mice to age, and performed histopathological evaluations to
determine whether disease in TxA23 mice progressed beyond SPEM to dysplasia. Sections from
stomachs of 4 and 12 month old mice were examined by a pathologist using a murine gastric
histopathology scoring paradigm described previously [20] (Figure 6A). The analysis of mice at
4 months of age revealed that 15 of 19 had dysplasia scores of 0, and 4 of 19 mice had dysplasia
scores of 1, indicating focal irregularly shaped gastric glands, including elongated, slit, trident,
and back to back forms (Figure 6B). By 12 months of age, disease progressed to the point at
which 7 of 8 mice developed severe dysplasia, indicated by scores of 3.5. In this scoring system
a score of 3 is used to indicate severe loss of gland organization and columnar orientation,
marked cell atypia, visible mitoses, gastric intraepithelial neoplasia (GIN), and 0.5 is added for
carcinoma in situ or invasion without frank malignancy. We observed both focal and wide
spread dysplasia, and most cases involved pseudoinvasion into the submucosa and/or serosa
(Figure 6C-E). We also observed the formation of irregular glandular forms on the adventitial
surface of the stomach, some of which contained papillary projections of atypical epithelium
(Figure 6F). These data demonstrates that precancerous lesions observed in 4 month old TxA23
mice ultimately progressed to neoplastic disease.
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Fig. A.2.6. TxA23 mice develop masses with dysplastic foci as they age. A, dysplasia scores
(where 1 = irregular glad forms, 3 = severe loss of glands and of columnar orientation of
epithelium with regions of cellular atypia, increased mitotic figures, and 0.5 added when
invasion of muscle or carcinoma in situ was identified) for sections at given ages. Each point
represents an individual mouse. B, section of a mouse at 10 months of age (magnification, ×10).
Note to formation of mass with abundant, dense chronic inflammatory infiltrates. C–F, images of
stomach sections that represent pathology observed in 12-month-old mice with various degrees
of pseudoinvasion of irregular glands into the submucosa. C, section showing submucosal focus
of irregular gland formations (magnification, ×10). D, section showing focus of irregular glands
in submucosal tissue with surrounding chronic inflammation (magnification, ×20). E, section
showing deep submucosal pseudoinvasion by an irregular gland (magnification, ×10). F,
irregular glandular form on the adventitial surface of the stomach (magnification, ×20).
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Discussion
Although chronic atrophic gastritis is believed to be important in initiating gastric
carcinogenesis, the precise role(s) of inflammation in the complex changes in gastric epithelial
cells during the progression of gastric cancer are not understood. Furthermore, the relationship
between AIG/PA and gastric cancer has been controversial and requires further investigation. In
this study we describe a new mouse model demonstrating that autoimmune gastritis induces
precancerous lesions similar to those that precede gastric cancer in humans. Mice with chronic
inflammation caused by H+/K+ ATPase-specific CD4+ T cells developed severe oxyntic atrophy
coupled with metaplasia, including SPEM by 4 months of age. Similar to H. pylori infection and
AIG in humans, inflammation in TxA23 mice contained CD4+ T cells of the Th1 (IFN-γ+) and
Th17 (IL-17+) phenotype [33, [34]. Consistent with the Correa pathway that describes the
progression of gastric cancer in humans, TxA23 mice progressed through a series of stages that
included inflammation, atrophic gastritis, mucous neck cell hyperplasia, SPEM, which over time
progressed to dysplasia, and neoplasia. These data indicate that the TxA23 model system is
unique in that it allows for the study of the development and regulation of gastric carcinogenesis
in a setting where chronic inflammation, in the absence of infection, toxins, and drugs, is the
primary upstream instigator. Our findings of carcinogenesis in our mouse model are consistent
with reports that humans with AIG/PA are 3- to 6- times more likely to develop gastric
adenocarcinoma and other cancers [35, [36]. It has been reported that a subset of individuals
contain T cells and antibodies specific for H+/K+ ATPase after they are infected with H. pylori
[37, [38, [39, [40]. It is possible that individuals that develop autoimmune responses during H.
pylori infection may remain at risk for gastric cancer even if they are treated for H. pylori
infection. Studies have shown that the eradication of H. pylori reduces risk for subsequent
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gastric cancer by about 25% [40, [41, [42]. Strategies to reduce inflammation in addition to
eradicating H. pylori may further reduce the risk of gastric cancer.
With the two recent studies reporting that individuals with Pernicious Anemia developed
gastrointestinal cancers at a higher than expected rate, animal models that mimic AIG are likely
to be useful for understanding the link between AIG and GI cancers. There is no doubt that
infection with H. pylori is an important, prerequisite risk factor for gastric cancer; however, the
vast majority of infected patients do not develop cancer. Therefore, it may be the types of
chronic inflammation in the gastric mucosa that is triggered by H. pylori that are downstream
adjuvants or causes of actual cancer. The TxA23 mouse model described here mimics the
human disease and demonstrates the progression of AIG to the development of SPEM and
eventually severe to dysplasia. Other genetically engineered mouse models have been useful for
studying factors that influence the development of gastric cancer independently of Helicobacter
infection. For example, mice expressing gastrin under the insulin promoter [43], mice deficient
in: TFF1 [44], Smad4 [45], and Hip1r [46], and mice expressing a mutated form of the IL-6
family co-receptor gp130 [47] all develop forms of gastric metaplasia and some cases dysplasia.
Our model specifically focuses on the immune response to H+/K+ ATPase and its role in
promoting SPEM with progression to severe dysplasia. By inducing severe dysplasia in the
absence of infection, this model will allow for a direct examination of the mechanisms whereby
inflammation influences gastric epithelial cell biology. For example, when examining disease in
cytokine knockout mice, using our model, we do not have to be concerned with the potential
indirect effects of the importance of the cytokine in modulating Helicobacter infection itself.
Our model will be also useful for evaluating the importance of immune cells, such as regulatory
T cells and how they influence changes in gastric epithelial cells that are associated with the
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progression of gastric cancer. Finally, future studies using this model will address how various
host factors, especially immune-related genes, influence the risk of developing gastric cancer.
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